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ABSTRACT 
 
The adrenal gland is a vital organ consisting of an outer cortex surrounding an inner medulla.  
The adrenal cortex has three zones: zona glomerulosa (zG), zona fasciculata (zF) and zona 
reticularis (zR) which synthesise the steroids aldosterone, cortisol and 
dehydroepiandrosterone, respectively.  The adrenal gland responds to constant physiological 
changes to maintain homeostasis by rapidly producing hormones, such as cortisol during stress 
or aldosterone in hypotension.  The factors that determine differentiation and zonation of the 
adrenal cortex are not fully understood, although there is consensus that adrenal 
stem/progenitor cells residing in the subcapsular region of the gland can differentiate to renew 
and remodel the gland according to steroidogenic requirements.  
 
Bone morphogenetic protein 3b (Bmp3b) was previously found in a rat microarray study to be 
exclusively expressed in the outer part of the adrenal cortex that contain capsular/zG cells.  We 
have confirmed the findings of the microarray study and demonstrate that BMP3b acts locally 
to upregulate CYP11B2 (specific to zG) and in a gradient dependent manner to downregulate 
the expression of steroidogenic enzymes specific to zF and zR in H295R cell lines. This action 
of BMP3b is possibly through inhibition of BMP2 expression and activity.  BMP2 was found 
to be most highly expressed in the inner cortex and was shown to upregulate the expression of 
zR specific enzymes.  Animal experiments confirmed the presence of Bmp3b in the capsular 
region but indicated that Bmp3b knockout mouse did not have abnormal adrenal morphology.   
 
BMP3b expression was increased in some human adrenocortical carcinoma samples but this 
was not consistent across the cohort.  Those tumours with increased expression of BMP3b 
correlated with a less aggressive histology.  BMP3b could therefore potentially be used as a 
prognostic factor and help guide patient treatment and prognosis.   
 
This study demonstrates that BMP3b could play a role, probably in concert with other factors, 
in adrenal zonation and tumourigenesis. 
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1.1 The stress system: Hypothalamo-pituitary-adrenal 
(HPA) Axis 
 
Hans Selye was the first to describe a biological response to stress as a general adaptation 
syndrome in 1936 (Selye, 1936).  Stress is defined as a real or anticipated disruption of 
homeostasis, or an anticipated threat to well-being (Ulrich-Lai and Herman, 2009).  This can 
be an emotional or physiological response to an external/environmental situation.  For 
example, it can be a non-specific response of the body to any demand placed upon it or a life-
threatening situation such as a major physical trauma, prolonged starvation or illness.  Stress 
has also been summarised as any condition where an environmental demand exceeds the 
natural regulatory capacity of an organism (Koolhaas et al., 2011).  Selye observed the 
behavioural, hormonal, and autonomic responses to stress.  These changes occur as a result of 
the activation of the autonomic nervous system (ANS) as the immediate response which is 
followed by activation of the hypothalamic-pituitary-adrenal axis (HPA).  In response to stress, 
both the sympathetic and parasympathetic systems lead to immediate changes in the body’s 
physiological state through the action of the adrenal medulla and secretion of catecholamines 
(adrenaline and noradrenaline), termed the ‘fight or flight’ response.  This response is rapid 
and also wanes quickly as the parasympathetic system activates.  If stress is prolonged then the 
HPA is activated and cortisol is produced, with an approximate delay of 10 minutes from the 
onset of stress (Droste et al., 2008).  Upon activation of the HPA axis, the paraventricular 
nucleus synthesises and secretes corticotrophin-releasing hormone (CRH) and arginine 
vasopressin (AVP) from the hypothalamus into the hypophyseal portal circulation (Carrasco 
and Van De Kar, 2003; Chrousos, 1995; Sapolsky et al., 2000).  Stress is also associated with 
the release of other hormones such as oxytocin, prolactin and renin in order to ensure maximum 
ability for survival, should there be dysregulation in the main stress HPA axis (Aguilera, et al., 
1995; Carrasco and Van De Kar, 2003; Levine and Muneyyirci-Delale, 2018; Onaka and 
Takayanagi, 2019).  CRH, along with AVP, works synergistically acting on the corticotroph 
cells of the anterior pituitary gland to release adrenocorticotropic hormone (ACTH) into the 
systemic circulation (Chrousos, 1995; DeBold et al., 1984).  ACTH is a 39 amino acid peptide 
derived from the cleavage of proopiomelanocortin (POMC) by the peptidases PC1/PC3 (Chan 
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et al., 2011).  The release of CRH, AVP and ACTH happen in a matter of seconds (Sapolsky 
et al., 2000).   
 
ACTH released from the anterior pituitary into the peripheral circulation acts on the ACTH 
receptor, also known as the melanocortin 2 receptor on the surface of adrenal cells to increase 
the production of glucocorticoids (cortisol in humans and corticosterone in rodents).  The 
presence of glucocorticoid will then act on the hypothalamus and pituitary to negatively 
feedback and supress further release of CRH and ACTH.   
 
The HPA axis is constantly regulated to maintain homeostasis.  Without stress, circulating 
ACTH and glucocorticoid levels fluctuate in a pulsatile, circadian manner over a 24 hour 
period (Carnes et al., 1988; Spiga et al., 2011; Windle et al., 1998).  In humans, cortisol levels 
peak between the hours of 0600-0900 am, on waking.  Cortisol levels then fall throughout the 
day, reaching a nadir at midnight, after which levels slowly rise again.  On waking, cortisol is 
required to increase energy level, increase blood pressure and activate gluconeogenesis.  
Cortisol levels are very low by night time in preparation for sleep.  This pulsatility is vital as 
chronic exposure to glucocorticoids leads to desensitisation of the body’s response to stress 
(Spiga et al., 2011).  Over time, if the stressor prevails, our body can become conditioned, 
resulting in a blunted response to stress as the system is desensitised.  This chronic stress can 
also lead to disease, such as hypertension, diabetes and gastric ulcers, as well as affecting 
growth and fertility (Sapolsky et al., 2000).   
 
More recently, the 24 hour circadian rhythm of glucocorticoids have been further investigated 
and it is now clear that the nature of pulses is far more dynamic, consisting of oscillatory pulses 
of ACTH and glucocorticoids known as the ultradian rhythm.  The ultradian rhythm consists 
of regular pulses of ACTH which then stimulate the adrenal gland to produce glucocorticoids, 
with a built in delay at the adrenal cortex. The glucocorticoids then feed back to the pituitary 
to suppress any further ACTH release.  This system of regular pulsitility is thought to produce 
a self-sustaining oscillatory activity of glucocorticoid ultradian rhythm (Russell and Lightman, 
2019; Walker et al., 2010).   
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1.2 The adrenal gland 
 
The adrenal gland is an important organ that is essential for life.  It is the key organ for the 
regulation of the stress response, producing hormones that maintain blood pressure and glucose 
utilisation at times of illness and injury. The adrenal gland has three distinct outer zones, which 
are responsible for the production of steroid hormones. The organisation and zonation of the 
gland is critical for the normal function and production of these hormones. It is thought that all 
three zones of the adrenal cortex derive from a single source of progenitor cells.  Understanding 
the process of zonation and steroidogenesis will provide insight into conditions where there is 
over and underproduction of hormones from the adrenal gland and adrenal carcinomas, where 
survival remains poor.  
 
1.2.1 Development of the adrenal glands 
The adrenal medulla has a different developmental origin to the adrenal cortex with the former 
arising from the neuroectoderm, where cells of the neural crest lineage migrate in to the adrenal 
anlage ultimately forming the chromaffin cells of the medulla (Mesiano and Jaffe, 1997).  The 
medulla is part of the sympathetic nervous system and is responsible for the secretion of 
catecholamines (Carrasco and Van De Kar, 2003; Chrousos, 1995; Miller and O’Callaghan, 
2002).  
 
The adrenal cortex in contrast originates from the urogenital ridge, as do the gonads and the 
kidneys.  Human adrenal development begins around the fourth week of gestation from the 
mesoderm, where the coelomic epithelium thickens and the underlying mesonephric 
mesenchymal cells, found in the notch between the primitive urogenital ridge and the dorsal 
mesentery, migrate to form the adrenogonadal primordium and the kidney (Hatano et al., 1996; 
Ikeda et al., 1994; Parker et al., 2002).  Development and division of the adrenogonadal 
primordia (AGP) occur by week 8, when there is a distinct separation into the adrenocortical 
and gonadal primordium.  This then becomes the fetal adrenal (see Figure 1.1) that comprises 
of a large inner fetal zone (FZ) composed of large eosinophilic cells that are capable of 
steroidogenesis.  The FZ is surrounded by a very thin outer layer of tightly packed basophilic 
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cells known as the definitive zone (DZ) that have no steroidogenic role during development.  
In between the two zones lies the transitional zone (TZ).  The transitional zone is also able to 
synthesise cortisol after mid-gestation.  By the 30th week of gestation, the DZ and TZ begin 
to resemble zG and zF of the adult adrenal cortex respectively (Mesiano et al., 1993).  At birth, 
the FZ begins to regress by apoptosis and the DZ and TZ begin to expand to form the zG and 
zF. By age 3 years the zG and zF are fully formed (Spencer et al., 1995, 1999).  In primates, 
the zR begins to form producing androgens after the age of 6, a process known as adrenarche, 
and may continue to grow until the age of fifteen (Kempná and Flück, 2008; Kim and Hammer, 
2007).   
 
During development, the transcription factor Sf-1 (steroidogenic factor 1) is the earliest marker 
of steroidogenic cells in the adrenogonadal primordium and it is essential for the development 
of both the adrenals and the gonads (Kim and Hammer, 2007; Mesiano and Jaffe, 1997).  
 
 
Figure 1.1 Adrenocortical zones in the human adrenal gland in fetal development and 
adult with its associated hormone production 
The fetal adrenal consists of the inner fetal zone containing large eosinophilic cells in the centre 
with the definitive zone subcapsularly and the transition zone lying in the middle. The adult 
adrenal cortex consists of 3 concentric zones: Outer zG secretes aldosterone, inner zF secretes 
glucocorticoids and innermost zR secretes DHEA and DHEA-S. The cortex abuts the adrenal 
medulla which secretes adrenaline and noradrenaline. The gland is encapsulated by the adrenal 
capsule. zG = zona Glomerulosa, zF = zona Fasciculata and zR = zona Reticularis, DHEAS = 
dehydroepiandrosterone, DHEAS = dehydroepiandrosterone sulphate.  
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In the mouse, the adrenogonadal primordium is first detected at embryonic day 9.5 (E9.5) with 
expression of Sf-1 and Dax-1.  Development and division of the adrenogonadal primordia 
(AGP) into the gonadal and adrenal primordia occurs by E10.5.  The zF forms by E14.5, but 
the zG is not observed until the perinatal stages of E20 when expression of Cyp11b2 is present 
(King et al., 2009; Mitani et al., 1999).  Mice have an equivalent zone to the human FZ, the X-
zone, which regresses in male mice at puberty (about 5 weeks of age) and in females after their 
first pregnancy (Holmes and Dickson, 1971).  Adrenal development in rats is similar to mice 
but with developmental milestones that are typically delayed by one day. Rats do not have an 
equivalent X zone (Klepac et al., 1977; Mitani et al., 1999). 
 
Apart from histological differences, another important difference between the primate and 
rodent adrenal gland is the lack of a functional zR in rodents. This is due to a lack of CYP17 
enzyme, necessary for the androgen synthesis.  In rats, there is the formation of a fourth zone; 
the undifferentiated zone (zU) that does not stain for any steroidogenic antibodies (CYP11B1, 
CYP11B2 and CYP17).  This zone is not seen in many other species, such as mice, pig or 
rabbit and its size is also variable across rat strains, being most prominent in Sprague-Dawley 
rats (Mitani, 2014; Xing et al., 2015). 
 
 
1.2.2 Adrenal anatomy  
The adrenal gland is a component of the HPA axis, producing an array of hormones that are 
essential for life, which, if dysfunctional, is associated with mortality and morbidity (Kempná 
and Flück, 2008).  The first description of the adrenal gland was made in the second century 
by the Greek physician, Claudius Galenus of Pergamon (Galen), but the first definitive 
illustration of the gland was by Bartolomeo Eustachio (an Italian anatomist) in the 16th century 
in his book entitled ‘Tabular Anatomica. Chapter VL, Vemica’ (Leoutsakos and Leoutsakos, 
2008; Mezzogiorno and Mezzogiorno, 1999; Rochester, 1989).  In the 18th century, Cuvier 
Lenard first used the terms ‘cortical’ and ‘medulla’ and recognised that they were distinct 
morphological entities within the adrenal gland (Lenard, 1951).  However, it was not until 
1852 when significant advances in microscopy allowed Albert Von Kölliker to fully describe 
the cortex and medulla as two physiologically and functionally distinct areas within the adrenal 
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gland (Leoutsakos and Leoutsakos, 2008).  In 1855, Thomas Addison was the first to recognise 
the importance of the adrenal gland and that it was essential for life.  In his monograph, ‘On 
the constitutional and local effects of disease of the supra renal capsules’, he described patients 
with destruction of the adrenal gland (due to tuberculosis) to have “anemia, debility, feebleness 
of the heart, irritability of the stomach and peculiar changes of the color in the skin, occurring 
in connection with a diseased condition of the suprarenal capsules”. The condition was later 
named “Addison’s disease” (Pearce, 2004).  Charles-Edouard Brown-Sequard found that 
animals could not survive if bilateral adrenalectomy was performed (Brown-Sequard, 1856; 
Miller, 2013), thus demonstrating that the glands are essential for life.  Ever since its discovery, 
there has been a vast amount of work investigating the physiology, development and 
maintenance of this gland in health and disease.     
 
The adrenal glands are V, or pyramidal shaped on the right side and Y, or crescent shaped on 
the left.  In adult humans they weigh approximately 8-10 g each and in rats 20-30mg each.  
They sit anterosuperiorly to the kidneys.  Each adrenal gland is contained and surrounded by 
a capsule, made up of fibroblasts and myofibroblasts. A network of arterioles lie subcapularly, 
forming a plexus that supplies blood to the adrenal cortex and medulla (Ishimoto and Jaffe, 
2011; Mesiano and Jaffe, 1997).  
 
Beneath the adrenal capsule is the adrenal cortex (cortex, meaning ‘bark’), which accounts for 
approximately 90% of the adrenal mass in healthy individuals. The cortex is divided into three 
histologically and functionally distinct concentric zones: the outermost zona glomerulosa (zG), 
the middle zona fasciculata (zF) and the innermost zona reticularis (zR) (Figure 1.1) (Mitani, 
2014; Yates et al., 2013).  The zG is named due to its appearance being similar to the glomeruli 
of the kidneys, with cells arranged in ‘balls’ (Latin glomus = ball). The zG is a narrow zone 
with small columnar cells arranged in round clusters with intense nuclei and basophilic 
cytoplasm with a low lipid content.  It produces the mineralocorticoid aldosterone, which is 
part of the feedback system of the renin-angiotensin adrenal system to regulate sodium balance 
via the kidneys, maintaining water and blood pressure homeostasis (discussed in more detail 
in Section 1.5). The zF, named from the appearance of cells lining up in parallel fascicles or 
bundles, is responsible for the production of cortisol in humans and corticosterone in rodents. 
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Glucocorticoids are known as the stress hormone because at times of stress, an increased level 
of cortisol is produced and this allows the body to upregulate mechanisms to deal with the 
stress, such as gluconeogenesis.  Glucocorticoids are essential in maintaining homeostasis 
during stressful events by controlling metabolism and affecting vascular tone.  This includes 
the regulation of glucose by glucocorticoids, in order to maintain glucose supply for maximal 
brain function at times of stress.  It does this by promoting gluconeogenesis in the liver and 
increasing insulin resistance in muscles and white adipose tissue (Kuo et al., 2015) by 
inhibition of GLUT4 recruitment (Weinstein et al., 1998).  Glucocorticoids also have a role in 
glycogen storage in the liver and glycogen usage in skeletal muscle as well as the secretion of 
glucagon and insulin through pancreatic a and b cells (Kuo et al., 2015).   
 
The innermost zone of the cortex, which is found in humans and primates but not rodents, is 
the zR.  Histologically, the cells appear as a network or “cord” of cells hence giving it its name 
(Latin rete = network). The zR is responsible for the production of adrenal androgens, and is 
involved in sexual development (Rainey, 1999; Vinson, 2016).  
 
The most inner part of the adrenal gland is the medulla (meaning ‘marrow’ or core) which has 
a separate embryological origin and function to the cortex.  It produces catecholamines 
(adrenaline and noradrenaline), as part of the fight and flight hormones and contributes to the 
sympathetic nervous system (Kempná and Flück, 2008).   
 
 
1.3 Zonation theories 
 
Research into adrenal development and steroidogenesis has provided insight into the signalling 
pathways and the function of the adrenal cortex.  Zonation research has expanded over the last 
two decades with many pathways implicated in the formation of the various zones within the 
adrenal cortex as well as its maintenance.   
 
The adrenal gland is a highly dynamic organ with the capability to remodel rapidly in response 
to homeostatic perturbations (Dallman et al., 1976; Kawai et al., 1979; Kifor et al., 1991).  Rats 
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fed on a low sodium diet will exhibit an expansion of the zG (Cohen, 1965; Mitani et al., 
1994)due to activation of the RAAS (Renin Angiotensin Aldosterone System) to conserve 
sodium.  This results in increased AT1 and AT2 mRNA levels, to allow for increased receptor 
expression and Ang II binding (Aguilera et al., 1980).  Increased levels of Ang II will result in 
increased production of aldosterone in the zG to act on the collecting tubules in the kidneys to 
increase sodium reabsorption (Pacha et al., 1993).  To accommodate the high levels of 
aldosterone production, the zG layer expands as a result.   
 
ACTH administration causes the zF to expand.  ACTH exerts its effects via cAMP, resulting 
in upregulation of ACTH receptors (de Joussineau et al., 2012).  This leads to an increase in 
the synthesis of enzymes within the steroidogenesis pathway necessary for increased 
glucocorticoid production (Pudney et al., 1984; Simpson and Waterman, 1988).  Unilateral 
adrenalectomy will cause the remaining contralateral adrenal to compensate and become 
hyperplastic (Engeland et al., 2005; Sidorova and Stepanova, 1983).  In earlier studies, this 
hyperplasia was thought to occur in the capsule, zG and outer zF (Holzwarth et al., 1996).  
However, more recent studies by Engeland et al., using triple label immunostaining against 
aldosterone synthase to label the zG, 11β-hydroxylase to label the zF and a mouse monoclonal 
antibody against Ki-67.  Ki-67 is an antigen present in all active phases of the cell cycle and in 
this study demonstrated that cell proliferation occurred mainly in the outer zF (Engeland et al., 
2005).  
 
The adrenal cortex is rapidly responsive to stresses the body is subjected to.  In order for the 
adrenal glands to respond by increasing aldosterone or cortisol secretion as necessary, it is 
thought that a pool of undifferentiated, pluripotent cells exist, ready to be differentiated as 
required, in order to maintain homeostasis.  The idea of possible progenitor cells stemmed from 
studies in the 1950s and 1960s demonstrating regeneration in zonation and function of the 
adrenal gland following bilateral adrenal enucleation in rats (Mesiano et al., 1993; Skelton, 
1959).  For adrenal enucleation, the rats were anaesthetised and an incision was made through 
the flank, exposing the adrenal glands.  A slit was made in the adrenal capsule and the inner 
regions of the gland were squeezed out using small forceps (Alexander et al., 1976) leaving 
only the capsule and adherent cells.  The cortex re-established itself with appropriate zonation 
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within a few weeks (Engeland and Levay-Young, 1999; Engeland et al., 1995) indicating that 
pluripotent cells were present in the capsule or subcapsular region that can differentiate into 
both zG and zF cells.  More recent studies also support this idea (Ennen et al., 2005; Perrone 
et al., 1986).  These data, together with early lineage tracing experiments using trypan blue 
(Salmon and Zwemer, 1941) or tritiated thymidine (Wright et al., 1973) led to the idea that 
progenitors at the capsule/subcapsular region migrate towards the medulla in a centripetal 
manner. During this migration the cells differentiate into the properties of the zone in which 
they are traversing and undergo apoptosis at the medulla boundary.  This is currently the most 
accepted theory of zonation.  Regeneration experiments by Kim et al., took donor 
capsule/subcapsular units and implanted them subcutaneously into syngeneic mice.  They 
observed the regrowth of Sf-1 positive cells and by 3 months, the entire cortex was repopulated 
and functioning (Kim et al., 2009).  In other studies where primary adrenocortical cells were 
implanted into immunodeficient mice, steroidogenic potential was evident but no zonation or 
continued cell renewal was seen (Thomas and Hornsby, 1999; Thomas et al., 2002), 
highlighting the importance of the presence of capsular/subcapsular tissue for regeneration.   
 
Further confirmation supporting the centripetal migration theory was carried out by King et 
al., using both Shh-cre and importantly Gli1-cre, to specifically follow the capsule cells during 
development.  They found that these cells populated the entire cortex, at least in part via an 
Shh expressing intermediate (King et al., 2009).  Freedman et al., followed on from this to 
show direct conversion of Cyp11b2 to Cyp11b1 cells, by introducing Cre recombinase into the 
genetic locus for Cyp11b2 (aldosterone synthase).  AS-Cre+/- mice were then crossed with a 
R26R+/mTmG mice.  Using this mouse model, the zG cells were GFP positive at birth in the 
subcapsular region and by 12 weeks of age, zF cells were noted to be GFP positive, indicating 
that they were descended from the once Cyp11b2 expressing zG cells.  The direct lineage 
conversion was suppressed by treatment with dexamethasone. Furthermore, zG maintenance 
and lineage conversion was also shown to be dependent on Sf-1 and zG cells were unable to 
convert to zF cells in the absence of Sf-1.  However, despite that, a fully functional zF is 
maintained throughout life in these mice, indicating that a zG independent mechanism is also 
present to make and maintain zF cells (Freedman et al., 2013).     
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Alternative theories on the location of progenitor cells that have fallen out of favour include 
the zonal hypothesis and the transformation field hypothesis.  The zonal hypothesis dictates 
that each zone will have their own pool of cells that will increase or decrease under the control 
of its own zone.  The transformation field hypothesis predicted that cells resided on the zG/zF 
border and the zF/zR border and cells would be transformed as needed and regress when they 
were not required (Vinson, 2003; Wolkersdorfer and Bornstein, 1998).  These alternative 
theories may be out of favour following the studies performed by King et al., and Freedman et 
al., as described above and suggesting that more than one mechanism for progenitor cell 
maintenance and differentiation exists (Freedman et al., 2013; King et al., 2009).   
 
The localisation of the adrenal progenitor cells may differ between species. Mitani et al., 
defined the physiological significance of a zone in the rat adrenal that is 5-10 cell layers thick 
under normal conditions, that lies in between the zG and zF.  This zone is known as the 
undifferentiated zone (zU) (Mitani et al., 1994).  The zU was first described in the 1930s, but 
Mitani’s group were the first to discover that cells in the zU do not express the zF or zG 
terminal steroidogenic enzymes (Cyp11b1 and Cyp11b2 respectively) and do not produce 
adrenal androgens due to a lack of CYP17 enzymes, indicating that they are non-steroidogenic.  
They proposed that the progenitor cells resided within this layer because these cells do express 
Sf-1, indicating steroidogenic capacity.  This is further supported by their BrdU studies, where 
BrdU was incorporated preferentially into cells around the zU, which had a high mitotic rate.  
By subjecting rats to a salt deficient diet, they were able to show an increase in BrdU-positive 
cells within the outer zU that abut the zG. This is in contrast to normal conditions, where BrdU-
positive cells would reside nearer the inner zU that abuts the zF (Mitani et al., 1994).  The 
location of the adrenal progenitor cells within the undifferentiated zone of the rat adrenal gland 
is further supported by work by Guasti et al.,.  In this study, Shh was found to be expressed in 
the outer half of the zU in rat adrenal (Guasti et al., 2010).  Ablation of Shh in adrenal specific 
manner was achieved by crossing Shh floxed mice with a Sf-1-Cre mice.  Analysis of the 
adrenal glands from Shh conditional KO animals demonstrated a reduction in proliferation of 
capsular cells, reduction in cortical thickness and smaller adrenal glands.  These mice, despite 
having morphologically smaller adrenal glands, were still capable of undergoing zonation and 
producing steroids, indicating that SHH is more likely to have a role in stem/progenitor cell 
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dependent cell maintenance than zonation (Huang et al., 2010). Taken together, these data 
suggest that the Shh expressing cells could represent the stem/progenitor population in adult 
animals and respond to changes in homeostasis by differentiating into zG or zF cells as required 
(Guasti et al., 2010).     
 
Whether stem /progenitor cells reside subcapsularly or in the undifferentiated zone or both 
remains unclear. However, there are likely to be species differences such as in rats and mice. 
For example, SHH positive cells reside in the zU in rats whilst such cells cluster beneath the  
capsule in mice (King et al., 2009), with no apparent zU of note. This could explain the 
differences in zonation theories that have been suggested through the years, although there is 
agreement that the stem/progenitor cell niche exists in the adrenal gland, and these are non-
steroidogenic with the potential to become steroidogenic cells to maintain homeostasis.  There 
are now a growing number of genes and pathways that have been implicated in stem/progenitor 
cell function that determine adrenal gland development, zonation and differentiation (El Wakil 
and Lalli, 2011; Guasti et al., 2013a; King et al., 2009; Wolkersdorfer and Bornstein, 1998). 
 
 
1.4 Adrenal function and Steroidogenesis  
 
All steroids are synthesised from the precursor cholesterol.  Cholesterol is obtained from 
exogenous dietary sources and transported through the circulation in lipoprotein particles, 
principally from low density lipoproteins (LDL) (Gwynne and Strauss, 1982) via LDL-
receptor mediated endocytic pathway (Goldstein and Brown, 2009) and a lesser contribution 
from high density lipoproteins (HDL) via SR-B1/selective pathway (Azhar and Reaven, 2002; 
Azhar et al., 2003).  Stored cholesterol, in the form of cholesterol esters in lipid droplets, can 
be released for steroidogenesis upon unesterification by lysosomal acid lipase (LAL) (Du et 
al., 1998; Goldstein et al., 1975).  Cholesterol can also be synthesised de novo from acetate 
(Mason and Rainey, 1987).  The availability of cholesterol is dependent on the presence of 
ACTH, angiotensin II and potassium, where increasing levels of these agents would increase 
the expression and activity of LDL receptors, stimulating HMG CoA reductase and hormone 
sensitive lipase (Lehoux and Lefebvre, 1991).  
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Cholesterol is transported to the mitochondria by a number of mechanisms such as vesicular 
trafficking, by interaction with sterol carrier proteins or cytoskeleton proteins and by specific 
plasma membrane-mitochondrial or ER-mitochondrial interactions (Ikonen, 2008). 
Cholesterol is then trafficked from the outer to the inner mitochondrial membrane (IMM) by 
the transporter steroidogenic acute regulatory protein (StAR). This is the rate limiting step in 
steroid synthesis (Jefcoate, 2002; Simpson and Waterman, 1983) regulated by ACTH, which 
can rapidly stimulate production and activation of StAR (Arakane et al., 1997).  Once inside 
the IMM, steroid synthesis begins through a multi-enzymatic process (Figure 1.2).  The first 
step is the conversion of cholesterol to pregnenolone by cytochrome P450 cholesterol side 
chain cleavage enzyme (CYP11A1 or P450scc).  From this point on, all the other steroid 
hormones can be synthesised, dependent on the isoform of ‘cytochrome P450’ present.  
Pregnenolone can then be converted into progesterone by 3b-hydroxysteroid dehydrogenase 
(3bHSD, HSD3B) or transported to the smooth endoplasmic reticulum, where some of the 
enzymatic processes take place, P450c17 (CYP17A1) catalyses 17a-hydroxylase and 17,20 
lyase.  Following this, 21-hydroxylation occurs with P450c21 (CYP21A1) before the final 
steps of steroid synthesis occur, back in the mitochondria.  Within the mitochondria, 2 
isoenzymes of P450c11 are present for the final steps of steroidogenesis, these are aldosterone 
synthase (CYP11B2) and 11b–hydroxylase (CYP11B1).  CYP11B2 is found exclusively in 
the zG for the production of aldosterone by the catalysis of 11b-hydroxylase, 18-hydroxylase 
and 18-methyl oxidase to convert deoxycorticosterone to aldosterone. Similarly, CYP11B1 is 
exclusive to the zF for the production of cortisol after 11b-hydroxylation of 11-deoxycortisol 
(Payne and Hales, 2004).  Androgen production require the same initial steps to produce 
dehydroepiandrosterone (DHEA), relying on both CYP17 isoenzymes (Rainey et al., 1994, 
2004; Staels et al., 1993) with the process being regulated by cytochrome b5 (CYTB5) to 
stimulate 17,20 lyase activity in the zR (Akhtar et al., 2005; Auchus et al., 1998).  DHEA-
sulfotransferase (SULT2A1) is another important enzyme within the zR as it can use 
pregnenolone, 17a hydroxypregnenolone and DHEA as its substrate to form DHEA-S (Rainey 
and Nakamura, 2008). 
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Steroidogenesis differs in rodents due to the lack of enzyme CYP17 (cytochrome P450 c17), 
which is required for both cortisol and androgen production via its 17α-hydroxylase and 17,20 
lyase activities respectively.  Without CYP17, a hydroxyl (-OH) group cannot be added to the 
C17 position (by 17α-hydroxylase) to progesterone or pregnenolone to form 17α-
hydroxyprogesterone and 17α-hydroxyprenenolone, respectively. 17,20 lyase would then 
cleave the C17-C20 bond of either 17α-hydroxyprogesterone and 17α-hydroxyprenenolone to 
form androstenedione and DHEA respectively (Akhtar et al., 2005).  Therefore, in the absence 
of CYP17, these substrates would not be available for rodents to produce cortisol or androgens.  
Hence rodents are only capable of producing corticosterone and aldosterone.  
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Figure 1.2 Biosynthesis of human steroid hormones 
Multiple enzymatic steps necessary for the conversion of cholesterol to steroid hormones.  
Cholesterol is the common precursor for all steroid production and the conversion to 
pregnenolone by CYP11A1 (P450scc) is the rate limiting step and is present in all 3 zones.  
Prenenolone is trafficked back to the mitochondria.  Pregnenolone then undergoes 17a-
hydroxylation or 17,20 lyase to convert 17OH-pregnenolone.  17OH-pregnenolone, 
progesterone and 17OH-progesterone can then continue towards androgen production 
(dehydroepiandrosterone and androstenedione) if co-factors, such as cytochrome b5 in the 
reticularis is present to favour 17,20 lyase activity.  Pregnenolone, 17OH-pregnenolone and 
dehydroepiandrosterone can also undergo conversion of their C-3 hydroxyl to a keto group to 
form progesterone, 17OH-progesterone and androstenedione.  17bHSD is responsible for the 
conversion of androstenedione to testosterone, which can then interconvert to oestrogen. 
CYP21 is a 21a-hydroxylase enzyme and converts progesterone to 11-deoxycorticosterone 
and 17OH-progesterone to 11-deoxycortisol.  11-deoxycorticosterone and 11-deoxycortisol 
are trafficked back into the IMM, where the final step takes place.  11-deoxycortisol is 
converted to cortisol through 11-hydroxylation by CYP11B1 and 11-deoxycorticosterone is 
converted to aldosterone by CYP11B2 (P450c11AS), catalyzing 18-hydroxylation and 18-
methly-oxidation.   
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1.4.1  Cortisol, aldosterone and adrenal androgens 
Cortisol is a glucocorticoid produced in the zF of the adrenal cortex.  The role of glucocorticoid 
includes metabolic, cardiovascular and anti-inflammatory responses.  About 90% of the 
cortisol produced is bound to corticosteroid binding globulins (CBG) in the blood and is 
biologically inactive (Breuner and Orchinik, 2002).  The unbound cortisol, known as free 
cortisol, is the biologically active form.  There are two isoforms of 11b-hydroxysteroid 
dehydrogenase (type 1 and type 2), responsible for the interconversion of the active form, 
cortisol to the inactive form, cortisone and vice versa.  11b-HSD1 acts as a reductase, allowing 
cortisol action in target tissues.  11b-HSD2 is a NAD-dependent dehydrogenase which 
converts cortisol into cortisone to prevent, for example, cortisol from acting on 
mineralocorticoid receptors in the kidney distal tubule (see below)  (Stewart and Krozowski, 
1999; Tannin et al., 1991; Yang and Zhang, 2004). CBG and cortisol will dissociate upon stress 
and this is believed to occur due to the release of elastase from activated neutrophils 
(Beishuizen et al., 2001; Hammond et al., 1990; Pemberton et al., 1988). 
 
The action of cortisol is exerted on binding to glucocorticoid receptors (GR) in the cytoplasm 
of target cells.  GR is a member of the nuclear receptor family of ligand-dependent transcription 
factors.  Upon cortisol binding, the GR dissociates from a large complex of heat shock proteins 
and FK506-binding proteins (Lai et al., 2003; Pratt and Toft, 1997; Sinars et al., 2003).  The 
GR is then phosphorylated upon ligand binding and translocate to the nucleus and binds to 
glucocorticoid-responsive elements (GREs) in the genome (Tsai et al., 1988; Wrange et al., 
1989).  This results in the recruitment of coactivator or corepressor proteins to either up- or 
down-regulate target genes under the control of GREs.  The cortisol-GR complex also has the 
ability to modulate transcription factors in other pathways, such as the inflammatory and 
immune pathways (De Bosscher et al., 2003; Rhen and Cidlowski, 2005).  Glucocorticoid 
receptors can also exert non genomic effects where they can rapidly regulate other signalling 
pathways, such as the mitogen-activated protein kinase (MAPK) and P13K/Akt signalling 
pathway (Ayroldi et al., 2012; Hafezi-Moghadam et al., 2002; Kharwanlang and Sharma, 
2011). 
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Aldosterone is the mineralocorticoid secreted by the zG of the adrenal cortex.  Its role is in 
controlling electrolyte and water balance via the kidneys to maintain optimal blood pressure.  
However, aldosterone does not act exclusively in the kidneys.  It also acts on the CNS and the 
cardiovascular system to maintain blood pressure (Cannavo et al., 2018; Connell and Davies, 
2005; Gomez-Sanchez, 1997; Huang and Leenen, 2011; Ren et al., 2019).  The main control 
of aldosterone is by angiotensin II (Ang II) and potassium (K+) and to a lesser extent ACTH 
and Vasopressin (VP)  (El Ghorayeb et al., 2016; Muller, 1987; Quinn and Williams, 1988) 
but many other factors have been implicated, such as ouabain, a toxin derived from 
Acokanthera schimperi and Strophanthus plants (Huang and Leenen, 2011).  Aldosterone 
production can be inhibited by dopamine and atrial natriuretic peptide (ANP) (Cannavo et al., 
2018; Kohzuki et al., 1989; Mc Kenna et al., 1979). 
 
Ang II stimulates aldosterone production in the zG via the angiotensin 1 receptor (AT1), which 
is a GCPR coupled to Gαq.  On stimulation of the AT1 receptors, phospholipase C is released 
to stimulate protein kinase C (PKC) activation by the increase in the production of inositol 
1,4,5-triphosphate (IP3) and 1,2-diacylglycerol (DAG).  A rise in IP3 increases intracellular 
free calcium which in turn leads to the phosphorylation and activation of transcription factors 
such as activating transcription factors 1 and 2 (ATF), and cAMP response element binding 
protein (CREB) via calcium/calmodulin-dependent protein kinases (Hunyady and Catt, 2006).  
This results, within minutes, in binding of the transcription factors to cis-acting elements in the 
promoter of the CYP11B2 gene.  Ang II and K+ increases the synthesis of neuronal growth 
factor induced clone-B (NGFI-B) to upregulate CYP11B2 expression.  Furthermore, Ang II 
and K+ work synergistically with ATF/CREB to increase CYP11B2 expression. CRE and 
NBRE (NGFI-B response element) are important in aldosterone production as mutations in 
these response element regions result in a 70% and 40% reduction in CYP11B2 promoter 
responsiveness, respectively.  Mutations in both  CRE and NBRE result in the complete 
inability of AngII or K+ to induce expression of CYP11B2 (Nogueira and Rainey, 2010; 
Nogueira et al., 2009).  Chronic Ang II stimulation leads to hypertrophy and hyperplasia of the 
zG with increased production of aldosterone via increased CYP11B2 gene expression.   
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Aldosterone production is also stimulated by increased extracellular potassium concentration, 
independent of the RAAS.  This is achieved by cell membrane depolarization and activation 
of voltage-dependent L- and T- type Ca2+ channels, resulting in a rise in extracellular calcium 
levels.  This in turn activates calmodulin dependent kinase resulting in activation of 
transcription factors such as CREB to promote CYP11B2  gene expression (Nanba et al., 2015; 
Spat and Hunyady, 2004; Spät et al., 2016).  ACTH exerts its main effects on glucocorticoid 
production in the zF but does have an effect on aldosterone production.  Acutely, ACTH 
increases aldosterone production via cAMP pathways (Cozza et al., 1990) but chronically, it 
appears to suppress aldosterone levels (Aguilera et al., 1996).  Further evidence is that ACTH 
receptor knockout mice are aldosterone insufficient, although this is not seen in patients with 
mutations in the ACTH receptor (Chida et al., 2009; Novoselova et al., 2019). 
 
The action of aldosterone is initiated upon binding to mineralocorticoid receptors (MR) which, 
like GRs, are steroid receptors located in the cell cytosol.  In the cytosol, unliganded MR is 
part of a multiprotein complex, including heat shock protein 90 (Hsp90) and immunophilins 
(Faresse et al., 2010).  Aldosterone binding to MR leads to dissociation of the MR to enable 
translocation of the receptor to the nucleus where it homodimerises and acts as a transcription 
factor (Couette et al., 1998).  Within the nucleus, the complex binds to steroid responsive 
elements in the promoter leading to an upregulation or downregulation of aldosterone 
responsive target genes.  The complex can also act indirectly via other transcription factors to 
bind target DNA through a process known as transcription interference or synergy (Karin, 
1998).  Sgk1 (serum/glucocorticoid regulated kinase isoform 1) is a serine threonine kinase 
that activates sodium channels together with ENaC (epithelial sodium channel) to promote 
resorption of sodium in the distal renal tubules and is a well-established example of an 
aldosterone target gene (Connell and Davies, 2005; Wulff et al., 2002).  
 
Glucocorticoid and mineralocorticoid can bind to the MR with equal affinity but aldosterone 
is present in circulation at one hundredth of the concentration of cortisol.  To allow aldosterone-
specific effects, type 2 11β-hydroxysteroid dehydrogenase is expressed in target tissues to 
convert cortisol to the inactive form cortisone (or corticosterone to 11-dehydrocorticosterone 
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in rodents), hence favouring binding of aldosterone (Lombes et al., 1994; Odermatt et al., 
2001). 
 
Adrenal androgens, produced in the zR in primates, are known as the C19 steroids and consist 
mainly of dehydroepiandrosterone (DHEA) and its sulphated metabolite DHEA-S.  DHEA and 
DHEAS are precursors of oestrogen and testosterone production.  Other adrenal androgens, 
found in smaller quantities, include androstenedione (A4), androstenediol and 11ß-
hydroxyandrostenedione (11OHA) (Rege et al., 2013).  Adrenal androgen production begins 
around the age of 6-8 years at a stage known as ‘adrenarche’, with an expansion of the zR 
(Labrie et al., 2005).  Adrenal androgens are produced and secreted in large quantities through 
ACTH stimulation and released into the bloodstream.  ACTH binds to MC2R and activates 
cAMP/PKA dependent pathways to increase STAR, which in turn delivers cholesterol to the 
mitochondria for DHEA production (Clark and Stocco, 1997; Hammer et al., 2005; Prough et 
al., 2016).  In women, DHEA/DHEA-S is synthesised mostly in the adrenal cortex and some 
in the ovary.   There is also de novo DHEA/DHEA-S synthesis in the brain (Maninger et al., 
2009).  In men, approximately a quarter of circulating DHEA is produced in the testes and 
adrenal DHEA/DHEA-S provides 50% of all androgens.  In premenopausal women, 75% of 
oestrogens are derived from DHEA/DHEA-S, whereas this is 100% in post-menopausal 
women (Kroboth et al., 1999; Labrie et al., 2005; Maggio et al., 2015).  DHEA-S is readily 
converted back to DHEA by sulfohydrolases.  ACTH is known to be the main control in the 
production of DHEA but whether alternative factors exist or how this system is regulated 
remains unclear (Kempná and Flück, 2008).   
 
 
1.5 The Renin Angiotensin Aldosterone System 
 
The renin-angiotensin-aldosterone system (RAAS) is vital in maintaining a normal blood 
pressure through sodium control (Hall et al., 1990).  Renin is released from the juxtaglomerular 
cells of the kidney into the bloodstream in response to a reduction in renal afferent arteriole 
pressure (ie renal blood flow) and low plasma sodium concentration.  Renin is an aspartyl 
protease that cleaves angiotensinogen (produced in the liver) to form the decapeptide, 
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angiotensin I (Ang I). Ang I itself has been shown to stimulate catecholamine release, increase 
systemic arterial pressure and induce thirst (Miller, 1981). More recently,  Angiotensin II (Ang 
II), generated from the cleavage of Ang I by Angiotensin-converting enzyme (ACE), has been 
shown to be the main stimulus for thirst and acts to facilitate sympathetic neurotransmission 
in noradrenaline production via neuropeptide Y, resulting in hypertension (Byku et al., 2010; 
Westfall et al., 2013). 
 
ACE, an enzyme found on the surface of predominantly lung but also kidney epithelium, then 
cleaves Ang I to produce the octapeptide angiotensin II (Ang II).  Ang II is the physiologically 
active component and binds to Ang II type I and II receptors (AT1 and AT2).  It acts directly 
on the AT1 receptors in the zG of the adrenal gland to stimulate the production of aldosterone, 
which promotes active reabsorption of sodium in the distal tubule of the kidney nephron by 
transcriptionally upregulating SGK1 (serum- and glucocorticoid-induced kinase-1) which 
causes translocation of the ENaC sodium channel to retain sodium (Chen et al., 1999; Shigaev 
et al., 2000).  SGK1 has also  been shown to be recruited by GILZ1 (glucocorticoid-induced 
leucine zipper protein-1) to form a ENaC-regulatory complex that stimulates ENaC surface 
expression and activity through further stabilisation of SGK1 by GILZ1 (Soundararajan et al., 
2010). 
 
Independent of its effects on aldosterone production, Ang II is also a potent vasoconstrictor of 
arteriole smooth muscle.  Furthermore, Ang II has been shown to act directly on angiotensin 
II type 1 (AT1) receptors in the proximal tubule to stimulate sodium resorption and alter 
glomerular filtration rate (Crowley et al., 2006; Lavoie and Sigmund, 2003; Ploth and Gabriel 
Navar, 1979).   Aldosterone too has a direct effect on the vasculature, causing remodelling 
(Pacurari et al., 2014) as well as nongenomic vasoconstriction through activation of 
phospholipase C and nitrous oxide release (Arima Shuji et al., 2004). 
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1.6 Signalling pathways in the developing adrenal cortex 
 
Two key signalling pathways that are known to be involved in adrenal development are the 
hedgehog (Hh) and Wingless-related integration site (Wnt) pathways.  However, signalling 
pathways involved in zonation and differentiation are less clear.  Other factors that are 
important in adrenal development include WT1 (Wilm’s tumour 1), SF-1 (steroidogenic factor 
1) and DAX-1 (dosage-sensitive sex reversal, adrenal hypoplasia critical region, on 
chromosome X, gene 1).  There is also evidence that ACTH signalling has a role in 
stem/progenitor cell regulation as well as cortex zonation and maintenance.  
 
1.6.1 The Hedgehog Signalling Pathway 
The hedgehog (HH) signalling pathway has 3 hedgehog proteins: Desert hedgehog (DHH), 
Indian hedgehog (IHH) and Sonic hedgehog (SHH).  Dhh, Ihh and Shh are vertebrate 
homologues of the Drosophila Hh gene and are involved in germ cell development, bone 
development and organ development/stem cell maintenance respectively (Bitgood et al., 1996; 
Vortkamp et al., 1996).  
 
The Hh gene was first discovered in the fruit fly, Drosophila melanogaster (Nüsslein-Volhard 
and Wieschaus, 1980).  The HH proteins are produced in the endoplasmic reticulum as 
precursor proteins that are 45 kDa in length with a 20 kDa amino-terminal (HH-N) and a 25 
kDa carboxy-terminal (HH-C).  Cholesterol and a palmitoyl moiety is then added to HH-N, to 
allow HH signalling (Chamoun et al., 2001; Etheridge et al., 2010; Farzan et al., 2008). 
 
For the HH pathway to activate, HH ligands bind to Patched (PTCH), a 12-pass transmembrane 
receptor, which then relieves PTCH’s repression of Smoothened (SMO), another 7-pass 
transmembrane G protein-coupled receptor (GPCR) and the HH pathway signal transducer 
across the plasma membrane (Figure 1.3).  This allows for SMO to be phosphorylated and 
activated by Casein kinase 1a (CK1a ) and GPCR kinase 2 (GRK2) (Chen et al., 2002, 2011; 
Pietrobono et al., 2019; Wilson et al., 2009).  In the absence of Hh, Smo is repressed and Gli2 
and Gli3, GLI (glioma-associated) transcriptional factors, which are a family of zinc finger 
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transcription factors, are proteolytically cleaved to form repressors which inhibit expression of 
Hh regulated genes.  There are 3 GLI genes in mammals; GLI1, GLI2 and GLI3.  In the 
presence of activated SMO, are no longer cleaved to form the repressive forms and full length 
GLI2 can act as a transcriptional activators and induce expression of Gli1 which is the primary 
transcription factor for activation of transcription of HH target genes (Chen et al., 2011; 
Pietrobono et al., 2019).  As Gli1 is only expressed in cells receiving a Hh signal, its presence 
is used as a marker of HH signalling pathway activation (Gupta et al., 2010; Vokes et al., 
2007). 
 
HH pathway can be manipulated with agonists and antagonists by changing the conformation 
of SMO.  HH pathway agonists include purmorphamine and smoothened agonist (SAG) and 
its main antagonist is cyclopamine (Wang et al., 2009).   
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Figure 1.3 Hedgehog (Hh) signalling pathway 
(A) In the absence of HH ligand, PTCH (Patched) remains in the cell membrane and represses 
SMO (Smoothened) activity. As a result, GLI undergoes proteasomal cleavage, resulting in the 
repressor form (GLIR) being translocated into the nucleus.  No HH target gene translation 
occurs. (B) Upon HH ligand binding, PTCH is displaced from the cell membrane and SMO is 
activated and accumulates in the primary cilium.  SMO activation leads to a signalling cascade 
to allow for translocation of activated GLI (GLIA) into the nucleus and HH target genes are 
expressed. 
 
 
 
The HH signalling pathway has been identified to play a major role in adrenal development 
and the maintenance of a subcapsular stem cell population of the adrenal gland, that are SHH 
positive (King et al., 2009).  Shh null mice are non-viable, dying of severe developmental 
defects (Chiang et al., 1996; Stone et al., 1996). Shh is detected from E11.5 in mice, possibly 
initiated by Sf-1 expression and sits in the subcapsular region of the adrenal cortex (King et al., 
2009).  Shh co-localises with Sf-1 in the subcapsular region only in non-steroidogenic cortical 
cells.  Conditional Shh null mice in which Shh is knocked out from steroidogenic tissues, 
including the adrenal, by cre recombinase under the control of the Sf-1 promoter, have adrenal 
hypoplasia where normal function and zonation is maintained but with reduced proliferation 
and a significantly thinner adrenal capsule (Ching and Vilain, 2009; King et al., 2008).  This 
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indicates that the role of Shh is in cell proliferation and maintenance of the adrenal cortex 
stem/progenitor cells rather than initiation of cell differentiation and population of the separate 
cortical zones (Huang et al., 2009; Laufer et al., 2012).  
 
Shh is expressed in the subcapsular region, whereas its receptor, PTCH and activated 
transcription factor GLI1 are located in the capsule (King et al., 2009).  Studies using Gli1-Cre 
recombination and Shh LacZ reporter allele performed by King et al., identified a dual lineage 
model of adrenal development (a primary and secondary lineage).  They showed that the cells 
of the primary lineage are SF1 positive and derived from the coelomic epithelium The 
secondary lineage cells are SF1 negative and of mesenchymal origin. The primary lineage cells 
then initiate Shh expression to convert neighbouring secondary lineage mesenchymal cells to 
become steroidogenic cells and this is achieved through Shh signalling (King et al., 2009).  
This correlates with the fact that Shh KO adrenals are smaller but functional (Ching and Vilain, 
2009).  
 
 
1.6.2 WT1, DAX1 and ACTH signalling 
The Wilm’s tumour suppressor gene 1 (Wt1) is one of the earliest genes expressed within the 
AGP and with another transcriptional co-factor Cited2 (CREB-binding protein/p300-
interacting transactivator, with ED-rich tail, 2) has been shown to activate Sf-1 expression.  It 
has been shown that in Wt1 KO mice, there is no Cited2 or Sf-1 expression  (Val et al., 2007; 
Wilhelm and Englert, 2002).  SF-1 is an orphan nuclear receptor and is a transcriptional 
regulator of genes encoding steroidogenic enzymes (Luo et al., 1995).   After activation of SF-
1 and separation of the AGP, the adrenocortical cells lose Wt1 expression, while the gonadal 
primordium retains both Sf-1 and Wt1 expression.  Bandiera et al., showed that overexpression 
of Wt1 blocks the differentiation process into steroidogenic cells.  They generated mice that 
allowed Cre-mediated activation of WT1. Specifically, they studied 2 isoforms of WT1 
generated through alternative splicing of exons 9 and 10 to generate an isoform that includes 
or excludes three critical amino acids (lysine, threonine and serine) between the zinc fingers 3 
and 4. These isoforms were named WT1+KTS or WT1-KTS. The mice generated in this way 
had WT1 activation in a  tissue specific manner (Bandiera et al., 2013; Barbaux et al., 1997; 
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Bor et al., 2006; Hastie, 2017).  Both isoforms are important in development, as global KO 
mice of either isoform die in utero (Hammes et al., 2001). The WT1-KTS isoform is a 
transcriptional regulator and has a high affinity for DNA (Bickmore et al., 1992) whereas the 
WT1+KTS preferentially bind to RNA (Caricasole et al., 1996).  The WT1+KTS mice had 
normal adrenal architecture and the WT1-KTS mice had small adrenal glands with abnormal 
morphology.  Further analysis of these glands showed a reduction in the size the gland but the 
zonation and function of the cortex was maintained except for a dramatic reduction of the X-
zone.  Lineage experiments with WT1 and GLI1 E18.5 embryos demonstrated only partial 
overlap of expression of these two genes and that WT1 and GLI1 expression are likely to 
denote a different subpopulation of cells within the adrenal capsule.   Further experiments on 
adult Wt1:Cre-ERT2 mice, activated with tamoxifen, showed that at 7 months after tamoxifen 
injection, a group of GFP labelled cells retained WT1 expression and remained within the 
adrenal capsule whilst many of the other cells that have migrated into the cortex have lost WT1 
identity and gained steroidogenic features with SF1, AKR1b7 and 3βHSD2 expression 
(Bandiera et al., 2013).  
 
DAX1, an orphan nuclear hormone receptor, co-localises with SF-1 at the urogenital ridge at 
E9.5 (Ikeda et al., 1996).  However, its role in differentiation is unclear and young Dax1 KO 
mouse have enhanced steroidogenesis (Babu et al., 2002).  With aging the adrenal glands of 
these mice becomes dysplastic and they develop adrenal failure, with premature depletion of 
the pool of progenitor cells (Scheys et al., 2011).  The phenotype of older Dax1 KO mice is in 
line with humans with DAX1 mutations who develop X-linked adrenal hypoplasia congenita 
(AHC), resulting in primary adrenal failure (Muscatelli et al., 1994; Scheys et al., 2011).   
 
ACTH signalling is another pathway implicated in adrenal stem cell regulation (El Ghorayeb 
et al., 2016).  The importance of its role in adrenal development was shown in MC2R (Chida 
et al., 2007) and Mrap knockout mice, which both show a significantly reduced adrenal gland 
with a thickened adrenal capsule. The absence of ACTH signalling in these mice led to an 
expansion of the capsular stem cell niche.  The subcapsular cells and throughout the cortex 
were Shh, Wnt4 positive. A proportion co-expressed with CYP11B2 staining pointing to zG 
status (Novoselova et al., 2018).  ACTH signalling in the adrenal gland has been shown  to 
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repress the WNT/b-catenin pathway, via cAMP/PKA activation, for zF conversion by lineage 
conversion (Drelon et al., 2016a).  The Mrap KO mice has an intact functional zG but an absent 
zF and a concentric zone between the zG and medulla that are negative for Cyp11b1, Cyp11b2 
and 20-aHSD.  These cells were WNT4/b-catenin positive but not for the downstream targets 
of WNT signalling, namely Lymphoid enhancer factor (LEF1) and Disabled homolog 2 
(DAB2), suggesting that these cells may have never had or lost their zG identity (Novoselova 
et al., 2019, 2018). 
 
1.6.3 The Wnt Signalling Pathway  
WNT signalling is known to be involved in development, cell fate specification and 
differentiation and stem cell maintenance (Logan and Nusse, 2004).  WNT signalling takes 
place via canonical and non-canonical pathways.  The canonical pathway regulates β-catenin, 
which is a transcriptional co-activator.  In the absence of WNT signalling, the amino terminal 
region of β-catenin is bound by the destruction complex which includes the tumour suppressors 
Axin and adenomatous polyposis coli (APC) and kinases casein kinase 1β (CK1β) and 
glycogen synthase kinase-3β (GSK-3β). β-catenin is sequentially phosphorylated by CK1β and 
GSK-3β, which creates a substrate for the E3 ubiquitin ligase β-TrCP, also part of the complex. 
The ubiquitinated molecule is then degraded by proteasomes. This process is essential in the 
maintenance of a low level of β-catenin to prevent activation of WNT target gene transcription, 
which is under the repressive influence of the T cell-factor/lymphoid enhancer factor 
(TCF/LEF) and Groucho/TLE co-repressor complex.  During WNT signalling, the ligand binds 
to Frizzled, (Fz), a GPCR.  Fz also interacts with the transmembrane proteins LRP5 or LRP6 
(low density lipoprotein receptor related protein) which acts to further stabilise the complex. 
This complex then recruits dishevelled (DVL), which inhibits the phosphorylation of β-catenin 
by GSK-3β, allowing β-catenin to dissociate from the destruction complex.  This process will 
lead to an accumulation of free β-catenin in the cytoplasm which then translocates into the 
nucleus.  Once within the nucleus, β-catenin, a co-activator, binds with TCF/LEF displacing 
the co-repressor complex, thus enhancing the expression of WNT target genes (El Wakil and 
Lalli, 2011; Huang and He, 2008; Zeng et al., 2008). 
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The non-canonical pathway of WNT does not involve β-catenin and is known as the WNT/JUN 
N-terminal kinase (JNK) or WNT/calcium pathway.  The endogenous antagonists to this 
pathway are Frizzled related proteins (sFrps) which binds to WNT proteins (Kawano and 
Kypta, 2003) and DKK, part of the Dickkopf family of secreted proteins, which inhibit WNT 
signalling by binding to the LRP5/6 co-receptors (Niehrs, 2006; Rao and Kuhl, 2010). 
 
In the mouse adrenal cortex, WNT4 and β-catenin are seen in the adrenocortical primordium 
(AP) at E11.5 (Heikkila et al., 2002) and E12.5 (Kim et al., 2008) respectively, whereas Sf-1 
is expressed in the urogenital ridge at E9.5 (Parker and Schimmer, 1997) and remains 
expressed in the AP after its separation from the gonads (Ikeda et al., 1994).  As the mouse 
develops, β-catenin expression, which initially overlaps with Sf-1 expression throughout the 
adrenal cortex, becomes exclusively subcapsular by E18.5 (Kim et al., 2008).  Complete β-
catenin KO is embryonically lethal therefore conditional KO models were used to study the 
adrenal gland instead (Haegel et al., 1995; Kim et al., 2008).  In a partial adrenal β-catenin KO 
mouse model, where β-catenin is deleted in Sf-1 expressing cells, the adrenal glands were 
aplastic by E18.5 with depletion of adrenocortical cells as the mice aged. β-catenin and Sf-1 
have been shown to act in synergy within the cortex to activate target genes (Gummow et al., 
2003; Mizusaki et al., 2003), suggesting that β-catenin may have a role in steroidogenesis.   
 
WNT 4 appears to be a key factor in cortical differentiation and zonation, especially in the zG, 
where it is located and functionally active.  Wnt4 mutant mice have reduced Cyp11b2 and Dlk1 
expression and profoundly lowered aldosterone production.  Wnt 4 is present in the mouse 
adrenal from E11.5 but its role in development is less well defined (Heikkila et al., 2002).  
WNT 4 also plays a significant role in humans, as a loss of WNT 4 function leads to SERKEL 
syndrome, with organ dysgenesis including the adrenals (Mandel et al., 2008).  Recently, 
RSPO3 (R-spondin-3, which activates the canonical WNT signalling pathway) appears to play 
a key role in initiating adrenal progenitor cell differentiation and possibly cortical zonation.  
RSPO3 binds to LGR receptors in the adrenal capsule and activates β-catenin signalling to 
determine and maintain glomerulosa cell fate throughout life.  Upon activation of the pathway 
via WNT4, Shh is activated to initiate steroidogenesis via Gli1.  Without RSPO3, SHH 
signalling is not present, resulting in impaired adrenal growth and inability to maintain the zG 
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as well as a reduction in Cyp11b2 expression and ultimately decreased aldosterone production 
(Vidal et al., 2016).  The Wnt/b-catenin is also dependent on ZNRF3 (zinc and ring finger 3) 
for adrenal homeostasis. Basham et al., demonstrated that  Znrf3 is expressed beneath the 
Rspo3 expressing cells, throughout the adrenal cortex and that the loss of ZNRF3 results in 
adrenal hyperplasia, favouring the zF phenotype (Basham et al., 2019).        
 
Studies on the WNT pathway show that WNT signalling, unlike SHH, may have a contribution 
to adrenal cortex zonation. In the adrenal ß-catenin KO mouse model, where only 50% of ß-
catenin was knocked out in adrenocortical cells,  adrenal development continued as normal at 
birth but the adrenal began to fail after birth with progressive cortical thinning, reduced 
steroidogenic capacity and a loss of progenitor cells (Kim et al., 2008, 2009).  On the other 
hand, exaggerated increase in WNT pathway signalling has recently been shown to cause over 
expansion of the zG and hyperaldosteronism, indicating a direct effect of WNT signalling on 
the zG (Berthon et al., 2010).  
 
WNT/b catenin is also able to inhibit zF differentiation suggesting that it promotes progenitor 
cells to differentiate into zG cells rather than zF cells (Walczak et al., 2014).  It has been shown 
that PKA stimulation can decrease ß-catenin activation and can be a driver of WNT inhibition 
in the zF to allow zF differentiation (Drelon et al., 2016a). 
 
PKA activation has been shown to be important in cell conversion from zF to zR, via lineage 
conversion of the innermost zF cells.  This was achieved by the creation of a constitutive PKA 
activation model with genetic deletion of Protein Kinase cAMP-Dependent Type I Regulatory 
Subunit Alpha (Prkar1a).  This lineage conversion appears to be sexually dimorphic: testicular 
androgens antagonise PKA to increase WNT signalling and delay adrenocortical cell turnover 
and zR formation, whereas mice with gonadectomies resulted in zG like formation and 
hypercortisolism (Dumontet et al., 2018).  In females, adrenocortical cell turnover was 3-fold 
higher than males and females have additional stem/progenitor compartments in the adrenal 
capsule (Grabek et al., 2019). 
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Another inhibitory effect of WNT signalling on the zF can be seen with Mc2r expression, 
which  has been suggested to be important in zF zonal patterning (Drelon et al., 2016a).  There 
is Mc2r and Mrap expression throughout the rat adrenal cortex, with weak expression in the 
zG and higher expression in the zF.  Its principal site of action is in the zF to generate 
glucocorticoids in response to ACTH (Gorrigan et al., 2011; Novoselova et al., 2019).  
However, in the acute setting, ACTH is known to stimulate aldosterone production and can 
also stimulate DHEA production in adrenal cells (Clark et al., 2016; El Ghorayeb et al., 2016; 
Funder, 2016).  Interestingly, as the zG has low levels of StAR and Cyp11b1, aldosterone 
production via ACTH is speculated to be from cells within the zF that become zG cells and 
migrate to the zG to function (Vinson, 2003).  In the rat adrenal gland Mrap and Mc2r are 
expressed in the UZ (Gorrigan et al., 2011), pointing to a role in progenitor cell regulation. 
Mc2r KO mice have an atrophied zF but a histologically normal zG, indicating that in the 
absence of ACTH signalling the zG alone cannot sustain a zF phenotype or produce 
corticosterone (Chida et al., 2007).  In humans, MC2R and MRAP mutations result in familial 
glucocorticoid deficiency (FGD).  FGD patients have an atrophied zF and require lifelong 
glucocorticoid replacement but is not mineralocorticoid deficient (Clark and Weber, 1998).  
 
More recently, the histone methyltansferase Enhancer of Zeste Homolog 2 (EZH2) have been 
shown to have a role in adrenal gland zonation and development (Drelon et al., 2016b). 
Targeted adrenal inactivation of Ezh2 in mice through the use of Sf1Cre showed adrenal 
hypoplasia with primary glucocorticoid deficiency and high ACTH levels and reduced zF 
differentiation.  Aldosterone production appeared normal in females but low in males (Mathieu 
et al., 2018).     
 
Transmembrane E3 ubiquitin ligase zinc and ring finger 3 (ZNRF3) is another novel factor 
implicated in adrenal gland development and zonation. Adrenal specific loss of Znrf3, driven 
by Sf1Cre, resulted in adrenal hyperplasia with the expansion of the zF, induced a moderate 
activation of Wnt/ß-catenin signalling, maintaining the inner cortex histologically and 
functionally (Basham et al., 2019).  
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1.7 Bone morphogenetic proteins (BMPs)  
 
Bone morphogenetic proteins (BMPs) were first identified in 1965 by Urist whilst 
investigating rat bone and cartilage formation (Urist, 1965). BMPs are members of the 
Transforming Growth Factor beta (TGF-β) family of cytokines that have been shown to be 
involved in a multitude of processes including the regulation of growth, differentiation and 
chemotaxis (Chang et al., 2002; Nohe et al., 2004; Xiao et al., 2007).  They are also involved 
in the mediation of programmed cell death and apoptosis (Chen et al., 2004), as well as the 
regulation and maintenance of stem cells (Munoz-Sanjuan and Brivanlou, 2002; Ying et al., 
2003).   
 
Many Bmp knockout rodent models show disruption in development, such as heart defects and 
limb shortening.  BMPs have been linked with many types of cancers (Bach et al., 2017; 
Thawani et al., 2010; Zhang et al., 2016).  Within the adrenal gland, BMPs, especially BMP4, 
have been shown to be expressed in adrenocortical cells (Farnworth et al., 2006a, 2006b; 
Vinson, 2016) and to affect steroidogenesis, by decreasing DHEA, DHEAS and 
androstenedione production (Rege et al., 2015).   
 
There is evidence of BMP crosstalk with other signalling pathways.  For example, BMP 
regulation can have an effect on Shh induced proliferation (Bhardwaj et al., 2001).  Shh and 
BMPs are also known to co-expressed at many sites (Bitgood and McMahon, 1995).  BMPs 
interact with the Wnt pathway and may be involved in many other biological processes 
(Hiyama et al., 2011; Perez et al., 2011).  BMPs can act as morphogens as demonstrated in 
drosophila wing patterning (Nellen et al., 1996).  In humans, there is evidence of a 
morphogenic effect in the growth plates of bones (Nilsson et al., 2007). 
 
BMP is the mammalian homologue of the drosophila morphogen decapentaplegic (Dpp).  
There are more than 20 BMPs discovered so far and they are further subdivided into groups 
according to structure and amino acid similarity.  BMPs are distinct within the TGF-ß 
superfamily as they have seven cysteine residues, of which 6 build a cysteine knot and the 
seventh is used for dimerization (Allendorph et al., 2011; Hinck and Huang, 2013; McDonald 
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and Hendrickson, 1993).  BMPs are synthesised as large precursor molecules and are secreted 
proteins.  BMPs have a signal peptide, pro-domain and a mature peptide.  The signal peptide 
is cleaved first at a dibasic site, releasing the C-terminal active domain.  This is then 
glycosylated and dimerised.  The pro-domain is then cleaved and the mature peptide is secreted 
following proteolytic cleavage to yield a carboxy-terminal mature protein dimer that is 
bioactive.  The mature BMP is secreted as a homodimer or heterodimer (formed with other 
members of the BMP family) (Hogan, 1996; Xiao et al., 2007).     
 
All BMP ligands bind to serine-threonine kinase receptors forming a hetero-oligomeric 
complex of type I and II receptors (Figure 1.4) (Kawabata et al., 1998).  In mammals, there are 
seven type I and five type II receptors.  Of the seven Type I receptors (ALK1-7) for the TGF-
β family of ligands, only three bind to BMP: type 1A BMP receptor (BMPR1A or ALK3), type 
1B BMP receptor (BMPR1B or ALK6) and type 1A activin receptor (ActR-1A or ALK2).  
Three out of four Type II receptors for the TGF-β family interact with BMPs: type 2 BMP 
receptor (BMPR2), type 2 activin receptor (ActR2A) and type 2B activin receptor (ActR2B) 
(Wang et al., 2014).  Both type I and type II receptors have a short extracellular domain with 
several conserved cysteine residues and a single transmembrane domain.  The intracellular 
domain contains a serine-threonine region (Yamashita et al., 1996).  When BMPR2 receptors 
bind with a BMP ligand, activation of  the BMPR1 receptor occurs via phosphorylation, 
forming a heterotetrameric complex, allowing signal transduction to the nucleus (Blanco Calvo 
et al., 2009).  Although BMP receptors are limited in type, the diversity of BMP function is 
immense.  This diversity is due to different affinities of the BMPs to the receptors and that 
different cell types express the receptors and downstream components in different quantities 
and combinations (Kawabata et al., 1998).   
 
The Smad family of transcription factors are responsible for signal transduction and the family 
is divided into three distinct groups.  Upon activation, a type I receptor will then phosphorylate 
the R-Smads (receptor-regulated Smads) of which Smad 1, 5 and 8 act in the BMP signalling 
pathway.  The R-Smad undergoes phosphorylation and is released into the cytoplasm.  The 
phosphorylated R-Smad is then recruited by the only Co-Smad (common Smad), Smad 4, to 
form the Smad complex.  This complex is then translocated into the nucleus and upon binding 
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with co-activators or co-repressors modulates expression of downstream target genes (Wang 
et al., 2014).  
 
Smad 6 and Smad 7 are I-Smads (inhibitory Smads) (Nakao et al., 1997; Zhang et al., 1996) 
and act by stably binding to type I receptors and preventing phosphorylation of the R-Smads, 
hence halting the pathway (Imamura et al., 1997).  I-Smad is also able to interact with Smurf-
1 (Smad ubiquitin regulatory factor 1) and smurf-2 to modulate Smad proteins for proteosomal 
and lysosomal degradation (Kavsak et al., 2000; Murakami et al., 2003; Xiao et al., 2007).   
 
 
 
 
Figure 1.4 Bone morphogenetic protein signalling pathway 
Upon binding of Bone morphogenetic protein (BMP) ligands with its receptors, BMPRI (Bone 
morphogenetic protein Receptor I) and BMPRII (Bone morphogenetic protein Receptor II), 
BMPRII phosphorylates and activates BMPRI. Phosphorylated BMPRI subsequently 
phosphorylates receptor-activated Smad proteins (R-Smads).  The R-Smad will then associate 
with common mediator-Smad (Co-Smad) and enter the nucleus to regulate promoter activity 
by interacting with transcriptional co-activators or co-repressors to positively or negatively 
control gene expression. Endogenous extracellular antagonists (inhibitors), such as noggin, 
bind BMP ligands so it cannot bind with BMP receptors.  Inhibitory Smads (I-Smad) works 
intracellularly to prevent R-smad and co-smad association and hence cannot enter the nucleus 
for target gene expression or repression.     
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Extracellularly, BMPs are regulated by a host of endogenous antagonists, such as follistatin, 
which was originally thought to be activin–binding but increasing evidence reveals that it 
exerts its antagonistic effect by directly binding non-competitively to the BMP-receptor 
complex, forming a trimeric complex (Iemura et al., 1998; Weisinger et al., 2008).  A large 
group of BMP antagonists has been classified according to the size of their cysteine knots: the 
DAN family (eight membered ring) which includes Dan, Cerberus, Coco, Protein related to 
DAN and Cerberus (PRDC), Gremlin, USAG-1 and sclerostin; Twisted gastrulation (tsg) has 
a nine-membered ring; and chordin and noggin form the third group with ten-membered rings. 
They act by direct binding to BMP ligands to form inactive complexes (Avsian-Kretchmer and 
Hsueh, 2004; Yanagita, 2005).  However, there has been a debate about whether USAG-1 and 
sclerostin form a separate group as they are secreted as monomers while many of the others 
form dimers and they do not contain extra cysteine residues to form homodimers (Avsian-
Kretchmer and Hsueh, 2004; Groppe et al., 2002; Kusu et al., 2003).  
 
Below, the individual BMPs discussed are the ones that have been shown to be present in the 
adrenal gland (Inagaki et al., 2006; Johnsen and Beuschlein, 2010; Johnsen et al., 2009; Mitsui 
et al., 2014; Otani et al., 2010; Rege et al., 2015).  BMP3 is not expressed in the adrenal gland 
and has not been shown in published data to play a role in adrenal gland physiology.   
 
1.7.1 BMP3b 
BMP3b and GDF 10 are synonymous terms used for this protein.  BMP3b is located on 
chromosome 10 and encodes a 478 amino acid protein.  It was first identified as a new member 
of the transforming growth factor-beta (TGF-β) in 1995, showing a high similarity to BMP3, 
with 83% amino acid identity in the mature C-terminal region and only 30-35% homology in 
the pro-region.  Together, BMP3 and BMP3b form their own subgroup within the TGFb  
superfamily (Cunningham et al., 1995).    Bmp3b was first cloned from rats in 1996 by the 
Kangawa group in Japan (Takao et al., 1996).  Other studies have shown the importance of 
Bmp3b in brain (Cunningham et al., 1995), skeletal and uterine development (Zhao et al., 
1999).  The same Japanese group was able to clone the human BMP3b gene later on in the 
same year.  The human BMP3b gene is found at chromosome 10q11.22 and spans about 13 
kilobases and has 3 exons and 2 introns.  The precursor protein has 478 amino acids, with a 
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molecular weight of 53,122 Daltons.  By proteolytic cleavage of the precursor protein at the 
putative polybasic proteolytic processing site containing Arg-Arg-Lys, a mature, biologically 
active, BMP3b protein is generated.  This mature protein is 110 amino acids long with one N-
glycosylation site and contains the carboxy-terminal region which has 7 conserved cysteine 
residues.  BMP3b is highly conserved through species as the mature protein is 98% similar to 
rat Bmp3b.  From this original paper, Bmp3b was shown to be expressed in many organs other 
than bone, especially brain, lung, skeletal muscle, pancreas and testes, with little expression in 
the heart and prostate (Hino et al., 1996).   
 
In 1999, Zhao et al., produced a Bmp3b KO mouse model to determine its biological function.  
This mouse was generated by using a targeting construct that replaced endogenous Bmp3b 
exon 2 and 3 with a neo cassette resulting in deletion of the BMP3b C-terminus.  The resulting 
Bmp3b KO mice were all viable with normal reproduction capacity, comparable to wild type 
littermates.  Despite high expression of BMP3b in mouse cerebellum, skeleton and uterus, the 
KO mouse phenotype appeared normal during development of all these organs.  As Bmp3 and 
Bmp3b share 83% similarity, compensatory upregulation and function of Bmp3 was postulated 
to explain the normal development (Zhao et al., 1999).  However, only a few tissues were 
investigated and the adrenal glands were not studied in this animal.  
 
1.7.2 BMP2 
BMP2 is found on chromosome 20 and encodes a 396 amino acid protein.  BMP2 is a potent 
inducer of osteoblastic activity, with the ability to induce all markers of osteoblast activity 
(Cheng et al., 2003) and has been used in its recombinant form for fracture healing (Govender 
et al., 2002; Tsuji et al., 2006).  Bmp2 is essential for development as Bmp2 KO mice is 
embryonically lethal and its expression is found in many other organs such as the heart and 
brain (Zhang and Bradley, 1996).  Within the brain, Bmp2 induces medulloblastoma cell 
apoptosis, which can be blocked by noggin (Hallahan et al., 2003).  Within the adrenal gland, 
it has been reported to have reduced expression in adrenocortical carcinomas (Johnsen et al., 
2009) and overexpression of BMP2 has been seen in rare cases of adrenal myelolipomas 
(Mitsui et al., 2014). 
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1.7.3 BMP4 
BMP4 is a highly conserved protein in evolution.  BMP4 is located on chromosome 14 and 
encodes a 408 amino acid protein.  It is involved in many developmental processes, including 
the development of the dorsal-ventral  axis (in synergy with Shh expression) (Liem et al., 
2000), bone, teeth (Jia et al., 2013), eyes (Bakrania et al., 2008), heart (Jiao et al., 2003) and 
blood (Sadlon et al., 2004). 
 
Within the adrenal gland, Bmp4 is expressed throughout all the zones, with highest expression 
within the zG (Huber et al., 2008; Rege et al., 2015).  However, its function appears to be 
mainly related to androgen production for the zR and regulation of the medulla.  Rege et al., 
overexpressed BMP4 in H295R cells and found that it suppressed C19 steroid synthesis via 
P450c17, resulting in reduction of DHEA, DHEA-S and androstenedione (Rege et al., 2015). 
In the chick embryo, Huber et al., found that Bmp4 was essential in the early induction of 
neuronal and catecholaminergic phenotypes in neural crest cells.  BMP4 appears to augment 
the number of tyrosine hydroxylase (TH) positive cells by inducing TH in TH negative cells 
and not by proliferation, hence it influences cells to become chromaffin cells (Huber et al., 
2008). 
 
1.7.4 BMP5  
BMP5 is within the subfamily of BMPs which include other members BMP2, 6 and 7.  The 
BMP5 gene is located on chromosome 6 in humans and encodes a 454 amino acid protein.  Its 
role includes generation of osteoclasts for bone regeneration (Wutzl et al., 2006) and dendritic 
growth in neurons (Beck et al., 2001).  In the adrenals, it has been shown to have reduced 
expression in adrenocortical carcinoma cell lines (Johnsen et al., 2009).  There is also a reduced 
expression of BMP5 in other cancers including colorectal, pancreatic and non small cell lung 
cancer (Chen et al., 2018; Deng et al., 2015; Virtanen et al., 2011).  However, there is increased 
BMP5 expression in lung adenocarcinoma (Deng et al., 2015).  
 
1.7.5 BMP6 
The BMP6 gene is found on chromosome 6 in humans and it encodes a 513 amino acid protein.  
It is similar to other members of its subfamily in that it will induce all markers of osteoblastic 
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differentiation, as shown in mesenchymal progenitor and osteoblastic cell models 
(C3H10T1/2, C2C12 and TE-85 cell lines) (Cheng et al., 2003).  Bmp6 null mice are viable 
and fertile.  The only defect noted is of delayed ossification of the sternum (Kugimiya et al., 
2005; Perry et al., 2008; Solloway et al., 1998).  Further studies have shown that Bmp6 null 
mice had haemochromatosis where iron is deposited on organs such as the liver (Meynard et 
al., 2009). The KO mice are hyperglycaemic with reduced insulin production due to a decrease 
in pancreatic islet cell number, hence indicating that Bmp6 may have a role in glucose 
regulation in diabetes mellitus.  In support of this, treatment of NOD (Non Obese Diabetic) 
mice or ob/ob (obese/obese) with recombinant Bmp6 (rhBmp6) for 7 days resulted in a 
reduction in glucose levels and improved glucose clearance, lipid profile and increased bone 
volume (Paralkar et al., 2010).   
 
Within the adrenal cortex, BMP6 is linked to aldosterone synthesis.  BMP6 treatment of H295R 
cells augments Ang II induced CYP11B2 transcription and ultimately increases aldosterone 
production by activation of SMAD 1,5,8 through binding to  ALK2/3 with ActRII resulting in 
an enhancement of Ang II induced MAPK activation.  However, BMP6 has no effect on 
potassium-induced aldosterone production (Inagaki et al., 2006).  BMP6 is also found to act 
through receptors of the BMP pathway, namely ALK2, ALK3 and type 2 activin receptors.  
BMP6 is thought to enhance the induction of ERK1/2 phosphorylation by AngII which would 
increase activation of CYP11B2 leading to increased aldosterone production (Inagaki et al., 
2006). 
 
1.7.6 BMP7 
BMP7 is a 431 amino acid polypeptide, with its gene found on chromosome 20. Like BMP5, 
it is able to elicit dendritic growth in rat neurons (Withers et al., 2000) and is also able to induce 
all markers of osteoblastic differentiation (Cheng et al., 2003).  Zeisberg et al., found that the 
presence of Bmp7 can reduce cardiac fibrosis (Zeisberg et al., 2007) and Tseng et al.,  showed 
evidence that Bmp7 can promote differentiation of brown adipocytes and thermogenesis, with 
a potential role in obesity treatment (Tseng et al., 2008).  Bmp7 null mice have severe renal 
and ocular defects (Dudley et al., 1995) as well as impaired skeletal axis and retarded bone 
ossification (Jena et al., 1997).  The adrenals and gonads were observed to be normal though 
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the mice were not viable beyond a maximum of 10 days, with the majority dying at day 1 
(Dudley et al., 1995).  In cases of phaeochromocytoma (tumours of the adrenal medulla), 
BMP7 is overexpressed, resulting in increased cell division and migration (Leinhauser et al., 
2015). 
 
 
1.8 BMP Signalling in the adrenal 
 
There is some evidence of the role of BMP signalling in adrenal steroidogenesis and possibly 
development (Johnsen and Beuschlein, 2010).  However, direct evidence is difficult to gather 
as many animal models that modify the BMP signalling pathway die in utero (Wang et al., 
2014).  In vitro evidence suggests TGFβ1, BMP6, activins and inhibins play a role in 
steroidogenesis in the human adrenocortical cell line, H295R cells (Hotta and Baird, 1986; 
Liakos et al., 2003; Suzuki et al., 2004; Vanttinen et al., 2003).  TGFβ1 inhibits both 
aldosterone and cortisol production via CYP11B2 and CYP11B1 respectively in H295R cells 
as described by Liakos et al., (Liakos et al., 2003).  Suzuki et al., demonstrated that BMP6 can 
stimulate the transcription of CYP11B2 by activating the Smad1/5 pathway through Type I and 
Type II receptors in H295R cells (Suzuki et al., 2004).  Activin A treatment of H295R cells 
inhibited STAR which led to a reduction in CYP17 mRNA expression, resulting in a reduction 
in androstenedione, DHEA, DHEAS and cortisol production (Vanttinen et al., 2003).  
Interestingly, Booroola sheep have a naturally occurring mutation of Bmpr1b gene leading to 
a single amino acid substitution of arginine at amino acid postion 249 to a glutamine residue 
(Q249R). The adrenal glands from these sheep are small, whilst all other organs such as heart, 
liver, lungs and kidneys are normal, suggesting a role for Bmpr1b in adrenal development 
(Fabre et al., 2003; Souza and Baird, 2004; Souza et al., 2001).  
 
1.8.1 Microarray of the rat adrenal cortex  
The involvement of BMPs in adrenal gland development and physiology is further supported 
by unpublished microarray data from the King group. The rat adrenal gland has a natural 
fracture plane between the zG and zF. Two adult male Sprague Dawley rat adrenals were 
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squashed between 2 glass slides which separated the adrenal gland into 2 parts: capsule/zG 
cells and zF/medulla cells (King et al., 2009).  The 4 samples (2 of each section) were snap 
frozen in liquid nitrogen and RNA was extracted and first strand cDNA synthesis was 
performed with primers designed to introduce an RNA polymerase sequence.  This was then 
used to direct RNA synthesis and the cRNA populations were analysed on the rat genome 
Affymetrix RG34A chips.  Data was analysed by comparing the differences in expression in 
the outer and inner zones, with AT1 and tyrosine kinase expression demonstrating the 
successful separation of these zones.   
 
Among the microarray results, Bmp3b, Gdf11, Smad-7 and follistatin-like, Bmpr1a and activin 
receptors along with Shh and Dax1 were all overexpressed in the capsule/zG whereas Bmp2, 
Bmp3, Gdf-8 and Gdf-15 were more highly expressed in the inner zone.  To verify these 
findings, real-time qPCR was performed with each of the BMP components (work performed 
by ex-PhD student Dr. Bakmanidis, Figure 1.5).  The most significant difference was that 
Bmp3b was exclusively expressed in the outer zone and Bmp2 had the biggest difference in 
expression between the 2 zones, being highest in the inner zone.   
 
 
Figure 1.5 Real time qPCR of BMPs in rat adrenals 
Real time qPCR analysis of BMPs in capsular (capsule and zG) and inner zone (zF and 
medulla) cDNA from Sprague Dawley rat adrenals normalised against GAPDH. Inset shows 
end point PCR analysis of BMP3b (B) run on an agarose gel, with GAPDH (G) as a house 
keeping gene. C=capsular zone, IZ = Inner zone.  * p<0.05, ** P<0.01, *** P<0.001 
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1.8.2 Expression of BMPs and BMP pathway components in H295R cells 
In H295R cells, a human adrenocortical carcinoma cell line, the role of BMP6 in aldosterone 
production has previously been published (Inagaki et al., 2006, 2007; Otani et al., 2010; Suzuki 
et al., 2004).  Suzuki et al., showed that BMP6 seemed to augment Angiotensin II-induced 
aldosterone production and act through receptors of the BMP pathway, namely ALK2, ALK3 
and activin type II receptors.  However, BMP6 was not shown to be relevant in potassium 
induced aldosterone production (Suzuki et al., 2004).    
 
The role of BMPs in adrenal development, zonation, steroidogenesis and tumorigenesis is still 
not clearly defined.  Following on from the rat expression data, shown in Figure 1.5, Dr 
Bakmanidis showed that both BMP3b and BMP2 mRNAs were present in H295R cells. The 
receptors for BMP3b and BMP2 were also present. The finding of BMP receptor expression 
in H295R cells is consistent with published data (Inagaki et al., 2006).    
 
Using a luciferase reporter assay containing a promoter driven by a BMP responsive element, 
upstream of luciferase, Dr Bakmanidis showed that BMP3b was able to inhibit the 
transcriptional activity of BMP2 and that BMP3b has no effect on this promoter in the absence 
of BMP2 (Figure 1.6), indicating that there could be a direct suppressive effect of BMP3b on 
BMP2 activity.  Furthermore, Figure 1.7 shows a significant reduction in the mRNA 
expression of BMP2 in H295R cells that have been stably transfected with BMP3b. Together 
these data demonstrated that BMP3b can inhibit both BMP2 expression and activity. 
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Figure 1.6 Transfection of H295R cells with Xvent2-luc 
Xvent2-luc contains a promoter driven by a BMP responsive element, that is activated by 
BMP2, leading to luciferase expression.  ** P<0.01 
Graph taken from work by Dr A Bakmanidis. 
 
 
 
 
Figure 1.7 Real time RT PCR of BMP2 expression in H295R cells following 
Overexpression of BMP3b 
H295R cells were transfected with an empty vector (pIRES) or a vector expressing BMP3b 
(pIRES/BMP3B).  BMP2 expression was measured using real time PCR. * p<0.05 
Graph taken from work by Dr A Bakmanidis. 
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1.9 Adrenocortical tumours and BMPs 
 
1.9.1 Benign adrenal adenomas 
Adrenocortical tumours can be benign or malignant.  Benign tumours, especially adenomas 
that secrete aldosterone are much more common than malignant tumours.   
 
Primary aldosteronism (PA) is a condition where patients classically present with hypertension 
and associated hypokalaemia.  However, hypokalaemia is found less frequently with increased 
screening or following the incidental finding of adrenal nodules on imaging (Sze et al., 2014).  
Other symptoms can include headaches, fatigue, muscle weakness, numbness or paralysis: PA 
thus encompasses a whole array of diagnoses of which some can be cured surgically.  The 
prevalence is thought to be around 10% of hypertensive patients (Douma et al., 2008; Fardella 
et al., 2000; Lim and Morad, 2004; Rossi et al., 2006).  Although benign, it is vital to identify 
these patients early as treatment could potentially be curative or medically controlled to reduce 
cardiovascular morbidity and mortality (Abad-Cardiel et al., 2013; Bunda et al., 2007; Reincke 
et al., 2012; Young, 2008).  Conn’s syndrome is PA with an aldosterone producing adenoma 
(APA) and this type of PA is potentially curable with surgery (Mattsson and Young, 2006).  
Bilateral adrenal hyperplasia (BAH) does not have a distinct mass but the whole adrenal gland 
is involved and these patients will respond well to aldosterone receptor antagonist treatment 
such as spironolactone or eplerenone (Funder et al., 2008; Handler, 2012).  APA and BAH 
account for the majority of PA cases.  The much rarer causes include the familial forms of PA. 
Type 1, also known as glucocorticoid remedial aldosteronism (GRA) follows an autosomal 
dominant pattern and accounts for <1% of PA cases (Chao et al., 2013; Moraitis and Stratakis, 
2011).  In patients with GRA, there is abnormal fusion of CYP11B1 and CYP11B2 genes which 
are located in close proximity to each other on chromosome 8, making the gene responsive to 
ACTH.  As a result, when ACTH is secreted, this abnormal gene is activated to produce 
aldosterone synthase, leading to excess aldosterone production (Lifton et al., 1992; Pizzolo et 
al., 2005).  GRA is usually diagnosed in young patients (<20 yr) with severe and treatment 
resistant hypertension or a haemorrhagic stroke, though some may present with milder 
phenotypes (Gates et al., 1996).  Treatment is with glucocorticoids to suppress ACTH 
production (Ulick et al., 1990).  Type 2 is also autosomal dominant, occurring in families and 
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reported to account for <7% of PA cases. These families may have adrenal glands which 
harbour APAs or BAHs (Funder, 2012; Stowasser and Gordon, 2003).  The newest type, Type 
3 can be sporadic or familial and results in a somatic mutation of the KCNJ5 gene.  This gene, 
found on chromosome 11q24 encodes an inwardly rectifying potassium channel GIRK4.  
Mutation of this gene leads to reduced selectivity of the potassium channel, allowing the entry 
of sodium ions into adrenal cells. This excess sodium influx affects cell membrane potential 
and activates the calcium/calmodulin pathway increasing aldosterone production (Choi et al., 
2011).   
 
Since the discovery of KCNJ5, there has been an explosion of interest in the genetics of APAs 
with the identification of ATP1A1, ATP2B3 and CACNA1D.  These are all somatic mutations 
affecting the ion channels (Na+, K+ and Ca2+), which have a strong biological effect in the zG.  
ATP1A1 is a gene that codes for the a1 subunit of the Na+/K+-ATPase, ATP2B3 codes for the 
plasma membrane Ca2+-ATPase, type 3, and CACNA1D encodes the Cav1.3 channel (calcium 
channel, voltage dependent, L type, a-1d subunit).  KCNJ5 and ATP1A1 mutations has an 
effect on the membrane potential of zG through increased K+, leading to increased sodium and 
hence causing chronic depolarisation of the cell membrane, resulting in the opening of voltage-
dependent calcium channels.  This increased calcium flux will activate the Ca2+ signalling 
pathway and upregulate CYP11B2 expression and hence increase aldosterone biosynthesis 
(Boulkroun et al., 2012; Choi et al., 2011; Williams et al., 2015).  Both ATP2B3 and CACNA1D 
mutations increase intracellular calcium concentration leading to increased aldosterone 
production.  CACNA1D mutations alter segments bordering the channel pore, resulting in 
channel activation and opening at a lower voltage (Azizan et al., 2013; Fernandes-Rosa et al., 
2014).  A large genetic study was carried out by Fernandes-Rosa et al., using samples collected 
in the European Network for the Study of Adrenal Tumors (ENSAT), they found that 54.2% 
of APAs had a somatic mutation.  Of those, KCNJ5 was by far the common mutation identified  
accounting for 38% of cases, similar to other studies indicating its prevalence at around 40% 
(Azizan et al., 2012; Monticone et al., 2012).  This percentage varies depending on ethnic 
background, as in South East Asia cohorts, the proportion of KCNJ5 mutations range from 65-
77%, with a predominance of female patients (Kitamoto et al., 2015; Yamada et al., 2012; 
Zheng et al., 2015).  In the European cohort, 9.3% had CACNA1D, 5.3% ATP1A1 and 1.7% 
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ATP2B3 mutations.  Each of these genes had mutations on various sites.  KCJN5 had mutations 
in p.Gly151Arg (c.451G>A or c.415G>C) and p.Leu168Arg (c503T>G).  CACNA1D had 
multiple mutations with the commonest being p.Gly430Arg (c.1207G>C), p.Phe747Leu 
(c.2239T>C) and p.Val1338Met (c.2248A>T).  The most prevalent mutation in ATP1A1 is 
p.Leu104Arg (c.311T>G).  The two most common ATP2B3 mutations found were 
p.Leu425_Val426del (c.1272-1277delGCTGGT) or pVal426_Val427del (c.1276-
c.1281delGTCGTG) (Fernandes-Rosa et al., 2014).  Attempts have been made to correlate the 
genetic mutation to the morphology of the adrenal cortex and the phenotype of patients.  No 
genotype correlation was found with the zG or zF cellular make up of the adenomas 
(Fernandes-Rosa et al., 2014), though others have reported a more zF like phenotype with a 
KCNJ5 mutation and more zG like in CACNA1D and ATP1A1 mutations (Azizan et al., 2013, 
2012).  In most published cohorts, KCNJ5 mutations are more common in younger females 
(Boulkroun et al., 2012; Lenzini et al., 2015).  It was also reported by Fernandes-Rosa et al., 
that patients with a CACNAD1 mutation have smaller adenomas, whereas other studies have 
shown KCNJ5 mutations have larger adenomas (Azizan et al., 2012; Fernandes-Rosa et al., 
2014; Zheng et al., 2015).  However, there was no difference in the level of aldosterone 
production in the Fernandes-Rosa cohort whereas the other cohort did demonstrate a higher 
aldosterone level. 
 
Another somatic mutation found in APA is CTNNB1, which encodes b-catenin.  Åkerström et 
al., found 5.1% of their 198 APAs had a CTNNB1 mutation.  This mutation alters 
serine/threonine residues in the GSK3b binding domain in exon 3.  The mutation prevents 
phosphorylation, and thus degradation of b-catenin, resulting in aberrant upregulation of Wnt 
signalling (Akerström et al., 2016; Azizan et al., 2013; Tadjine et al., 2008).    More recently, 
there has been interest in ACTH/MC2R as the driver of PA (El Ghorayeb et al., 2016; Funder, 
2016).  
 
1.9.2  Malignant adrenocortical carcinoma 
The incidence of adrenocortical carcinoma (ACC) is estimated to be between 0.5 and 2.0 cases 
per million population.  Most patients are diagnosed at stage II and beyond and the 5 year 
survival drops from 66% in stage I disease to 0% in stage IV (Icard et al., 2001; Sidhu et al., 
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2004).  The pathogenesis of adrenal tumours is not fully understood and treatment options are 
limited and rarely curative.  Gene mutations, such as in IGF II, leads to an overexpression of 
IGF II in ACC (Ilvesmaki et al., 1993).  β-catenin is another key player emerging in ACC.  Its 
relationship with tumourigenesis was first documented in familial adenomatous polyposis coli 
(APC), which result from mutations in the APC gene.  It is now clear that APC mutations will 
also cause an overactivation of the Wnt pathway, leading to ACC (Blaker et al., 2004).  TP53 
is a well-established gene associated with childhood adrenocortical carcinoma in South Brazil, 
where the incidence of ACC is ten times that of the world population (Figueiredo et al., 2006).  
It is a p53 germline mutation where there is an arginine to histidine mutation at codon 337 of 
the TP53 gene with a penetrance of 9.9%.  Childhood ACC are thought to be embryological in 
origin and one of the genes thought to be crucial in adrenal development, SF-1, is 
overexpressed in childhood ACC (Figueiredo et al., 2005).  Other ACC genes investigated 
include MEN1, VEGF, FGF2 and Ras (Libe et al., 2007).  Adrenal tumours are present in 26-
45% of MEN1 cases (Barzon et al., 2001; Burgess et al., 1996; Gibril et al., 2004; Langer et 
al., 2002; Skogseid et al., 1992, 1995).  MEN1 is a gene with an autosomal dominant mutation 
in exon 2 or 10.  The majority of patients have non-functioning or hyperplastic adrenal nodules 
but 2.6-6% do present with ACC (Griniatsos et al., 2011).  Both VEGF and FGF2 are growth 
factors that are overexpressed in ACC.  FGF2 is expressed in the adrenal gland and is a potent 
mitogen.  VEGF upregulation would increase angiogenesis and support tumourigenesis.  The 
involvement of Ras oncogene in human ACC is still unclear with no convincing evidence 
currently (Libe et al., 2007).     
 
 
1.10 BMPs in adrenal tumourogenesis  
The role of BMPs in adrenal tumourigenesis remains under investigation by various groups.  
BMP pathways have been linked to various different cancers (Johnsen and Beuschlein, 2010).  
Mutations in SMAD 4 or BMPR1A is associated with an increased risk of colon cancer (Howe 
et al., 1998; Zhou et al., 2001).  Depending on cell type, receptor presence and receptor affinity, 
BMPs appear to exert different responses and hence the over- or under-expression of BMPs 
can occur in different cancers.  BMP2 and BMP3 are down regulated in colon and prostate 
cancer (Horvath et al., 2004; Loh et al., 2008) but BMP2 and BMP4 are upregulated in lung 
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and colorectal cancer respectively (Langenfeld et al., 2003; Nosho et al., 2005). BMP4 is also 
upregulated in hepatocellular and ovarian cancer (Kallioniemi, 2012) and also plays a role in 
reducing tumour growth in human glioblastomas  (Piccirillo et al., 2006). 
 
Within the adrenal specifically, Beuschlein’s group in Germany found a downregulation of 
BMP2 and BMP5 in adrenocortical carcinomas (Johnsen et al., 2009).  Using ACC cell lines, 
they demonstrated that there was reduced activity of Smad 1, 5 and 8 along with the reduced 
expression of BMP2 and BMP5.  On treating these cells with BMP2 or BMP5, there appeared 
to be a dose and time dependent reduction in cell proliferation and viability, indicating that 
they have a suppressive effect on tumour growth.       
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1.11 Hypothesis and Aims  
 
Understanding adrenal zonation and its impact on steroidogenesis is extremely important to 
understand adrenal function in health and disease.  This understanding could result in the 
development of biomarkers and treatments for adrenal diseases, especially in adrenocortical 
carcinomas where survival remains poor despite advances in medicine.  This could also lead 
to targeted therapy of the signalling pathway or even targeted gene therapy. 
 
In cases of adrenal insufficiency, increased morbidity and mortality exists despite hormonal 
replacement with glucocorticoids. By understanding the process of stem cell differentiation 
and gland maintenance, future treatments could aim to direct pluripotent stem cells to become 
steroidogenic cells hence providing a renewed adrenal gland.  
 
The hypothesis for this thesis is: 
 
BMP3b and BMP2 play an important role in adrenal zonation and steroidogenesis. 
 
The aims of this thesis are: 
1. To demonstrate that BMP3b and BMP2 expression are present in the adrenal gland and 
to elucidate their effect on steroidogenesis in H295R cells 
2. To localise the expression of Bmp3b, BMP2 and its receptors in rodent adrenal glands 
3. To study the effect of Bmp3b and Bmp2 on steroidogenesis in cells and rodent adrenal 
glands 
4. To investigate the role of BMP3b and BMP2 expression in adrenal adenomas and 
carcinomas 
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2 Materials and Methods 
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Laboratory reagents were supplied by Sigma-Aldrich (Poole, UK) unless otherwise stated. 
Chemicals were all certified as analytical grade. Plasticware was purchased from Greiner Bio-
one Ltd (Gloucestershire, UK) unless otherwise stated. Ultra pure water (dH2O) was obtained 
using the Purite Select Analyst HP water purifier, and used when making all solutions. Where 
sterility was required, solutions were autoclaved using a Priorclave TACTROL2 or filtered 
through a 0.2 µm membrane (Nalgene).  
 
 
2.1 General Buffers and solutions 
PBS - 0.2g/L KCl, 0.2g/L KH2PO4 (anhydrous), 8.0g/L NaCl, 1.15g/L Na2HPO4 
(anhydrous), pH 7.4 (Sigma)  
Phenol - Add 10ml of equilibration buffer (10mM Tris pH 10 - Sigma) to 100ml of 
equilibrated phenol (pH6.7) (Sigma) to adjust to pH 7.9. Add 8-Hydroxyquinoline to final 
concentration of 0.1% (v/v). Store in the dark at 4oC.  
3M Sodium Acetate - Dissolve 40.8g of sodium acetate.3H2O in 80ml of H2O. Adjust to 
pH5.2 with glacial acetic acid, make up to a final volume of 100 ml and autoclave.  
TE - 10mM Tris pH 8.0, 1mM Ethylenediaminetetraacetic acid (EDTA) 
TAE (50x) - 2M Tris, 1M acetic acid and 50mM Na2EDTA (pH 8.3 at 1x conc.)  
6X loading dye - 0.5mM EDTA, 40% sucrose (v/v), 0.25% (v/v) Orange G.  
RNAase free dH2O - Diethyl pyrocarbonate (DEPC) was added to dH2O to a final 
concentration of 0.1 % (v/v) and incubated overnight in a fume cupboard prior to 
autoclaving.  
Ethidium bromide - Dissolve 0.5g ethidium bromide in 50ml of 0.1M EDTA solution and 
store at RT in a light sealed container.  
dNTPs - 100 mM dNTPs (Promega) were combined in a 1:1:1:1 ratio of 
dATP:dCTP:dGTP:dTTP and diluted in dH2O to make a 10 mM stock solution which was 
stored at –20 °C.  
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Tris buffers – Solutions of 1 M Tris-OH and 1 M Tris-HCl were prepared. To prepare a 
solution of Tris buffer at a particular pH, the two solutions were mixed at the appropriate ratio 
as shown in Table 2.1and pH confirmed using a calibrated pH meter.  
pH 1M Tris-HCl 1M Tris-OH 
6.8 969 31 
7.2 889 111 
7.3 867 133 
7.4 837 163 
7.5 804 196 
7.6 767 233 
7.7 724 276 
7.8 673 327 
7.9 618 382 
8 562 438 
8.1 509 491 
8.2 448 552 
8.3 389 611 
8.4 334 666 
8.5 208 792 
8.6 232 768 
8.7 190 810 
8.8 156 844 
8.9 122 878 
9 96 904 
   
Table 2.1 Ratios of Tris-HCL to Tris-OH for required pH 
 
2.2 Cell Culture 
All work involving the culture of cells was carried out in a class II sterile cell culture hood. 
Hoods were regularly cleaned with Virkon (Antec International, Sudbury, UK) and with 70 % 
(v/v) ethanol before and after each use. All sterile plasticware for cell culture was purchased 
from Greiner unless otherwise stated. Other laboratory plasticware and media were autoclaved 
prior to use and opened in the cell culture hood. Gloves were worn at all times during cell 
culture procedures. All cells were incubated in a humidified Sanyo MCO-17A/C incubator 
(Jencons-PLS, East Grinstead, UK) at 37 °C and 5% CO2.  
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2.2.1  Adrenal cell line H295R 
NCI-H295R (H295R, ATCC number: CRL-2128) is a human adrenal cortical cell line adapted 
from the original NCI H295 cells (Gazdar et al., 1990).  H295R cells were grown as a 
monolayer with media made from 1:1 mix of DMEM:F12, 10 ml/L Penicillin/Streptomycin 
solution [10000 u penicillin and 10 mg streptomycin per ml in 0.9% (w/v) NaCl], 2% (v/v) 
Ultroser (Biosepra), 1% (v/v) ITS [containing 1mg/ml insulin, 0.55mg/ml transferrin and 
0.5µg/ml sodium selenite], at 37oC in 95% air/5% CO2 incubators (Cobb et al., 1996).  
 
2.2.2  Maintenance and sub-culture of H295R cells 
Solutions:  
• Dulbecco’s Modified Eagle’s Medium (DMEM) – 4500 mg/L glucose, 0.584 g/L L-
Glutamine, 3.7 g/L NaHCO3 (Sigma #D5796)  
• F12 nutrient media (Ham) – 1802 mg/L glucose, 0.146 g/L l-glutamine, 1.18 g/L 
NaHCO3 (Gibco, Paisley, UK)  
• Penicillin/Streptomycin – formulated to contain 10,000 units/ml penicillin and 10 
mg/ml streptomycin in 0.9% (w/v) sodium chloride (Sigma)  
• ITS (100 x) – 1 mg/ml insulin, 0.55 mg/ml human transferrin, 0.5  g/ml sodium 
selenite (Sigma #I3146)  
• Trypsin-EDTA 1x Solution (T/E) – 0.5 g/L of trypsin and 0.2 g/L EDTA.4Na in 
Hanks’ balanced salt solution (Gibco). 
 
2.2.3 Trypsinisation and passaging 
After removal of media from the wells or flasks, trypsin-EDTA (TE) (0.5g/l trypsin, 0.2g/l 
Ethylenediaminetetraacetic acid (Invitrogen) was added (3mls of TE for a 10cm plate) for 30 
seconds and then removed and cells were left for 1-2 minutes with some gentle tapping to 
allow the cells to fully detach.   
When cells reached 80-90% confluency, they were split into new plates. Warm media was 
added to the cells, the solution was pipetted up and down a few times to break up cell clumps, 
aliquots were pipetted into new plates and topped up with new media. Based on the rate of cell 
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growth, the cells were split every 3-4 days in a 1-to-3 dilution.  The H295R cell passage number 
used was between 5 and 15.   
 
2.2.4 Cell freezing for storage and thawing for use 
Cells not utilised were frozen for long term storage. The media was aspirated, cells trypsinised 
and with 2 ml of new media added, cells were transferred to a 15 ml polypropylene tube. This 
was centrifuged at 100 g for 5mins and the supernatant was removed, leaving the cell pellet at 
the bottom.  The pellet was re-suspended in a freezing solution containing 10% DMSO 
(Dimethyl Sulphoxide) and 90% FBS (fetal bovine serum).  Subsequently, 1 ml aliquots were 
pipetted into cryotubes (Nalgene), wrapped with tissue paper (to ensure a slow freezing 
process) and placed in a -80 oC freezer overnight to achieve a cooling rate of 1 oC/min.  The 
tubes were placed into a liquid nitrogen tank the following day for long term storage.  
  
To thaw the cells for use, they were removed from liquid nitrogen storage and quickly thawed 
at room temperature and transferred to a 15ml tube where warm medium was added and spun 
for 5 minutes at 100g.  The medium was then removed and the cells were resuspended in new 
medium and plated, with change of medium the next day, after cell adherence, to remove any 
traces of DMSO. 
 
2.2.5  Cell counting – Haemocytometer 
Cells were trypsinised and a 50µl sample of cells was applied to the edge of the coverslip with 
a pipette.  The medium was sucked in by a capillary mechanism to fill the chamber, taking care 
to allow the chamber to fill itself in order to avoid overloading.  4 large grids in the corners 
were used, with each grid containing 16 smaller squares.  Cells in each small square (as 
represented by the green square in Figure 2.1) were counted using the Leica DMIL light 
microscope set with a 10x objective.  If a cell lied over the grid lines, only the ones lying over 
the left and bottom lines were counted.  If there are too many cells to count accurately, the cell 
stock was diluted and recounted with a new sample.  The total number of cells counted in the 
4 big squares was divided by 4 and that number was multiplied by 104 to give the number of 
cells per ml of medium. 
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Calculation used to derive cell number: 
No. of cells counted ÷ 4 = no. cells/100nl 
No. cells/100nl x 104 = no. cells/ml 
No. cells/ml x ml of media in which the cells were diluted = total no. of cells 
 
 
Figure 2.1 Haemocytometer grid as seen under a microscope 
Grid demonstrating the volume of each square is shown in the colour key above. Taken from 
Dr. Katy Cogger (from the King laboratory) with permission. 
 
 
2.2.6  Cell Differentiation 
H295R cells were plated in a 6-well plate (2ml of medium per well) and grown to 50-60% 
confluency. They were differentiated over 96 hours with fresh media containing 10µM 
Angiotensin II (Ang II) or 10µM Forskolin in the presence and absence of BMP proteins.  The 
media was changed at 0, 24, 48 and 72 hour time points.  At 96 hours, cells were harvested and 
cDNA was made from total RNA by reverse transcription.  Addition of Ang II increases 
intracellular calcium levels via PKC signalling leading to induction of CYP11B2 expression, 
and hence increases aldosterone production (Bird et al., 1993; Rainey et al., 1994).  Forskolin 
activates adenylate cyclase to increase cAMP levels, thus activating PKA, and preferentially 
inducing CYP11B1 expression and cortisol production, acutely, and DHEA chronically 
(Denner et al., 1996; Oskarsson et al., 2006).  
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To investigate the effect of BMP3b on influencing the steroidogenic differentiation of H295R, 
leading to up or down regulation of CYP11B1 and CYP11B2, recombinant BMP3b protein 
(Abnova) at a concentration of 100ng/ml was used.  For the experiments investigating the 
effect of BMP2 and BMP3b on H295R cells towards a zR phenotype differentiation CYTB5 
and SULT2A1 were used as markers of zR.  H295R cells were treated with or without BMP3b 
or BMP2 (Shenandoah Biotechnology) recombinant proteins at 100ng/ml in fresh media, 
changed daily over 96 hours and harvested.   
 
 
2.3 Transfections 
 
Lipofectamine 2000 (Invitrogen) was diluted with optimem I (Invitrogen), and incubated at 
room temperature for 5 minutes. The DNA or RNAi was also diluted with optimem I then 
combined with the lipofectamine, vortexed, and left at room temperature for 20 minutes. Cells 
were then given fresh media and 100µl of the lipofectamine/DNA or lipofectamine/RNAi mix. 
The media was changed every 24 hours for 96 hours.  
 
2.3.1  siRNA Transfections 
Pre-designed BMP3b siRNA (Ambion) at a concentration of 40pmol was transiently 
transfected into H295R cells using the Lipofectamine 2000 reagent (Invitrogen). Cells were 
grown in a 12-well plate until they reached 40-50% confluency.  Lipofectamine 2000 was 
diluted with Optimem I (Invitrogen) and left at room temperature for 5 minutes.  siRNA was 
diluted with Optimem I in another tube and added to the Lipofectamine, vortexed and left to 
stand at room temperature for 20 minutes.  Fresh media with Ang II (10µM), Forskolin (10µM) 
or normal medium (Untreated) was added to the cells, along with 100µl lipofectamine/siRNA.  
Media and lipofectamine/siRNA was changed every 24 hours for 72 hours and harvested for 
RNA. The gene expression was analysed by Real-Time Quantitative PCR (qPCR). 
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2.4  RNA and DNA preparation 
 
2.4.1 Agarose gel electrophoresis 
This method was used to estimate the sizes of PCR products when compared to a DNA ladder 
of known fragment size. Negatively charged DNA was separated on 1-2% (w/v) agarose gel 
matrix (smaller fragments travel faster), containing GelRed, resulting in the visualisation of 
distinct DNA bands when examined under UV light. The gel was prepared by melting agarose 
powder in 1xTAE buffer (1% (w/v) agarose for fragments >500bp, 2% (w/v) agarose for 
fragments <500bp).  Then GelRed (5µl/100ml TAE) was added and the mixture left to set in a 
mould containing a comb (which would form the wells). The set gel was placed into the 
electrophoresis tank and covered with 1xTAE buffer. The samples were loaded into the wells, 
using 10x Orange G loading dye (4g sucrose dissolved in 10mls 1mM EDTA pH8.0 + 20mg 
Orange G) and run at 110V next to a GeneRulerTM DNA Ladder mix. The gel was viewed on 
a UV-light box. 
 
 
 
Human primers Tm 
(°C) 
Annealing  
Temp 
(°C) 
Sequence 
(from 5’) 
Product 
length 
(Bps) 
GAPDH F 62.6 55 TGCACCACCAACTGCTTAG 177 
GAPDH R 63  GGATGCAGGGATGATGTTC  
BMP2 F 60.4 53 CTACATGCTAGACCTGTATCG 385 
BMP2 R 69.3  ATTTCGAGTTGGCTGTTGCAG  
BMP3b F 64 55 CACTTCTACTCAGAGCCGCC 297 
BMP3b R 63.9  GGTCCCTCTCCTCAGAATCC  
BMP4 F 63.6 56 CTTTACCGGCTTCAGTCTGG 235 
BMP4 R 63.2  AGATCACCTCGTTCTCAGGG  
CHAPTER 2: Materials and Methods 
 
70 
 
 
BMP5 F 63.9 60 GAGCTGCTGGGTTCTAGTGG 156 
BMP5 R 64  AATGGTCTGGGTCTGTGAGG  
BMP6 F 64 51 TGTGAACCTGGTGGAGTACG 233 
BMP6 R 64.1  GGGTGTCCAACAAAAACAGG  
Pref-1 F 63.8 58 TGGCTTCTCAGGCAATTTCT 231 
Pref-1 R 64.2  GGCTTGCACAGACACTCGTA  
Ptch F 64 56 TGTCACAGCCTTCTTCATGG 241 
Ptch R 64.3  GTCGTGTGTGTCGGTGTAGG  
SHH F 64.9 58 ACATCACCACGTCTGACCG 218 
SHH R 65.1  GCTCAGGTCCTTCACCAGC  
Gli1 F 63.7 60 CTACAGTGGAGCCCAAGAGG 209 
Gli1 R 64.2  GGAGAGGTCTTCAGTGCTGC  
CYP11B1 F  66.5 60 TCCCACACTAATGGCCTAGC 206 
CYP11B1 R   66.3  AGCCAGATTTAGGGAGTGGG  
CYP11B2 F     CATACAATGGGTTTGGAGGG 210 
CYP11B2 R   65.5 60 TGTCAGATCCCCTAGCTTGC  
CytB5 F 63.7 57 AGTATGTCCGGTTCAATGGC 199 
CytB5 R 61.1  GAACCTCTTCTCCTCCAGGG  
SULT2A1 F 64.3 57 AGTGAAACGGAGAGTCCACG 220 
SULT2A1 R 64.6  ATGTGGTCAAACCATGACCC  
 
Table 2.2 List of primers used in RT-PCR and RT-qPCR 
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2.4.2  RNA Extraction 
RNA was extracted from both tissues and the cytoplasm of cultured cells using the Qiagen 
RNeasy® Mini Kit, as per protocol. RNA was extracted from human tissues that had been 
collected and stored in RNALater at -80 oC and approximately 20mg of tissue was 
homogenised with 600µl of RLT buffer in 2ml Precellys 24 tubes (cat. No. 03961-1-003) and 
homogenised using the Precellys 24 homogeniser (Bertin) for 3 cycles of 15 second agitations.  
The supernatant was collected after centrifuging at 12,000g for 3 minutes.   
 
RNA was extracted from cultured cells according to the protocol provided with the Qiagen 
RNeasy® Mini Kit.  The cells were trypsinised with Trypsin-EDTA, washed with cold PBS 
(Phosphate Buffered Saline) detached with a cell scraper and transferred to 1.5 ml 
microcentrifuge tubes.  The tubes were centrifuged at 12,000 g for 15 seconds, and following 
removal of the supernatant, 350 µl of RLT buffer with the addition of β-mercaptoethanol was 
added to the cell pellet.  If cells were grown in smaller wells (12 well plates or smaller), 
following the cold PBS wash, the cells were lysed directly in the wells with 350 µl of RLT 
buffer + β-mercaptoethanol.  The lysates were then transferred to 1.5ml microfuge tubes using 
a cell scraper.  The RNA concentration was determined using the Nanodrop ND-1000 
spectrophotometer to measure the optical density of the samples at 260 nm wavelength 
(OD260).  An OD260 of 1 corresponds to approximately 50 µg/ml for double stranded DNA and 
40µg/ml for single stranded DNA and RNA.  2µg of RNA was used to make cDNA, based on 
the following calculation: 
OD260 x f x d = concentration of nucleic acid (µg/ml)  
Where: OD260 = optical density of the sample at 1 cm path length, f = 40 for RNA or 50 for 
DNA, d = dilution factor of sample  
 
2.4.3 cDNA Preparation with DNase treatment 
This process cleaves and fragments any genomic DNA contamination.  This was achieved with 
DNaseI (Deoxyribonclease I), which non-specifically cleaves single- and double- stranded 
DNA and RNase inhibitor 40u/µl (Promega), which reduces any RNase activity, hence 
preventing RNA degradation.  
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A single reaction contains: 
 
 2µg RNA      => Xµl 
 RNase Free H2O (Qiagen)   => 43.5µl-Xµl 
 10x DNase Turbo buffer (Ambion)  => 5µl  
 DNase 1     => 1µl  
 RNase inhibitor    => 0.5µl 
 ------------------------------- 
 TOTAL     => 50µl 
 
The reaction was vortexed briefly and incubated in a water bath at 37oC for 15mins.   
 
2.4.4 Phenol extraction and precipitation:  
This step uses the organic solvent, phenol, equilibrated to pH8.0, to denature and remove 
protein contaminants, genomic DNA and enzymes from the RNA.  
An equal volume of phenol was then added to stop the reaction.  Each reaction was vortexed 
for 1 minute and centrifuged at 10000 g for 2mins.  The reaction then separates into 2 phases: 
the top aqueous phase, containing RNA, is removed and placed into a new microfuge tube and 
the lower phenol phase on the bottom containing the organic and inter-phases which is 
discarded.   
 
2.4.4.1 RNA precipitation: 
RNA precipitation allows any residual phenol to be removed: 
 
 RNA (x)     => 50µl 
 3M Sodium Acetate pH 5.3 (x/10)  => 5µl 
 Glycogen (inert carrier 5mg/ml, Ambion) => 2µl  
 Absolute Ethanol (2.5x)   => 125µl  
  
The reaction was vortexed for 30 seconds and left at -80 oC for 1 hour or -20 oC overnight. The 
sample was then centrifuged at 10000 g for 10 minutes at 4 oC.  The supernatant was aspirated 
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and the precipitant (white pellet) washed with 125 µl 70% (v/v) ethanol, to remove any 
precipitated sodium acetate.  Samples were centrifuged for 5 mins and the ethanol was 
aspirated. The final pellet was air-dried for 10 minutes.  
 
2.4.4.2  First strand cDNA synthesis: 
The air dried pellet was resuspended in 12.25 µl of RNase free H2O and 0.25µl of random 
primers (500 µg/ml) (Promega).  The sample was heated for 10 minutes at 80oC to denature 
the secondary structure in the RNA and immediately placed on ice for 2 minutes to allow the 
random primers to anneal.  
The sample was quickly centrifuged to pool any condensation and a 1 µl aliquot was removed 
to be used for RT-PCR negative controls (these should not contain any traces of genomic DNA) 
and the remainder used for cDNA synthesis.  
 
 
A single cDNA synthesis reaction contains: 
 
 2 µg RNA /Random primers sample   => 11.5µl 
 5x Reverse Transcription Buffer (Promega)  => 4µl 
 DTT (Dithiothreitol, 0.1M)     => 2µl 
 dNTPs (deoxynucleoside triphosphates,  
 10mM A+C+G+T; Promega)    => 1µl 
 M-MLV Reverse Transcriptase 200u/µl (Promega) => 1µl 
 RNase inhibitor 40u/µl (Promega)    => 0.5µl 
 
 ------------------------------- 
 TOTAL       => 20µl 
 
The reaction was then vortexed and centrifuged briefly and then incubated at 37oC for 1hour 
for the reverse transcription to occur.  After incubation, 20µl distilled water was added to the 
newly synthesised cDNA, giving a 1 in 2 dilution. Successful cDNA synthesis is verified by 
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RT-PCR with GAPDH followed by 1% (w/v) agarose gel electrophoresis of samples with 
negative control (water) (Figure 2.2). cDNA was stored at -20oC.  
 
 
Figure 2.2 Agarose gel (1%) electrophoresis to demonstrate successful cDNA synthesis 
using GAPDH primers 
+ = newly synthesized DNA, - = water as negative control, GR = GeneRuler, bp = base pair 
 
 
 
2.4.5 Silica gel extraction 
DNA was extracted from the Glass Milk gel extraction technique. The desired bands were 
excised from the gel using a clean scalpel.  The excised gel bands were melted at 55oC for 5-
10min (until gel has totally melted) in 3 volumes of 6M NaI for every 1 volume of gel. 10µl of 
the silica suspension was added and incubated at room temperature for 5 mins, flicking 
intermittently to keep silica in suspension. The suspension was centrifuged for 15 sec at 10000g 
and the supernatant aspirated. The pellet was then re-suspended in 500µl of New Wash buffer 
(50mM NaCl, 10mM TrisHCl pH7.5, 2.5mM EDTA, 50% (v/v) ethanol). This was repeated 
twice and centrifuged again to give a dry pellet. The pellet was then resuspended in 10 µl of 
dH2O and incubated at 55oC for 2mins. The suspension was finally centrifuged at 10,000 g for 
1 minute and the supernatant, containing the DNA, transferred to a new centrifuge tube and 
stored at -20  oC 
 
The silica suspension (100mg/ml) was prepared by mixing 10g of silica in 100ml PBS and the 
silica was allowed to settle for 2 hours. The supernatant was removed and the process repeated.  
The suspension was centrifuged at 2000g for 2mins; the silica pellet was resuspended in 3M 
NaI at 100mg/ml and used as a DNA-binding matrix (stored at 4oC in the dark).  
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2.5  Polymerase Chain Reaction (PCR) 
 
The analysis of cDNA was carried out by PCR (Polymerase chain reaction) where GAPDH 
primers were tested against the newly synthesised cDNA and the negative control aliquots 
(removed at the earlier stage). The reactions were analyzed on a 2% (w/v) agarose gel where 
GAPDH primers gave clear bands (PCR product) with the cDNA samples but no bands in the 
negative control lanes. PCR was used to analyse the newly synthesised cDNA.  PCR is 
generally used to amplify small quantities of DNA where Taq DNA polymerase (Thermus 
aquaticus, NEB) is used in a polymerisation reaction to make exact copies of the DNA 
template.  
 
 Intron spanning primers were designed using the “Biology WorkBench version 3.2” software 
(http://workbench.sdsc.edu) where certain designing parameters were met: GC clamp size of 
2, optimum primer size of 20 bases, optimum melting temperature of 60oC, GC content 40-
60%. A single PCR reaction contains: 
 
 
 
 dH2O      => 19.375µl 
 10x PCR Buffer   => 2.5µl 
 dNTPs (10mM)   => 1µl 
 Primers (10µM For + Rev)  => 1µl 
 Taq DNA Polymerase   => 0.125µl 
 DNA template   => 1µl 
 ------------------------------- 
 TOTAL    => 25µl 
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Cycles Temperature Time Process 
1 94°C 5 minutes Denaturation 
25-35 94°C 30 seconds Denaturation 
25-35 45-65°C 30 seconds Annealing 
25-35 72°C 30 seconds Extension 
1 72°C 10 minutes Further elongation 
 4°C ∞ Preservation 
 
Table 2.3 Cycle and temperature profile used for RT-PCR 
 
 
 
Denaturation at 94oC  
→  The double stranded DNA melts to single stranded DNA by denaturing hydrogen bonds. 
Annealing at 45-65oC  
→  The primers bind their matching single stranded sequences; the polymerase then attaches 
and begins copying the sequence. This temperature is variable depending on the nucleotide 
content, hence the melting temperature (Tm) of the primers. 
Extension at 72oC  
→ Optimum polymerisation temperature; Taq polymerase continues to add complementary 
dNTPs onto the sequence from 5’ to 3’. For longer PCR products an extension time of 1 min 
for every 1000k bp was used. 
 
The PCR products were analysed with agarose gel electrophoresis. Whenever no product was 
obtained from the PCR reaction, different reaction conditions were tested such as lowering the 
annealing temperature 
 
 
 
 
CHAPTER 2: Materials and Methods 
 
77 
 
 
2.6 Real-Time Quantitative PCR (SYBRgreen I) 
 
The differences in gene expression were quantified using the SYBRgreen Real-Time qPCR 
approach.  SYBRgreen exhibits greatly increased fluorescence (up to 1000 fold) when it non-
specifically binds to double-stranded DNA (dsDNA). The total fluorescence signal is 
proportional to the total amount of the target dsDNA amplification; hence mRNA levels can 
be calculated.  A value obtained from qPCR is called a Ct value.  The Ct value/level represents 
the point when amplification is first detected above background fluorescence, during the 
exponential phase of the amplification.  The lower the Ct value, the higher the amount of 
starting DNA present.  The initial (starting) gene copy number was calculated by plotting 
against the standard curve and the gene expression was normalized to GAPDH (Figure 2.3). A 
standard curve with serial dilutions of gel extracted product of known DNA concentration of 
each gene was made, so copy numbers were derived from the Ct values.  The reference gene 
GAPDH was used to account for differences in the amount of cDNA loaded.  The dissociation 
curve tests for non-specific amplification and contamination.  The dissociation melt separates 
double stranded DNA back into single strands. Pure products only give one peak at its 
corresponding melting temperature and the no template control (NTC) should give no peaks 
or a smaller peak at a different melting temperature to the target product, indicating primer 
dimers.   Intron spanning primers were designed to give products of approximately 200bp and 
the final primer concentration ranged from 100-200nM (to reduce primer dimers).  ROX in the 
reaction is used as a reference dye for evaporation during cycling.   
 
For the experiment to be valid, the following criteria were met: 
Efficiency = 100% (± 10%) 
Standard curve gradient = -3.3 (± 0.3) 
R2 = 0.97-1 
 
The KAPA SYBR FAST qPCR kit (Kapa Biosystems) was used. All of the reactions were 
performed in duplicates or triplicates, using a no-template control (NTC) which consists of 
water to look at background fluorescence. The cDNAs were plated out onto 96 well plates or 
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0.2ml strip tubes and centrifuged at 10000g for 2mins to remove any bubbles.  The reactions 
were loaded into the MxPro Real-Time PCR machine (Stratagene).   
 
A single reaction contains: 
 
 2x Master Mix  =>    5 µl  
 dH2O    => 2.3 µl  
 Low ROX  => 0.2 µl  
 Primers (F + R) => 0.5 µl  
 DNA template =>    2 µl 
 ---------------------------------------------------- 
 TOTAL  => 10 µl 
 
 
Cycles  Temperature  Time   
1 95°C 3 minutes Denaturation 
40 95°C 3 seconds Denaturation  
40 60°C 30 seconds Annealing 
40 72°C 1 second Extension 
1 95°C 1 minute Dissociation melt 
1 60°C 30 seconds  
 
Table 2.4 Cycle and temperature used for RT-qPCR  
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Figure 2.3 qPCR amplification plots and standard curves 
Demonstration of amplification plots (A,C) and standard curves (B,D) for qPCR experiment 
for GAPDH (A,B) and SULT2A1 (C,D) mRNA expression.  
 
 
2.7  Enzyme-linked immunosorbent assay  
 
H295R cells were transfected with BMP2, BMP3b and siBMP3b and each were treated with 
vehicle, Forskolin or Ang II.  The media was changed every 24 hours (for 3 days with siRNA 
and 4 days for other recombinant BMPs).  The media were stored at -20°C until ELISA carried 
out.  ELISA kits were obtained from Demeditec Diagnostics.  The media was tested for 
cortisol, DHEAS and aldosterone as per instruction provided.  The experiment was carried out 
at room temperature.  Calibrator wells were set up and experimental media was tested using 
50µl of media per well, in duplicates.  The media was centrifuged for 15 seconds at >10,000 x 
g to pellet any debris, and 25µl of supernatant was added to each well of a Demeditec ELISA 
microtiter plate.  Plates were pre-coated with either an anti- aldosterone, an anti-cortisol or an 
anti- DHEAS antibody. A standard curve containing known quantities of aldosterone, cortisol 
CHAPTER 2: Materials and Methods 
 
80 
 
 
or DHEAS was also plated.  100 µl of conjugate working solution was then added and placed 
on a shaker plate at 200 rpm for 1 hour at room temperature.  Wells were then washed 3 times 
with 300 µl diluted washer buffer.  150 µl TMB (tetramethylbenzidine) substrate was then 
added at timed intervals and then incubated for another 20 minutes on the shaker plate.  The 
enzyme reaction was stopped by adding 100 µl of Stop solution and the plate was read on a 
microwell plate reader at 450nm immediately (within 20 minutes) using the Perkin Elmer 
Wallac Victor2 1420 Microplate reader.  Using the calibrators, a standard curve was drawn to 
read the values of the experiment, where the concentration of aldosterone, cortisol or DHEAS 
was determined from the absorbance values from the standard curve.  
 
 
2.8  Cloning 
 
Primers were designed against the coding sequence of the desired gene, which was amplified 
by PCR. The product was run on an agarose gel and the expected product size was confirmed 
against a DNA ladder.  The band was cut out of the gel and DNA extracted was either 
sequenced or confirmed by a restriction digestion. After the sequence was confirmed the 
gene was thenncorporated into a plasmid. 
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Primer (Rat) Tm 
(°C) 
Annealing 
temp (°C) 
Sequence 
(from 5’) 
Product  
length 
(Bps) 
BMP2 F 64.3 58 CCCCTAGTGCTTCTTAGACGG 923 
BMP2 R 63  CTGGACTTAAGACGCTTCCG  
BMPR1A F 63.7 57 GTATGGATGGGTAAATGGCG 906 
BMPR1A R 63.9  TCCTTGGGTGAATTTCTTGC  
BMPR1B F 64 56 AGACCTCGGTACAGCATTGG 946 
BMPR1B R 63.7  TCATAAGCTTCCCCATTTGC  
BMPRII F 63.9 55 ATCCCAATGGATCTCTGTGC 955 
BMPRII R 63.8  CTAGGGATTCGAGCTTGTGC  
BMP3b F 59.9 57 AAATGATCCTCACAGCCACC 1024 
BMP3b R 60.0  ACCTTCAGAACCACATTCCG  
 
Primer (human) Tm 
(°C) 
Annealing  
temp (°C) 
Sequence 
(from 5’) 
Product  
length 
(Bps) 
BMP3b F 63.2 58 GGCCGTGTATTTCTTCAACC 1015 
BMP3b R 63.6  ACCCCAAGGGAGTTCATCTT  
 
Table 2.4 Primers used to produce inserts for in situ hybridisation 
 
 
2.8.1  Plasmids 
The pGEM®-T easy vector (Promega) (Figure 2.4) was used for the cloning. It is already cut 
and contains 3’ terminal thymidine overhangs at both ends; this prevents vector re-
circularization and provides a compatible overhang for PCR products. An advantage of using 
this vector is that it could be subjected to blue-white screening, making it easier to locate 
successfully cloned colonies. 
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Figure 2.4 pGEM-Teasy vector and restriction map used for ligation 
 
 
2.8.2 Ligation 
The concentration of plasmid and insert DNA was determined by spectrophotometry or 
compared to the expected weight by comparing with the DNA ladder. A 3:1 (insert:plasmid) 
ratio was used.  All the inserts used were around 1000bp, therefore, based on the insert:vector 
ratio calculation, 50ng of insert were used for each reaction, along with 50ng/µl of plasmid. 
 
A single ligation reaction contains: 
 
 2X Rapid Ligation Buffer => 5 µl (x1 final) 
 Insert    => X µl(50ng) 
 Plasmid (pGEMTeasy) => 1 µl (50ng) 
 T4 DNA Ligase  => 0.5 µl  
 dH2O    => 3.5µl - X µl 
 ------------------------------------------------ 
 TOTAL   => 10 µl 
The reaction was incubated at room temperature for 3-4 hours. After the ligation was complete, 
the plasmids were transformed into bacterial cells.  
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2.8.3  Transformation 
The ligated DNA (plasmid + insert) was transformed into competent bacteria which were 
grown on agar plates under selection to obtain colonies containing the plasmids. Agar plates 
were prepared by dissolving 10g L-Broth and 7.5g Agar in 500ml dH2O and autoclaved. The 
mixture was poured into sterile 10cm petri dishes, and once set, dried upside-down in 37oC 
bacterial incubators and stored at 4oC (upside-down). For antibiotic selection, 500µl of an 
Ampicillin stock (100mg/ml) was added to the 500ml of LB solution (100µg/ml final 
concentration), after it has been cooled to <50oC, before pouring the solution into the dishes. 
For blue/white screening, 100µl 0.1M IPTG (isopropyl-beta-D-thiogalactopyranoside) and 
50µl X-Gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) (20mg/ml) (Promega) were 
directly pipetted onto the agar plate and spread until dry (near a Bunsen-burner flame) and 
incubated at 37oC, until ready to be used. When the insert was successfully ligated into the 
plasmid, the coding sequence of the lacZ gene is disrupted resulting in the inability of the 
bacteria to cleave the chromogenic substrate X-Gal to form a blue coloured colony. In theory, 
all the white colonies should contain the plasmid with insert. 
 
The plasmid was transformed into the JM109 (Promega L2001) competent bacterial cells as 
per their protocol.  Briefly; 2-5 µl of the ligation reaction was gently mixed with the bacterial 
cells (60-100 µl), incubated on ice for 10 – 30 minutes (depending on which protocol), heat 
shocked at 42oC for 45 seconds and immediately returned into ice for 2 minutes.  The bacteria 
were incubated with SOC medium for 1 hour at 37oC with shaking at 225 rpm.  Subsequently, 
the bacteria were centrifuged for 5 minutes at 21oC, at 200 g.  800µl of the supernatant were 
removed and 50 µl of the transformation was plated onto one plate and about 150 µl onto a 
second plate.  Plates were incubated upside-down at 37oC overnight. The grown bacterial 
colonies were picked from the plate (for blue/white screening the white colonies were picked) 
and grown to saturation in 5ml of L-Broth with 5µl of Ampicillin [100mg/ml] in a shaking 
bacterial incubator, at 37oC overnight. The bacteria were used in further steps to isolate the 
desired plasmid. 
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2.8.4 Plasmid extraction and purification 
The plasmid was extracted from bacterial culture by alkaline lysis.  1.5 mls of bacterial culture 
was pelleted by centrifugation and the pellet was resuspended by vortexing in the residual broth 
after removing most of the supernatant (approximately 20 µl). The bacteria were lysed by 
vortexing in 300µl of a 1:2 mix of solutions 1 and 2and then neutralised with 150 µl solution 
3 (Bimboim and Doly, 1979). The resulting precipitated solution was extracted with 400 µl 
phenol pH8.0 and 400 µl of the aqueous phase was then removed and the nucleic acids 
precipitated by the addition of 1ml absolute ethanol. After pelleting the DNA by centrifugation 
at 10000g for 5 mins, the ethanol was aspirated and the pellet washed with 100 µl of 70% (v/v) 
ethanol. After air-drying for 5 mins, the pellet was resuspended in 50ul TE + 100 µg/ml RNAse 
A.  The plasmid DNA was then further analysed by restriction digestion.  
 
The plasmids were cut with restriction enzymes in order to either linearise them, excise the 
target gene out of a plasmid or to check if the PCR product insert is correct in size or 
orientation. The reaction was incubated in a 37oC water bath for 2 hours. A single restriction 
digestion reaction contains the following: 
 
Note that BSA is not needed with some enzymes, in these cases it was replaced with dH2O 
 
 10X Restriction Buffer => 2 µl 
 DNA    => X µl (1-2 µg) 
 Enzyme (10u/µl)  => 0.5 µl (5u) 
 BSA (10mg/ml)   => 2 µl (0.1mg/ml) 
 dH2O    => 15.5 - X µl 
 ------------------------------------------------ 
 TOTAL   => 20 µl 
 
 
To check if the PCR product was correct, the expected target sequence was analysed in 
NEBcutter v2.0 (http://tools.neb.com/NEBcutter2/index.php) and two restriction enzymes 
were chosen to cut the product into dissimilar fragments. These fragments were then run on an 
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agarose gel and if the pattern was comparable to the one expected then the product was thought 
to be correct (Figure 2.5). 
 
 
Figure 2.5 Agarose gel showing presence of an insert in the plasmid 
Following ligation and transformation, the plasmid is extracted and purified.  This is an 
example of BMP2 after digestion with Nco1.  The ‘Cut’ column includes the plasmid and insert 
with a combined size of 4106bp. 
 
 
2.9 Histology 
 
Adrenal glands were excised from male and female Wistar rats from embryological age E14.5, 
E15.5, E17.5, E19.5 and adults.  Adrenal glands were also excised from male and female 
Bmp3b knockout mice.  Tissues were either snap frozen and stored in a -80oC freezer or fixed 
in 4% (w/v) Paraformaldehyde/PBS overnight at 4°C for paraffin or sucrose embedding. 
Sectioned adrenal tissue were cut to a thickness of about 5-10µm and placed onto Superfrost 
Plus slides (for fresh frozen and sucrose embedded) and TESPA (3-Aminopropyl 
Triethoxysilane from Sigma) treated Superfrost slides for the paraffin slides.  The slides were 
used for immunohistochemistry, immunofluorescence or non radioactive in-situ hybridisation 
to locate gene expression, visualised under a light microscope.  
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2.9.1 TESPA treated slides: 
TESPA (3-triethoxysilylpropylamine) treatment of slides ensures that tissue sections adhere 
tightly and avoid detachment during subsequent washing procedures in all the staining 
processes.  The advantage of using TESPA is that the treated slides have a long shelf life but 
tissue sections need to be dried fully before use to ensure tight adherence.  The slides were 
dipped in Acetone and allowed to dry.  The slides were then dipped into an Acetone solution 
containing 2% (v/v) TESPA for 2 minutes.  The slides were washed twice in distilled water, 2 
minutes per wash and dried overnight at 37oC.    
 
2.9.2 Wax embedding and sectioning 
The adrenals were dehydrated through a series of increasing ethanol concentrations, after 
having been in 4% (w/v) Paraformaldehyde/PBS overnight at 4oC. The volume of washes used 
was approximately 8x volume of the adrenal.  The PBS and water used for dilution for the 
ethanol concentrations were all DEPC (Diethylpyrocarbonate) treated to prevent RNA 
degradation by RNases.  DEPC inactivates RNase enzymes by covalent modifications of the 
histidine residues.  To DEPC treat water or PBS, 1ml DEPC was added to 1L water or PBS 
(0.1% v/v), mixed, incubated at 37oC overnight and then autoclaved for 15 minutes to denature 
the DEPC (which is highly active).  In the meantime, the wax was melted in the oven at 56oC. 
The procedure is listed below: 
 
DEPC PBS for 1hour 
DEPC Water for 1hour 
DEPC Water for 1 hour 
50% v/v  Ethanol for 1hour 
70% v/v Ethanol overnight 
90% v/v Ethanol for 1hour 
100% v/v Ethanol for 1hour 
100% v/v Ethanol (new solution), overnight at 4oC 
Xylene for few seconds – minutes, depending on size of tissue 
Repeat Xylene for few seconds – minutes, depending on size of tissue 
Molten paraffin overnight at 56oC 
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The adrenals were placed into a mould, topped up with molten wax, covered and left to solidify 
overnight at RT. The block of wax was inserted and aligned into a Leitz 1512 microtome, ready 
for cutting and mounting using the floating out technique as described by Sack (Sack, 1963).  
The paraffin block was trimmed and paraffin ribbons were cut on the microtome, forming 
serial tissue sections of 5-7µm in thickness.  A small amount of DEPC water was placed onto 
a TESPA slide and the ribbon placed over the water and heated over a low heat (~ 40-45°C) to 
gently melt the paraffin to remove any folds within the sections.  Once the folds in the section 
has smoothed out, the water is removed from one corner, sucked up using a plastic 1ml pipette, 
leaving the sections bonded to the adhesive TESPA coating.  Slides were air-dried at room 
temperature for 30 minutes, then overnight at 37°C and stored at room temperature until use. 
 
2.9.3 Deparaffinisation 
For the slides to be used for staining, the paraffin will need to be removed.  To deparaffinise 
and rehydrate the slides, they were washed in xylene 3 times, 100% ethanol twice and once in 
90% (v/v), 70% (v/v) and 50% (v/v) ethanol and finally twice in H2O.  Each wash was for 10 
minutes. 
 
2.9.4 Cryo embedding   
Following the overnight incubation in 4% (w/v) PFA/PBS, the tissue was washed in DEPC 
PBS.  It was then transferred to a 30% (v/v) sucrose/DEPC PBS solution and left at 4oC, 
upright, in a 50ml Falcon tube until the tissue sank to the bottom.  Foil containers were made 
and placed in dry ice and the tissue placed in the centre, OCT medium (Lamb Laboratories) 
was added to totally cover the tissue and allowed to freeze at -80oC for at least 20 minutes 
before use.   Tissues were sectioned using a cryotome onto SuperFrost Plus slides and stored 
at -80oC, if not used immediately. 
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2.10 Staining 
 
2.10.1 Immunohistochemistry (tissue sections)  
The fresh frozen or cryoprotected tissues were cut on a Leica CM 1510 cryostat, set at -20°C 
and placed onto the positively charged Superfrost slides.  The slides were dried off at 37°C and 
then fixed in ice cold PFA for 15 minutes if fresh frozen or, if sucrose embedded, transferred 
to the PBS wash step, 3% (v/v) hydrogen peroxide in PBS for 1 hour and then antigen 
unmasking (see below).  
 
The paraffin adrenal slides were washed three times with xylene, and once with 100% ethanol.  
Each wash was for 10 minutes.  Peroxidase activity was blocked by incubating with a blocking 
solution made up of 3% (v/v) hydrogen peroxide in methanol for 1 hour. The slides were 
hydrated through a series of graded ethanol concentrations (10mins in 100%, 90%, 70%, 50% 
v/v) and then gently washed with dH2O twice, each 10 minutes.  Antigen unmasking was 
performed by boiling the slides for 30 minutes in 980mls dH2O with 20ml 0.5M Sodium 
Citrate, pH6 added.  The slides were cooled with a PBS wash and then blocked for 1 hour at 
room temperature with 10% (v/v) normal serum of the animal the secondary antibody was 
made in to reduce background staining.  The normal serum is made up with PBS + 0.1% (w/v) 
Sodium azide + 0.2% (v/v) Triton X-100.  The edges of the slides were marked with a 
hydrophobic marker (Pap pen from VWR) and 400µl were used per slide.   
 
For mouse sections, which are known to have an abundance of endogenous biotin, 2 drops of 
Avidin was added for 15 minutes, followed by a quick PBS/triton (Tr-PBS) wash and then 2 
drops of Biotin was added for 15 minutes.  Following this (and for rat and human sections), 
primary antibodies with Tr-PBS were added in the concentrations in Table 2.5 and were left 
overnight at room temperature.  The following day, three 10 minute Tr-PBS washes were done 
and then the secondary Biotinylated antibody 1:400 concentration was added.  The 
Biotinylated antibody used was raised against immunoglobulins from the animal in which the 
primary antibody was made.  300µl were used per slide and incubated for 2 hours at room 
temperature.  A further three 10 minute Tr-PBS washes were done and whilst the washes were 
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on going, the ABC reagents (Avidin + Biotinylated horseradish peroxidise macromolecular 
Complex) were made up (Vectorlab).  Firstly, the total amount of reagents needed was 
calculated and half of the amount is made with ABC.  For example, if the total amount needed 
was 1000µl, then 10µl of A and 10µl of B was added to 480µl of PBS and incubated for 30 
minutes at room temperature before use.  This incubation releases peroxidises necessary for 
the IHC reaction.  Just before use, 500µl of PBS was added.  250-300µl were used per slide 
and incubated for 1 hour at room temperature.  Then three 10 minute washes were done and 
DAB were made.  For each 2.5mls H2O (with a drop of tween added), 1 drop of buffer, 2 drops 
of DAB and 1 drop of hydrogen peroxide was added in this order.  250µl was added to each 
slide and incubated for 2-10 minutes, checking for development regularly and once the desired 
intensity was reached, the reaction was stopped by placing the slide in dH2O.  If there was no 
staining by 10 minutes, it would be unlikely that any further development will occur beyond 
this time.  The slides then went through a dehydration process of 5 minute washes of H2O, 
50% (v/v), 70% (v/v), 90% (v/v), 2x 100% EtOH and 3x xylene washes.  The slides were then 
mounted using DPX mounting medium and covered with a glass coverslip.  Images were 
acquired using a Leica DMR microscope (Leica, Nussloch, Germany), and digital images were 
captured using a Leica DC200 camera (Leica) and DCViewer software (Leica).  Images were 
imported into Photoshop (Adobe Systems, San Jose, CA). 
 
2.10.2 Immunofluorescence 
For fresh frozen slides, 12 µm sections were cut using the cryotome, placed onto SuperFrost 
Plus slides and were dried at 37°C (for about 3 hours) then fixed in cold PFA for 15 minutes 
before going onto 3x 10 minute PBS washes.  Sucrose embedded sections were dried and went 
straight to PBS washes.  Paraffin sections were deparaffinised as set out above. For paraffin 
and sucrose embedded tissue, the sections underwent an antigen unmasking step by boiling the 
slides in citrate buffer (pH6) for 30-40 minutes and then allowed to cool.  This step breaks any 
protein crosslinking formed by PFA treatment and thus exposes antigenic sites which may have 
been masked.  All sections were blocked for 2 hours at RT with 10% (v/v) normal animal 
serum, as in IHC and then primary antibody added and incubated at 4°C overnight in the 
concentrations set out in Table 2.5.  The next day, 3x Tr-PBS washes was followed by the 
addition of secondary antibodies for 3 hours at RT.  For a negative control, the primary 
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antibody was not added to assess the level of non-specific binding.  Another slide had only 
secondary antibody added in order to assess the level of background, to ensure the staining was 
valid.  3x PBS washes was followed by 1 minute incubation with DAPI (4’,6 Diamidino-2-
phenylindole dihydrochloride 1:5000 concentration with dH2O), used to label nuclei.  Slides 
were washed for 3x 10 minutes with PBS and mounted in glycerol: PBS (ratio 4:1) solution 
and covered with glass coverslip.  Images were acquired using a Leica DMR microscope 
(Leica, Nussloch, Germany), and digital images were captured using a Leica DC200 camera 
(Leica) and DCViewer software (Leica).  Images were imported into Photoshop (Adobe 
Systems, San Jose, CA). 
 
Antibody   Company Concentration  
CYP11B1 Monoclonal mouse Prof Celso 
Gomez-Sanchez 
1 in 15 
CYP11B2 Polyclonal rabbit Dr Ed Laufer 1 in 500 
Pref 1 Polyclonal rabbit Prof Gavin 
Vinson 
1 in 400 
Side chain cleavage Polyclonal rabbit Abcam 1 in 1000 
BMP 2 Polyclonal goat Abcam 1 in 200 
 
Table 2.5 Primary antibodies with concentrations used 
 
 
Antibody Company Fluorescence Colour Concentration  
Goat anti mouse Invitrogen  AF488 Green 1 in 1000 
Goat anti rabbit Invitrogen AF568 Red 1 in 1000 
Donkey anti rabbit Jackson 
ImmunoResearch 
CY2 Green  1 in 1000 
Donkey anti goat  Jackson 
ImmunoResearch 
CY3 Red  1 in 1000 
 
Table 2.6 Secondary antibodies with concentrations used 
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2.10.3 IN SITU HYBRIDISATION 
RNA was extracted from adult Wistar rat adrenal tissues or H295R cells using the RNeasy 
Mini kit (QIAGEN), and cDNA was prepared from random-primed total RNA using Maloney 
Murine Leukemia Virus-Reverse Transcriptase (MMLV-RT, Promega) following the 
manufacturer’s instructions.  See Table 2.4 for gene and primers used.  Amplified cDNAs were 
cloned into the dual promoter vector pGEM-T easy (Promega) and linearised with the 
appropriate restriction enzymes, as above.  Digoxigenin (DIG)-labelled antisense and sense 
cRNA probes were synthesised by in vitro transcription in the presence of DIG-labelling mix 
(Roche) following the manufacturer's instruction and using 1 µg of linearised template and T7 
or SP6 RNA polymerase (New England Biolabs). The concentration and integrity of each RNA 
probe was analysed by gel electrophoresis and spectrophotometrically (Nanodrop ND-1000); 
for each probe, the transcription reaction resulted in approximately 10 µg of DIG-labelled 
RNA, which was diluted with DEPC-treated H2O to a concentration of 100 ng/µl, aliquoted, 
and stored at 80°C. All probes were used at a concentration of 400-800 ng/ml in hybridisation 
buffer. Each probe was designed to include regions of low nucleotide identity with other related 
family members or other sequences located in the National Center for Biotechnical Information 
nucleotide database.  
 
Sections were either dehydrated through ascending alcohol series (paraffin) or fixed in PFA 
(fresh frozen or cryoprotected). They were then all permeabilised with Proteinase K (5 µg/ml 
in 100mM Tris HCl pH 7.5 and 50mM EDTA, pH 8.0) for 10 min at 37°C. After washes in 
PBS-0.1% (v/v) Tween-20 (T-PBS), slides were acetylated in T-PBS containing 0.25% (v/v) 
acetic anhydride and 0.1% (v/v) triethanolamine (pH 8.0) for 10 min at room temperature (RT). 
Finally, sections were prehybridised at 58°C in a solution containing 0.3 M NaCl, 10mM Tris-
HCl pH 7.5, 1mM EDTA, 50% (v/v) formamide, 5% (w/v) dextran sulfate, 1× Denhardt's 
solution, 0.5 mg/ml denatured salmon sperm DNA, and 0.02 % (v/v) SDS. After 1 hr 30 
minutes of prehybridisation, the probes were added (400 µl per slide, covered by a Parafilm 
M  coverslip), and the hybridisation reaction was allowed to proceed for about 17 hr at 58°C. 
After hybridisation, the sections were washed in decreasing concentrations of saline sodium 
citrate (SSC) (2X, 1X, 0.2X and 0.05X, where 2X is 0.3M sodium chloride and 0.03M sodium 
citrate, pH 7.0) at room temperature for 20 min then at 65°C for 15 min at each concentration. 
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The slides were then washed in STE buffer (0.5M NaCl, 10mM Tris pH 7.5, 5mM EDTA, 
0.1% (v/v) Tween) for 10 min at RT followed by treatment with RNase A (25 µL of 20mg/ml 
stock in 50 ml of STE buffer) for 30 minutes at 37°C. After washing the slides twice with 
Maleic Acid Buffer (MAB) (0.1M maleic acid, 0.15 NaCl, pH 7.5, stored at 4°C) they were 
incubated with anti-DIG alkaline phosphatase-Fab fragments (Roche) diluted to 1:2000 with 
0.5% (v/v) Blocking Reagent (Roche) in MAB/0.1% (v/v)Tween 20, overnight at 4°C. 
After two washes with T-PBS the slides were equilibrated in alkaline buffer (100mM Tris pH 
9.5, 100mM NaCl, 50mM MgCl2, 1% (v/v) Tween-20) for 10 min before being incubated at 
RT with NBT/BCIP (Roche) at 5µl/ml in alkaline buffer supplemented with levimasole 
(Vector, 1drop/5ml) to reduce background from endogenous alkaline phosphates. Sections 
were checked every hour until there was adequate staining. Sections were finally washed in T-
PBS and fixed with PFA for 10 minutes, followed by 2 further PBS washes and mounted with 
a glycerol-based mounting medium (PBS:glycerol 1:4). 
 
2.11 Human tissue collection  
 
Adrenocortical tissues collected between 2008-2010 at St. Bartholomew’s Hospital.  Patients 
were consented prior to surgery and samples were collected from theatre and immediately 
preserved in RNAlater and placed in dry ice.  Samples were then split, with some frozen in 
RNAlater and some fixed with formaldehyde and embedded in paraffin as described in Section 
2.9.2  
 
2.12  Data Analysis 
 
All data were analysed using Graphpad Prism 7 and 8 to run student t-tests for direct 
comparisons.  For group analysis ANOVA was used. Graphs were produced using Prism 8. 
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3 The presence of BMP3b and BMP2 
in H295R cells and their effects on 
steroidogenesis 
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3.1 Aim  
 
The aim of the work described in this chapter was to test the hypothesis that BMP3b and BMP2 
are expressed in the H295R cells and hence in the adrenal cortex.  Confirming these cytokines 
are present in H295R cells will provide a rationale to investigate their role in adrenal 
steroidogenesis.  This will include analysis of potential interplay between BMP3b and BMP2 
in controlling steroidogenesis and hence zonation of the adrenal cortex.  
This chapter will concentrate on the effects of BMP3b and BMP2 overexpression and 
knockdown on expression of zone specific markers of the adrenal cortex and steroidogenesis 
in H295R cells.      
 
 
3.2  Differentiation 
 
Rat microarray data from the King laboratory indicated that Bmp3b was specifically expressed 
in the capsular/subcapsular region of the adrenal gland (zG/capsule fraction) and Bmp2 was 
highly expressed in the inner cortex (which included zF, zR and medulla).  There was a 12 fold 
increase in Bmp3b in the zG/capsular fraction compared to the inner cortex (p <0.01) and a 2 
fold increase in Bmp2 in the inner cortex compared to the zG/capsular fraction (p<0.01).  The 
H295R cell line was used as a model to investigate the effect of cell differentiation in zG, zF 
or zR phenotypes when BMP3b or BMP2 protein was added.  H295R cells were chosen for 
these experiments as they can express all the components of the steroidogenesis pathway 
(Gazdar et al., 1990; Rainey et al., 2004) as compared to other human adrenocortical cell lines 
available, which is discussed below.  
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The cell lines listed below were considered for the experiments:  
 
3.2.1 SW13 
SW13 is a cell line generated from a small cell adrenocortical carcinoma of a 55 year old 
female. These cells do not secrete any steroid products and were thus not suitable for this study 
(Leibovitz et al., 1973).   
 
3.2.2 ACT-1 
ACT-1 was a cell line derived from a 62 year old male with a large necrotic and haemorrhagic 
adrenocortical carcinoma and metastases.  This cell line had limited use in this study to assess 
steroidogenesis due to the lack of CYP17 enzymes, which are necessary for the production of 
cortisol and androgens (Ueno et al., 2001).  
 
3.2.3 RL-251 
RL-251 is a human adrenal carcinoma cell line derived from a 75 year old male with cells that 
demonstrated abnormal steroidogenesis and was not responsive to ACTH stimulation, which 
again makes this cell line unsuitable for this study (Schteingart et al., 2001).    
 
3.2.4 Immortalised inactivating PRKAR1A mutation cell line  
The PRKAR1A inactivated adrenocortical cell line was derived from primary culture of a 
patient with primary pigmented nodular adrenocortical disease (PPNAD) and Carney’s 
complex but this cell line was not used as it has been reported to lose its cortisol production 
soon after repeated passages (Nesterova et al., 2008).   
 
3.2.5 Human adrenocortical carcinoma cell line (HAC) 
The only other cell line that could have been considered in our study would have been the 
human adrenocortical carcinoma (HAC) cell line, in particular HAC15 which responded to 
Ang II, K+ and ACTH (Parmar et al., 2008). It is a clonal cell line isolated from H295R and is 
more responsive to ACTH than H295R.  However, at the time of this study, this cell line was 
not commercially available.   
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3.2.6 Other cell line attempts 
Two other cell lines that do have the capacity for steroidogenesis are the paediatric 
adrenocortical adenoma cell line from a 1 year old female (Almeida et al., 2008) and Simian 
virus 40 (SV40) transformed cell line that produced human fetal adrenal cell clones (Hornsby 
et al., 1989).  However, both of these cell lines have not been able to continue their steroidgenic 
capacity with ongoing passages, hence limiting their use.   
 
3.2.7 H295R cell line 
The human adrenal carcinoma cell line, NCI-H295R was used throughout this project.  NCI-
H295R was derived from the original cell line NCI-H295.  NCI-H295 was first isolated and 
described by Gazdar et al., in 1990.  The cell line is derived from a 48 year old lady from the 
Bahamas who presented with clinical and biochemical features of adrenocortical carcinoma 
that later metastasised to the lungs and liver (Gazdar et al., 1990).  However, this tumour was 
unusual in that it secreted a combination of glucocorticoid, mineralocorticoid and 17-
ketosteroid.  The cells expressed all the enzymes required for steroidogenesis (Staels et al., 
1993).  They were capable of producing their own cholesterol for steroidogenesis and the cells 
were inducible for steroid production with Ang II, potassium, fsk and to a lesser extent ACTH 
to shift the steroidogenic pathway in the direction to upregulate the steroid, dependent on the 
stimuli.  Adding Ang II to H295 activates AT1 receptors resulting in an increase in intracellular 
calcium and up-regulation of CYP11B2, causing an increase in aldosterone production (Bird 
et al., 1993).  Potassium increases aldosterone production by increasing intracellular calcium 
(Pezzi et al., 1997).  Most likely due to the low expression of MC2R, ACTH appears to have 
a weak effect on H295 cells (Mountjoy et al., 1994).  However, fsk, a cAMP activator, induces 
CYP11B1 and CYP17 transcription.  This results in increased cortisol production initially 
(Denner et al., 1996) but chronic Fsk stimulation leads to activation of the androgen pathway 
with the production of DHEA (Cobb et al., 1996). 
 
Although this original H295 cell line was able to produce all the products of steroidogenesis, 
the cell line itself had a slow doubling time of 5 days (Rainey et al., 2004).  Therefore, a strain, 
known as H295R cells were selected for a shorter doubling time of 2 days by the addition of 
Ultroser G in the media (Hornsby and McAllister, 1991; Rainey et al., 2004).  H295R was also 
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able to grow as an adherent monolayer, unlike H295 which only grew as loosely attached cell 
clusters. H295R is able to express all the enzymes required for steroidogenesis, responds 
appropriately to Ang II, K+ and Fsk, representing the three zones of the adrenal cortex and is 
the most studied adrenocortical cell line to date.  Another strain of H295 is H295A, which 
again is able to produce all the steroids but it is not responsive to Ang II. 
 
3.2.8  Zone specific expression of BMP3b  
The following experiments investigated the effect of BMP3b on the expression of key 
steroidogenic genes (CYP11B1, CYP11B2, CYTB5, SULT2A1) in the three zones of the adrenal 
cortex (zG, zF and zR). 
 
The effects of adding BMP3b to H295R cells, over-expressing BMP3b and then silencing to 
see if the effects can be reversed was investigated.  cDNA was made following treatment of 
cells as described in Section 2.4.  RT-qPCR was performed to compare the relative mRNA 
levels of enzymes of steroidogenesis, with or without treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  CHAPTER 3: Presence of BMP3b and BMP2 and its effects on H295R cells 
98 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 CYP11B1 expression in H295R cells treated with BMP3b 
H295R cells were treated with either recombinant BMP3b or a vehicle only control.  CYP11B1 
expression in H295R cells with or without BMP3b treatment were compared with control cells 
and in response to Ang II or Fsk. N=3, performed in triplicates.  Error bars indicate SEM.  
**p<0.01, student’s T-Test,   Ang II = angiotensin II, Fsk = forskolin 
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Figure 3.2 CYP11B2 expression in H295R cells treated with BMP3b 
H295R cells were treated with either recombinant BMP3b or a vehicle only control.  CYP11B2 
expression in H295R cells with or without BMP3b treatment were compared with control cells 
and in response to Ang II or Fsk. N=3, performed in triplicates.  Error bars indicate SEM.  
**p<0.01, student’s T-Test,   Ang II = angiotensin II, Fsk = forskolin 
 
 
 
Figure 3.1 and Figure 3.2 have demonstrated a significant effect on expression of markers of 
steroidogenesis with the addition of BMP3b protein to H295R cells.  BMP3b causes 
significantly increased mRNA levels of CYP11B2 (p<0.01) in cells treated with Ang II and 
significantly reduced CYP11B1 mRNA levels (p<0.01) in cells treated with Fsk.  The use of 
recombinant protein was informative but further investigation was necessary to confirm this 
effect.  This was achieved by experiments overexpressing BMP3b. H295R cells were 
transfected with either an empty vector (pIRES) as control or a vector for expression of full 
length human BMP3b cDNA.   
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Figure 3.3 BMP3b, CYP11B1 and CYP11B2 expression in H295R cells stably expressing 
BMP3b 
H295R stably expressing BMP3b cells were generated by transfection with a pIRES vector 
containing a full length human BMP3b cDNA and subsequent antibiotic selection. A control 
line transfected with empty pIRES vector was made at the same time (A) BMP3b is 
significantly over expressed in stable cells compared with control cells, as indicated by 
elevated levels of BMP3b RT-pCR product. (B)(C) CYP11B1 and CYP11B2 expression in 
BMP3b over expressing H295R cells compared with control cells and in response to Ang II or 
Fsk. N=3, performed in triplicates.  Error bars indicate SEM. 
*p<0.05, ***p<0.001, student’s T-Test,   Ang II = angiotensin II, Fsk = forskolin 
 
 
The results shown in Figure 3.3 are consistent with published data on the effects of Ang II and 
fsk on H295R cells (Liakos et al., 2003).   Furthermore, H295R cells treated with Ang II have 
significantly increased levels of CYP11B2 mRNA expression (p<0.05) and decreased levels of 
CYP11B1 mRNA (p<0.05), when treated with Fsk, when BMP3b is overexpressed.  
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Zonation theories, as discussed in section 1.3, suggests that cells migrate in a centripetal 
fashion from the capsule towards the medulla.  As the cells travel inwards, their steroidogenic 
identity changes.  Many genes play a role in this process and have been discussed previously.  
With the prevalence of BMP3b in the zG and not in the inner cortex, we set out to investigate 
whether the presence or absence of BMP3b would have an effect on the steroidogenic 
expression of H295R cells into a zR phenotype.  Cytochrome b5 (CYTB5) and sulfotransferase 
family 2A member 1 (SULT2A1) are both important for the production of androgens (DHEA 
and DHEAS).  Treatment of H295R cells with recombinant BMP3b resulted in a significant 
decrease in levels of CYTB5 (p<0.01) and SULT2A1 (p<0.05) mRNA (Figure 3.4). This 
suggests BMP3b may have a suppressive effect on zR specific genes.     
 
 
 
 
Figure 3.4 CYTB5 and SULT2A1 expression in H295R cells treated with BMP3b 
H295R cells were treated with either recombinant BMP3b or a vehicle only control.  (A)(B) 
CYTB5 and SULT2A1 expression in H295R cells with or without BMP3b treatment were 
compared with control cells. N=3, performed in triplicates.  Error bars indicate SEM.  
*p<0.05, **p<0.01, student’s T-Test. 
 
 
 
Experiments using overexpression and recombinant BMP3b all showed that BMP3b protein 
can significantly increase levels of CYP11B2 and decrease levels of CYP11B1 mRNA 
expression in H295R cells undergoing different differentiation paradigms.  Treatment with 
BMP3b protein also decreased expression of the zR specific genes CYTB5 (p<0.01) and 
SULT2A1 (p<0.05). This significant downregulation of CYTB5 and SULT2A1 mRNA 
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expression could indicate that BMP3b, which was not suggested to be expressed in the inner 
zones of the adrenal cortex, based on our  microarray data, can exert an effect on zR specific 
genes. 
 
To further explore the importance of BMP3b for the up and down regulation of steroidogenesis 
genes, a knockdown study was designed using siRNAs targeting BMP3b.  These knockdown 
experiments were performed with addition of Ang II or Fsk at the time of transfection,  
 
The knockdown experiments shown in Figure 3.5 and Figure 3.6 show that reducing RNA 
levels of BMP3b resulted in significant upregulation of CYP11B1 (p<0.05) and CYTB5 
(p<0.05).  These results suggest that BMP3b expression may prevent mRNA expression of 
CYP11B1 and CYTB5, and is thus acting as a negative regulator of differentiation to a zF and 
zR phenotype.  However, there was no effect shown of siBMP3b on SULT2A1 mRNA 
expression.  This may be because the magnitude of the knockdown (approximately 60% 
reduction in mRNA) was insufficient to alleviate any negative regulation of expression in this 
case.  There was also no significant downregulation of CYP11B2 seen here, which does not 
support the hypothesis that BMP3b could play a key role in promoting the zG phenotype within 
the adrenal cortex but may also be a consequence of the incomplete knockdown.   
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Figure 3.5 BMP3b, CYP11B1 and CYP11B2 expression in H295R cells transfected with 
siBMP3b 
H295R cells were transfected with either a non-targeting control siRNA or an siRNA targeting 
BMP3b. (A) BMP3b expression was significantly reduced in siBMP3b transfected H295R 
cells compared cells transfected with the control siRNA. (B)(C) CYP11B1 and CYP11B2 
expression in siBMP3b transfected H295R cells were compared with controls in cells treated 
with Ang II or Fsk. N=6, performed in triplicates.  Error bars indicate SEM.  
*p<0.05, student’s T-Test,   Ang II = angiotensin II, Fsk = forskolin 
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Figure 3.6 CYTB5 and SULT2A1 expression in H295R cells transfected with siBMP3b 
H295R cells were transfected with either a non-targeting control siRNA or an siRNA targeting 
BMP3b (A). BMP3b expression was significantly reduced in siBMP3b transfected H295R 
cells compared to controls. (B)(C) CYTB5 and SULT2A1 expression in siBMP3b transfected 
H295R cells compared with empty vector control and in response to Ang II or Fsk. N=6, 
performed in triplicates.  Error bars indicate SEM.  
*p<0.05, student’s T-Test,   Ang II = angiotensin II, Fsk = forskolin 
 
 
The data so far have shown that BMP3b, by adding recombinant protein or through 
overexpression, significantly increases angiotensin-induced CYP11B2 mRNA expression 
(p<0.01 and p<0.05, respectively), indicating that it could have a direct effect on differentiation 
of H295R cells to the zG phenotype.  Conversely, BMP3b had an inhibitory effect on CYP11B1 
mRNA expression, which is found within the zF.   
 
In conclusion, this set of experiments have shown that BMP3b affects steroidogenic gene 
expression in H295R cells.  Taken together, the results are consistent with the ability of BMP3b 
to upregulate CYP11B2 expression, a marker of the zG phenotype, and downregulate the zF 
and ZR phenotype as assessed by CYP11B1 and CYTB5 expression, respectively.  It is tempting 
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to speculate that  BMP3b can promote the zG phenotype and/or inhibit the conversion of the 
cells to the zF/zR phenotype.  
 
3.2.9  Zone specific expression of BMP2 
Microarray studies have indicated that BMP2 is expressed at higher levels in the inner zones 
of the rat adrenal compared to outer zones.  H295R cells were treated with BMP2 protein to 
investigate the effects on steroidogenic gene expression of all 3 cortical zones and compare 
them to the effects of opposite BMP3b.   
 
Figure 3.7demonstrated that BMP2 treatment of H295R cells did not have any significant 
effect on CYP11B1 or CYP11B2 mRNA expression, indicating that it may not have a direct or 
indirect role in differentiation towards or steroidogenesis in the zF or zG respectively.  
Moreover, microarray data indicated that Bmp2 was most highly expressed in the inner cortex 
of the rat adrenal, which include zF, zR and the medulla.  Therefore, zR specific enzymes were 
investigated with BMP2 treated cells (Figure 3.8).   The results showed that both CYTB5 and 
SULT2A1 mRNA expression were significantly upregulated in the presence of BMP2 (p<0.05 
for both) compared with control.    
 
 
 
Figure 3.7 CYP11B1 and CYP11B2 expression in BMP2 treated H295R cells 
H295R cells were treated with either recombinant BMP2 or a vehicle only control.  (A) (B) 
CYP11B1 and CYP11B2 expression in H295R cells with or without BMP2 treatment were 
compared with control cells and in response to Ang II or Fsk. N=6, performed in triplicates.  
Error bars indicate SEM.  Student’s T-Test used.   Ang II = angiotensin II, Fsk = forskolin 
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Figure 3.8 CYTB5 and SULT2A1 expression in BMP2 treated H295R cells 
H295R cells were treated with either recombinant BMP2 or a vehicle only control.  (A)(B) 
CYTB5 and SULT2A1 expression in H295R cells with or without BMP2 treatment were 
compared with control cells. N=6, performed in triplicates.  Error bars indicate SEM.  
*p<0.05, student’s T-Test. 
 
                          
In conclusion, these experiments showed that BMP2 did not exert any significant effect on 
CYP11B1 or CYP11B2 mRNA expression.  However, it did show a significant upregulation of 
zR specific enzymes (p<0.05),.  This finding suggests that BMP2 may have a local role in 
promoting differentiation into a zR phenotype in normal adrenal zonation and differentiation.  
Limitations to these experiments are discussed in the general discussion. 
 
 
3.3  Steroid hormone production 
 
These experiments indicate a role of BMP3b in promoting a zG phenotype, while BMP2 
promotes a zR phenotype respectively.  It indicates that BMP3b and BMP2 can both have an 
effect on androgen steroidogenesis.  BMP3b could be a factor that negatively affects 
differentiation into a zR phenotype, which could be through suppression of BMP2 expression 
or action, as shown in previous experiments.  However, from these results, it was unclear if the 
interplay between BMP3b and BMP2 results in significant steroid production in H295R cells.    
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Changes in mRNA expression do not necessarily result in alterations in protein expression of 
a similar magnitude.  To investigate the correlation of mRNA expression with BMP protein 
levels, ELISA (Enzyme-linked immunosorbent assay) was performed.  
 
From the previous experiments, it was predicted that aldosterone would be highest in the Ang 
II +/- BMP3b treated group and would be unaltered with BMP2 presence.  The results shown 
below in Figure 3.9 did not show the predicted pattern.  Aldosterone production was not 
significantly increased or decreased in any of the groups. Thus the ELISA data did not correlate 
with our qPCR results.  Cortisol and DHEAS was also evaluated and significant differences 
were not found (Figure 3.10 and Figure 3.11).   
 
 
 
 
Figure 3.9 Aldosterone production in H295R cells treated with BMP2 or BMP3b 
H295R cells were treated with either recombinant BMP2, BMP3b or a vehicle only control.  
(A) Standard curve was generated to calculate the production of aldosterone. (B) Aldosterone 
levels were measured H295R cells treated with BMP2, BMP3b compared to control cells and 
in response to Ang II or Fsk.  N=3, performed in triplicates.  Error bars indicate SEM. Student’s 
T-Test used. Ang II = angiotensin II, Fsk = forskolin 
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Figure 3.10 Cortisol production in H295R cells treated with BMP2 or BMP3b 
H295R cells were treated with either recombinant BMP2, BMP3b or a vehicle only control.  
Cortisol levels were measured in H295R cells treated with BMP2, BMP3b compared to control 
cells and in response to Ang II or Fsk.  N=3, performed in triplicates.  Error bars indicate SEM.  
Student’s T-Test used. Ang II = angiotensin II, Fsk = forskolin 
 
Figure 3.11 DHEAS production in H295R cells treated with BMP2 or BMP3b 
H295R cells were treated with either recombinant BMP2, BMP3b or a vehicle only control.  
DHEAS levels were measured in H295R cells treated with BMP2, BMP3b compared to control 
cells and in response to Ang II or Fsk.  N=3, performed in triplicates.  Error bars indicate SEM.  
Student’s T-Test used. Ang II = angiotensin II, Fsk = forskolin 
The results of steroid hormone production from the ELISA experiments were not consistent 
with the RT-qPCR findings with BMP3b and BMP2.  No clear pattern was seen in hormone 
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production that would indicate that BMP3b was positively affecting aldosterone production or 
negatively affecting cortisol or DHEAS production, or that BMP2 was positively affecting 
DHEAS production.  There were limitations to this direct comparison, as BMPs are not the 
only pathway in adrenal steroid production.  Other mechanisms and pathways are likely to be 
involved to maintain appropriate steroid levels and homeostasis, which have not been 
accounted for in this study design.  Therefore, mRNA expression shown previously cannot be 
directly corrrelated to increased protein production or function.   
 
The effect of BMP3b and BMP2 on steroid production was investigated with knockdown 
experiments using siBMP3b and siBMP2 (Figure 3.12, Figure 3.13 and Figure 3.14). 
 
 
 
 
  CHAPTER 3: Presence of BMP3b and BMP2 and its effects on H295R cells 
110 
 
 
 
 
Figure 3.12 Aldosterone production in H295R cells transfected with siBMP3b or 
siBMP2 
H295R cells were transfected with either a non-targeting control siRNA or siRNAs targeting 
BMP3b or BMP2. (A)(B) BMP3b and BMP2 expression was significantly reduced in siBMP3b 
and siBMP2 transfected H295R cells, compared to controls. (C) Aldosterone production was 
measured in siBMP3b and siBMP2 transfected H295R cells compared with non-targeting 
control siRNAs and in response to Ang II or Fsk. 
N=3, performed in duplicates.  Error bars indicate SEM. 
*p<0.05, student’s T-Test,   Ang II = angiotensin II, Fsk = forskolin 
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Figure 3.13 Cortisol production in H295R cells treated with siBMP2 or siBMP3b 
H295R cells were transfected with either a non-targeting control siRNA or siRNAs targeting 
BMP3b or BMP2.  Cortisol production was measured in siBMP3b and siBMP2 transfected 
H295R cells compared with non-targeting control siRNAs and in response to Ang II or Fsk. 
N=3, performed in duplicates.  Error bars indicate SEM. 
*p<0.05, student’s T-Test,   Ang II = angiotensin II, Fsk = forskolin 
 
 
Figure 3.14 DHEAS production in H295R cells treated with siBMP2 or siBMP3b 
H295R cells were transfected with either a non-targeting control siRNA or siRNAs targeting 
BMP3b or BMP2.  DHEAS production was measured in siBMP3b and siBMP2 transfected 
H295R cells compared with non-targeting control siRNAs and in response to Ang II or Fsk. 
N=3, performed in duplicates.  Error bars indicate SEM. 
*p<0.05, student’s T-Test,   Ang II = angiotensin II, Fsk = forskolin 
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There was a significant difference in the production of cortisol and DHEAS with the presence 
of siBMP3b and siBMP2 (p<0.05 for both), repectively.  The latter result supports a role for 
BMP2 in zR phenotype establishment and steroidogenesis, but the former is a surprising result 
which is at odds on the previous data indicating that BMP3b should be inhibitory to the 
establishment of the zF phenotype.  
 
 
3.4 Discussion 
 
These results correlate with the rat microarray data (from the King group), which found 
BMP3b exclusively in the outer cortex in the region of the stem/progenitor cells.  This suggests 
BMP3B is likely to exert its effects locally.  However, in the H295R cell model it can also 
suppress markers of the zR: CYTB5 and SULT2A1. As a secreted molecule, it is possible that 
BMP3b could have an effect on the outer zF, but is unlikely to affect the zR in any appreciable 
manner, other than inhibiting the differentiation of progenitor cells to the zF/zR commitment 
pathway. The suppressive effects were significantly reversed for CYP11B1 (p<0.05) and 
CYTB5 (p<0.05) when BMP3b was knocked down with siBMP3b.    
 
H295R cells express components of the BMP pathway and these have an effect on 
steroidogenesis.  Previous data, suggesting that  expression of BMP3b occurs exclusively in 
the outer zone of the adrenal, while BMP2 is expressed highly in the inner zone, has led to the 
hypothesis that within the cortex BMPs exert specific effects within zonal area that may 
contribute to the process of zonation.  Indeed, BMPs have been shown to have a zonal effect 
in other studies (Liakos et al., 2003; Suzuki et al., 2004) and hence it is likely that, like BMP6, 
BMP3b acts within the zG (Inagaki et al., 2006).  BMPs are morphogens, thus the finding of 
zone specific BMPs fits in with the hypothesis of BMP3b being specific to zG and BMP2 to 
zF/zR.  However, their effects can be observed beyond the zones as they can work on a gradient 
dependent mechanism (Tabata and Takei, 2004).  Adrenocortical cell lines were used to allow 
for the investigation of steroidogenic gene expression on a mRNA level. Due to the lack of 
suitable antibodies available at the time of the experiments, it was not possible to investigate 
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protein expression using Western blotting techniques.  Ideally these experiments would be 
repeated to measure protein if suitable antibody tools become available.  
 
These experiments have shown that BMP3b and BMP2 are likely to have distinct regions of 
expression within the adrenal cortex and that BMP3b treatment of H295R cells can inhibit their 
conversion to the zF/zR phenotype. These data are consistent with a hypothesis that BMP3b is 
inhibitory to cell differentiation by inhibiting the expression and action of BMP2 (Figure 1.6 
and Figure 1.7).  It is hypothesised that as cells migrate from the capsule into the cortex they 
are exposed to increasing BMP2 signals which promote the differentiation of the cells to the 
zF and zR phenotypes.  A possible model of BMP signalling in the adrenal cortex is the 
establishment of a BMP3b gradient exclusively in the outer cortex.  This gradient antagonises 
BMP2 function, thus maintaining the phenotype of precursor cells.  As these cells proliferate 
and migrate centripetally, they exit the zG and hence BMP3b gradient.  This results in BMP2 
exposure with a change in phenotype to zF or zR (Figure 3.15). 
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Figure 3.15 Model for the structural and functional zonation in the adrenal gland 
A BMP3b gradient is established in the outer cortex. This gradient antagonises BMP2 
expression thus maintaining the phenotype of the precursor cells in the outer zones of the 
adrenal cortex. These cells proliferate and migrate into the inner cortex.  As they leave the zG, 
they exit the BMP3b gradient and become subject to the actions of BMP2 or other factors.  The 
cells differentiate into other cortical phenotypes and eventually die at the ZR/medulla 
boundary.  
 
 
This proposed model was based on mRNA levels detected in H295R cells.  Experiments in  
H295R cell using ELISA steroid assays demonstrated that the addition of Fsk increased cortisol 
production (p<0.05) and the addition of siBMP2 increased DHEAS production (p<0.05) which 
support the qPCR findings of mRNA levels.   However, the effects of BMP3b and BMP2 on 
aldosterone and DHEAS production respectively were not significant and so did not reflect the 
qPCR results to fully support this model on a functional basis.  Interestingly, the presence of 
siBMP3b decreased cortisol production significantly (p-<0.05), which contradicts the qPCR 
results of increased levels.  However, siBMP3b significantly increases CYTB5 expression in 
these cells (Figure 3.6) and it is possible that reduced cortisol production reflects the 
capsule 
zG 
zF 
zR 
Medulla 
BMP-3B 
Migration 
BMP-2 
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preferential androgen production.  DHEAS was not detected in the H295R cells by ELISA.  
This could be explained by previous results where siBMP3b had no significant effect on 
SULT2A1 expression, a key enzyme for the production of sulphated DHEA.  Therefore, if  
sulphation did not occur, then it is plausible that DHEAS would not be detected.  In addition, 
Ang II presence did not significantly increase aldosterone production.  A possible explanation 
is that these experiments did not take into account other BMPs present in the cortex, such as 
BMP6, which may have also had an effect on the synthesis of aldosterone in all conditions.  
Another possibility could be the kit used, which is only valid for human plasma or serum and 
not specifically for culture medium, though ELISA measurements are used in many cell culture 
studies.  A third reason could be a compensatory mechanism that could exist in H295R cells 
to maintain steroid production, which has been shown in bone formation and fracture repair, 
where the lack of BMP7 is compensated by BMP4 (Tsuji et al., 2010).  More tests with 
different assay platforms and more samples should have been used to further validate the 
findings in these experiments. 
 
Further experiments are needed to look at the interaction between BMP3b and BMP2, with the 
inclusion of all the other BMPs found in the adrenal cortex in order to demonstrate a direct 
effect. 
  
BMP3b is expressed in the outer capsular/subcapsular region of the cortex and is able to inhibit 
the differentiation of H295R cells to the zF/zR phenotype, suggesting that it may be a marker 
of stem or progenitor cells or can influence their differentiation.  H295R cells were a useful 
cell line in which to test this hypothesis as it is a relatively undifferentiated cell line with the 
capacity to differentiate into all cell types of steroidogenesis and is able to replicate infinitely. 
However, as H295R cells are derived from a carcinoma, further passaging of these cells can 
lead to new mutations and the cell characteristics may change over time, with differentiation 
and de-differentiation at an unknown rate.  This was avoided in our experiments by limiting 
the passages of cells used.  Ideally, to investigate stem cell progenitors, human primary adrenal 
cultures should be use.  This was considered but thought not to be feasible because of technical 
and ethical issues.  For this reason, H295R cells (or different undifferentitated cell lines that 
may be available in the future) remain the best model from which to gather initial data.  Other 
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cell lines, such as HAC15, are also available (Parmar et al., 2008).  HAC15, like H295R cell 
line, is derived from human adrenocortical carcinoma cells that is thought to be both ACTH 
and Ang II responsive, whereas H295R cells are less ACTH responsive. However, HAC has 
been shown to have been derived from monoclones of H295R cells, therefore this is not a 
totally novel cell line to corroborate the current data.  One possible approach in the future, 
when primary adrenal cell cultures are more easily accessible, more studies can be carried out 
over a longer period of time with the use of hTERT (human telomerase reverse transcriptase).  
hTERT has the ability to extend the life span of normal human cells by overcoming the problem 
of telomere shortening without causing cellular transformation and genomic instability (as 
would be expected in cancer cell lines) (Ouellette et al., 2000). 
 
Many studies on BMPs have demonstrated the vast number of roles and mechanisms of how 
BMPs can exert their effects in a local and gradient fashion, such as BMP4 in gastrulation 
(Jones and Smith, 1998).  Nilsson described the differences in concentration of various BMPs 
in the different zones of growth plate, contributing to the maintenance of the cells in their stem 
cell, proliferative or hyperplastic state (Nilsson et al., 2007).  This morphogen action also 
applies to drosophila where the BMP homolog, decapentaplegic (DPP) interacts with hedgehog 
(HH), to direct anteroposterior patterning of the wing with differing expression concentrations 
(Tanimoto et al., 2000).  The role of BMPs can be very tissue and cell specific, making 
extrapolation of findings in one organ to another difficult (Wang et al., 2014).  In conclusion, 
the in vitro studies have demonstrated that BMP3b, which was originally found in the capsular 
region of the rat microarray studies, act on H295R cells to increase CYP11B2 mRNA 
expression.  It also has exerts the opposite effect to BMP2, which is found in the inner cortex 
of the rat adrenal, on CYTB5 and SULT2A1 (zR specific) mRNA expression.  
 
The adrenal gland is such a complex and vital organ for survival, that it is highly unlikely for 
only one mechanism to have evolved for its zonation and maintenance in function.  Published 
data suggests that Rspo3, Wnt, Shh and PKA pathways are all required for the regeneration 
and zonation of the adult adrenal cortex (Drelon et al., 2016a; Vidal et al., 2016).  The data 
also support a centripetal model of recruitment of progenitors cells in the capsular region that 
are then differentiated to a zG phenotype initially then to zF phenotype by lineage conversion 
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(Vidal et al., 2016).  The published data suggests that Rspo3, found in the adrenal capsule 
induces β-catenin signalling which then activates Shh signalling.  Shh signalling is essential 
for recruitment of capsular cells (King et al., 2009), as a lack of Shh signalling will result in 
impaired adrenal cortical growth.  Shh activation will then activate Gli1 signalling in the 
capsular region to initiate cell recruitment for differentiation (Vidal et al., 2016).  Following 
cell recruitment, the PKA pathway appears to be important for lineage conversion of zG cells 
to the zF phenotype.  Activation of PKA also prevents zG differentiation through Wnt4 
repression and inhibition of the Wnt pathway (Drelon et al., 2016a).  There is also interplay 
between PKA and MRAP, an accessory protein that triggers the cAMP/PKA pathway and the 
recent study by Novoselova et al., demonstrated that a MRAP knock out mouse has impaired 
adrenal progenitor cell differentiation and gland zonation (Novoselova et al., 2018).  These 
pathways all have a role to play in adrenal renewal and zonation but this is unlikely to be the 
only pathways involved, as more association between pathways are being discovered.  BMPs 
are known to have interplay with the Hh and Wnt pathway in other organs (Ding and Wang, 
2017; Hu et al., 2005; Sanz-Ezquerro et al., 2017) and it could be postulated that BMPs may 
also have a role in adrenal zonation through interaction with any of these pathways, which 
would need further studies.        
 
Although my data support that BMP3b and BMP2 could be pathways affecting adrenal 
zonation and steroidogenesis, further experiments and controls would be required for definitive 
proof.  These would include: 
 
1. To normalise qPCR to additional reference genes because this increases the accuracy 
of data with geometric averaging.  Vandesompele et al., demonstrated that using 
single reference genes for normalisation can lead to erroneous normalisation of up to 
3 and 6.4 fold in 25% and 10% of cases, respectively.  Some reference genes were 
shown to be highly variable in different tissue types and could also be unstable 
(Vandesompele et al., 2002).   
2. To demonstrate transfection efficiency with either co-transfection with Renilla DNA 
and a luciferase assay or by GFP immunofluorescence.  This was not performed in my 
samples as the initial experiments for optimisation of transfection efficiency was 
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performed by my predecessor.  Therefore they were not repeated for these experiments 
as the reagents and BMP plasmids used were identical.  Future experiments should be 
with transfection efficiency reported in order to confirm my current findings.  However, 
if transfection efficiency were to be carried out with each transfection, there is no 
methodology to correct for the different transfection rates in relation to the results 
obtained for each experimental replicate.  My experiments were carried out with 
consistent methods and parameters to minimise variability between experiments.   
3. Immunoblot to confirm the knockdown efficiency of siRNAs used to demonstrate more 
than 50% reduction in protein levels.  siScrambled should have been used in all the 
knockdown experiments to show that the results were not a result of transfection 
methods.  It should be noted that in similar studies by Dr Bakmanidis a scrambled 
control had no effect on steroidogenic gene expression in this cell line nor did a 
GAPDH targeted siRNA (data not shown). However, given that the results obtained 
with validated siRNAs were in almost all cases the opposite of those seen with 
overexpression of the BMP and/or treatment with recombinant protein, it would be 
highly unlikely that the siRNA results presented here were as a consequence of off 
target effects. Future experiments using all these parameters to demonstrate 
knockdown would be ideal. 
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in the adrenal cortex  
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4.1 Aim  
 
Real-time PCR has established that BMP3b and BMP2 mRNAs are expressed in the outer and 
inner zones of the rat adrenal cortex respectively.  This chapter will investigate the location of 
Bmp3b and Bmp2 expression in rat and mice adrenal glands, using adrenal glands from Wistar 
rats and Bmp3b knock out mice.  The localisation of BMP receptors will also be investigated 
to identify where Bmp3b and Bmp2 may exert their effects.     
 
Due to the lack of good antibodies for detection of BMPs and their receptors in the adrenal 
cortex, a non radioactive in situ hybridisation (ISH) approach Figure 4.1 was used to look for 
endogenous mRNA expression.  In this technique, the probe was labelled with digoxigenin, 
that will stain a magenta colour upon mRNA binding to the probe.  Experiments were carried 
out with a ‘sense’ negative control, as shown in Figure 4.2 to ensure that any positive staining 
in tissues is specific to the probe, showing true expression.     
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4.2 In situ hybridisation 
 
(a)  
(b)  (c)  
 
Figure 4.1 Cloning of BMP3b, BMP2 and BMPR1a into pGEM-T Easy to create in situ 
hybridisation probes 
cDNAs (approximately 1kb in length) for BMP3b (a), BMP2 (b) and BMPR1a (c) were created 
by PCR from H295R cDNA and cloned into pGEM-T Easy.  Orientations were checked by 
restriction digest and the plasmids linearised with appropriate restriction enzymes targeting 
sites in the polylinker at the 5’ end of the cDNA. Antisense ISH probes were synthesised using 
T7 or SP6 RNA polymerases as appropriate. 
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Figure 4.2 In situ hybridisation using Bmp3b sense probe - negative control 
Representative light microscopy images of paraffin embedded adrenal sections from Wistar 
male rat, aged 17.5 days, incubated with Bmp3b sense riboprobe as a negative control, resulting 
in no specific staining.  The adrenal gland outlined by the black dotted line.  Images were taken 
using the Leica DMR light microscope with 10x objectives.  N=3, scale bar represents 200µm.  
 
 
4.3 BMPs and adrenal development 
 
To date there is no direct evidence linking BMPs to adrenal development.  However, indirect 
data from the Booroola sheep, which have a naturally occurring mutation in BMPR1B coupled 
with a phenotype of significantly smaller adrenal glands (Souza et al., 2001), suggests this 
could be the case.  Evidence of the presence and actions of BMPs within the adrenal cortex 
and medulla has been predominantly from in vitro studies using H295R and PC-12 cells 
respectively (Inagaki et al., 2006, 2007; Johnsen and Beuschlein, 2010; Rege et al., 2015).  
Within the adrenal medulla, there is in vitro and in vivo evidence showing that BMP2, 4 and 7 
are involved in the specification of sympathoadrenal cells (Schneider et al., 1999).  Within the 
adrenal cortex, the data is mainly in vitro, showing BMP6 as a key factor to augment Ang II 
secretion and hence aldosterone production (Inagaki et al., 2006; Suzuki et al., 2004) and data 
from Johnsen found that BMP2 and BMP5 are able to suppress forskolin-induced 
steroidogenesis in H295R cells (Johnsen et al., 2009). 
 
BMP3b has been documented to be involved in bone development and remodelling, hence 
vertebrae staining was used as a positive control to confirm the utility of the in situ probe 
generated.  Non-radioactive ISH was carried out at different developmental stages of the male 
Adr 
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Wistar rat - from E14.5 to adult - to identify when and where Bmp3b is expressed.  The same 
analyses were performed for Bmp2, Bmpr1a and Bmpr1b. 
 
 
4.4 Detection  
 
4.4.1 BMP3b 
 
 
Figure 4.3 Positive Bmp3b mRNA staining in vertebrae - positive control 
Representative light microscopy images of paraffin embedded adrenal sections from Wistar 
male rat, aged 15.5 days, incubated with Bmp3b antisense riboprobe as a positive control, 
staining seen in vertebral bone.  Images were taken using the Leica DMR light microscope 
with 10x (A) and 20x (B) objectives.  N=3, scale bar represents 200µm.  
 
 
At E14.5, no specific localised staining of Bmp3b in the adrenal gland/cortex was seen.  
However, by E15.5, there is some accumulation in parts of the subcapsular/zG area as shown 
in Figure 4.4.  E17.5, Bmp3b mRNA is specifically localised to the subcapsular region and this 
staining remains into adulthood (Figure 4.5). 
 
 
 
 
A B 
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Figure 4.4 In situ hybridisation of Bmp3b in developing rat embyros 
Representative light microscopy images of paraffin embedded adrenal sections from Wistar 
male rat, aged 14.5 days (A) and 15.5 (B,C).  They were incubated with Bmp3b antisense 
riboprobe in (A) and (C) and Bmp3b sense riboprobe in (B) as negative control.  Images were 
taken using the Leica DMR light microscope with 10x objectives.  N=3, scale bar represents 
200µm.  Black dotted line marks the adrenal gland. Arrow indicates staining around the 
capsular/zG boundary.  
 
 
 
         
Figure 4.5 In situ hybridisation of Bmp3b staining is seen in rat adrenals 
Representative light microscopy images of paraffin embedded adrenal sections from Wistar 
male rat, aged 17.5 days (A) and adulthood (B).  They were incubated with Bmp3b antisense 
riboprobe in (b,c,d) and Bmp3b sense riboprobe in (a,e) as negative control.  Images were 
taken using the Leica DMR light microscope with 10x (a,b), 20x (d,e) and 40x (c) objectives.  
N=3, scale bar represents 200µm.  Black dotted line marks the adrenal gland. Arrow indicates 
staining in the subcapsular region. V = vertebrae, K = kidney, Liv = liver, Adr = adrenal 
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Having established Bmp3b expression in the capsule of E17.5 rat adrenals, the expression of 
BMP receptors was investigated to identify the cells responding to BMP signals.  BMP 
receptors can bind to any of the BMPs.  Therefore, the presence of expression does not directly 
indicate an association with BMP3b.  In Figure 4.6 below, definite staining of Bmpr1a was 
seen in the capsular region of the rat adrenal cortex by E15.5, 2 days earlier than the definite 
appearance of Bmp3b.  The capsular staining remained throughout development (Figure 4.7).  
The staining of Bmpr1a was very uniform throughout the whole of the subcapsular region in 
contrast to Bmp3b staining that was patchy throughout the subcapsular region. 
 
4.4.2 BMPR1A 
 
Figure 4.6 In situ hybridisation of Bmpr1a in rat adrenal at E15.5 
Representative light microscopy images of paraffin embedded adrenal sections from Wistar 
male rat, aged 15.5 days.  They were incubated with Bmpr1a antisense riboprobe (b,c) and 
Bmpr1a sense riboprobe (a) as negative control.  Images were taken using the Leica DMR light 
microscope with 5x (a,b) and 40x (c) objectives.  N=3, scale bar represents 200µm. K = kidney, 
Adr = adrenal 
 
 
Figure 4.7 In situ hybridisation of Bmpr1a in rat adrenal at E17.5 
Light microscopy images of paraffin embedded adrenal sections from Wistar male rat, aged 
17.5 days.  They were incubated with Bmpr1a antisense riboprobe (b) and Bmpr1a sense 
riboprobe (a) as negative control.  Images were taken using the Leica DMR light microscope 
with 5x objectives.  N=3, scale bar represents 200µm.  K = kidney, Liv = Liver, Adr = adrenal 
(a) (b) (c) 
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Liver 
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4.4.3 BMP2 and BMPR1B 
No staining was found with Bmp2 and Bmpr1b probes in the adrenal cortex at any stage of 
development (Figure 4.8).  This was a surprising result as previous studies have shown the 
presence of a mutation in Bmpr1b in Boorola sheep, which was linked to the observation of 
smaller adrenals (Souza et al., 2001).  There was an absence of Bmp2 staining in the rat adrenal 
cortex, which did not reflect the findings within the microarray and cell culture experiments 
performed here.   This experiment was repeated 10 times with different probes made and in 
situs performed on samples from a wide range of embryonic stages.  Positive staining was 
observed within the kidneys (Figure 4.8), which would confirm the lack of Bmp2 staining 
rather than an issue with the probe. Therefore, immunofluorescence (IF) was performed with 
Bmp2 to investigate its expression within the adrenal cortex (Figure 4.9).  Using BMP2 
antibody for IF, there was increased signalling within the inner cortex in the rat adrenal.  
 
 
 
Bmp2 E17.5                                                         Bmpr1b E17.5 
Figure 4.8 In situ hybridisation of Bmp2 and Bmpr1b at E17.5 
Representative light microscopy images of paraffin embedded adrenal sections from Wistar 
male rat, aged 17.5 days.  They were incubated with Bmp2 antisense riboprobe (a,c) and 
Bmpr1b antisense riboprobe (b).  Images were taken using the Leica DMR light microscope 
with 5x (b), 10x (a) and 20x (c) objectives.  N=6, scale bar represents 200µm.  K = kidney, Liv 
= Liver, Adr = adrenal. Black arrows indicate renal tubules. 
(a) 
K 
(c) 
(b) 
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Figure 4.9 Immunofluorescence of BMP2 in adrenal gland 
Immunofluorescence with BMP2 (red) and DAPI (blue) antibody using fresh frozen human 
adrenal gland (A) and adult Wistar rat adrenals (B).  (C) shows immunofluorescence with only 
the use of secondary antibody (negative control).  N=2, Scale bar 250µm. ZG = zona 
glomerulosa, ZF = zona fasciculata, ZR = zona reticularis, Med = medulla 
 
1.  
4.5 BMP3b knockout mice  
Following the experiments localising mRNA for Bmp3b, Bmp2 and its receptor Bmpr1a, 
Bmp3b knockout mice were obtained from Professor Lee (Zhao et al., 1999) as a kind gift. 
These were 8 weeks old Bmp3b KO CD-1 mice that were sacrificed on our behalf and the 
adrenal glands of male and female KO and WT mice were sent.   
 
  
ed ed 
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The knockout mice were generated with the deletion of the Bmp3b (GDF10) coding region by 
gene targeting.  The gene consisted of 3 exons spreading over approximately 12 kb.  The C-
terminal domain, which is encoded in exons 2 and 3 was deleted and replaced by a neo cassette 
to ensure a full knockout was achieved (Figure 4.10).  The F1 heterozygotes were crossed and 
produced offsprings that were wild types, heterozygous and homozygous in the ratio of 1:2:1.  
Northern analysis of RNA of the wild type, heterozygous and homozygous mice was 
performed and it showed complete RNA absence of Bmp3b in the homozygous mice. All the 
homozygous mice were viable and the appearances were reported to be grossly normal.  The 
oestrous cycles of all the mice , pregnancy rate, gestation length and litter were no different 
(Zhao et al., 1999).         
 
 
 
 
Figure 4.10 Diagramatic representation for creation of Bmp3b KO mouse 
A Neo cassette was inserted to replace exon 2 and exon 3 to create a full length Bmp3b 
knockout model.    
 
 
 
The mice adrenals received were fixed in PFA and transported in PBS.  There were 3 WT and 
3 KO mice adrenals sent for each sex.  The adrenal glands were paraffin embedded and cut for 
immunohistochemistry (IHC) and IF.   
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The macroscopic appearance of the different zones of the adrenal cortex were similar in the 
wild type and knock out mice, when IHC was carried out using a CYP11B2 antibody specific 
to zG, which could be seen in the subcapsular region (Figure 4.11).  
 
 
 
 
 
Figure 4.11 Cyp11b2 expression in Bmp3b knockout mice adrenals 
Representative light microscopy images of paraffin embedded adrenal sections from wild type 
(WT) and Bmp3b knock out (KO) in both adult male and female mice. Immunohistochemistry 
were performed on adult male and female wild type and Bmp3b knockout mice adrenal glands, 
staining for Cyp11B2.  Images were taken using the Leica DMR light microscope with 10x 
objectives.  N=3, scale bar represents 200µm. Blue line indicates zona fasiculata (zF) and 
Medulla (M) boundary. Red dotted line represents zona glomerulosa (zG) and zF boundary. 
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Figure 4.12 Immunofluorescence of mice adrenal glands for SCC and CYP11B1 
Representative image of Immunofluorescence of mice adrenal glands: male and female wild 
types and Bmp3b KO. Nuclei are stained with DAPI (in blue), and antibodies against Side 
chain cleavage (SCC, in red and CYP11B1 in green) were used.  
WT = wild type, KO = knockout 
 
 
The comparison of the knockout and wild type mouse adrenals has shown that their anatomy 
and steroidogenic gene expression are very similar except in CYP11B1, where there appears 
to be a reduction in the knockout model compared to the WT (Figure 4.12).  The reduction 
seen was not quantified and also may not be enough to affect steroidogenesis, hence Bmp3b 
KO mice remain viable.    
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4.6 Discussion 
 
The histological studies have shown a preferential distribution of Bmp3b and Bmpr1a in the 
capsular region and Bmp2 in the inner cortex.  However, it was not possible to demonstrate the 
presence and location of many of the other BMPs, BMP receptors or antagonists (follistatin 
and noggin).  This could be explained by the theory that interactions of the BMPs themselves 
are controlling the expression of each other, such as Bmp3b acting as an inhibitor of Bmp2 
function as described in Chapter 3, hence an inhibitor, such as noggin, is not necessary.  
However, this theory would not fully explain why Bmpr1a is the only receptor expressed in 
the cortex.  Therefore, with different BMPs being expressed in different areas of the adrenal 
cortex, the gradients they form may act to enhance or inhibit the delicate control of adrenal 
zonation and differentiation.  
 
Bmp3b is present from E17.5 onwards in the rat adrenal, while Bmpr1a was detected from 
E15.5. Contrastingly, no expression of Bmp2 or Bmpr1b was detected at any developmental 
stage by with in-situ hybridisation.  We can detect Bmp2 mRNA in the rat adrenal by qPCR, 
so this presumably indicates that the ISH was not sensitive enough and that levels of Bmp2 
were below the detection limits of our in situ assay.  In the future, better antibodies or more 
sensitive ISH protocols may become available to give us a clearer understanding of the 
localisation of Bmp2 and Bmpr1b mRNA within the adrenal gland.  IF localisation of BMP2 
showed increased staining within the inner cortex, towards the location of zR.  
 
ISH has shown exquisite Bmp3b expression, supporting our microarray data of high Bmp3b in 
the ‘capsular’ fraction.  The ‘capsular’ fraction is not exclusively capsular as the fracture plane 
of the adrenal gland will inevitably be contaminated by some zF cells within the majority of 
zG and capsular cells (approximately 5%, as suggested by personal communication with Prof 
Gavin Vinson, QMUL). However, even though the inner fraction may contain some zG cells 
adjacent to the fracture plane, it is highly unlikely that there would be any capsular content, 
and hence no Bmp3b expression was detected in the inner cortex fraction.    Given the specific 
capsular location of Bmp3b expression, it is possible to speculate that it may play a role in stem 
cell and zonation of the adrenal cortex and  may even have interplay with other important genes 
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that are known to be involved in stem cell development and maintenance with the cortex, such 
as Shh and Rspo3 (Guasti et al., 2010; Vidal et al., 2016).  Rspo3 is expressed in the capsule, 
and these cells are the target of Shh signalling from the cortex, and lineage tracing studies have 
shown that capsule cells can differentiate into cortical cells both during development and in 
the adult organ. The effect of Shh and/or Wnt signalling on Bmp3b expression, and vice versa, 
would be interesting to define.  Other studies have shown interplay between SHH and BMP, 
such as in human haematopoietic cells (Bhardwaj et al., 2001) and co-localisation in other 
tissue such as teeth, hair and gut (Bitgood and McMahon, 1995).  Rspo3 has been shown to 
determine and maintain glomerulosa cell fate throughout life by inducing  Wnt4 and Shh 
expression (Vidal et al., 2016).  Therefore, Bmp3b may also have a role in the determination 
and maintenance of glomerulosa cell fate as the location of the gene makes it plausible that 
they could interact, though this has not yet been shown.  Rspo3 could act as the main driver of 
glomerular cell fate via Wnt and Shh, whilst Bmp3b could be the opposing factor to control or 
fine tune the cell’s fate, similar to our proposed theory of BMP2 and BMP3b in Figure 3.15, 
which would require further studies to show this potential interaction. 
   
However, the contribution of Bmp3b to glomerular cell fate may be small as the KO mouse 
models used in this work are all viable.  Therefore the role Bmp3b plays may be more towards 
stem cell behaviour or fine tuning of its function and would be useful to investigate the function 
of the adrenal gland in aging KO mice, as the stem cells deplete.  
 
Naturally occurring mutations in BMP3b have not been found in humans but the Bmp3b null 
mouse does survive, suggesting that BMP3b is unlikely to be crucial for control of the adrenal 
stem cell niche or adrenal zonation maintenance.  However, the adrenal glands of these mice 
have not been fully looked at in published data.  Therefore, using Bmp3b null mice in these 
experiments were useful to give a more detailed insight into the role of Bmp3b in adrenal 
morphology.  Given that the Bmp3b knock out mice survive, this indicates that Bmp3b cannot 
be essential adrenal function, which is known to be vital.  On comparing the wild type to 
Bmp3b KO mice, the size of the adrenals (although they were not weighed) and the cortical 
anatomy appeared similar, though IF suggests that there was less signal for Cyp11b1 and Scc 
but the IHC for Cyp11b2 was very similar in staining.  This suggests that there may be a 
  CHAPTER 4: Localisation of BMP3b and BMP2 in the adrenal cortex  
133 
 
 
reduction in steroidogenesis in Bmp3b KO mice, but not enough for it to be fatal if Bmp3b was 
not present. This result is inconsistent with the in vitro data which suggest that BMP3b is 
inhibitory to CYP11B1 expression, at least in H295R cells. The mouse adrenals were not re-
genotyped on receipt and it remains formally possible that they were mislabelled by our 
collaborators. However, they have assured us that this has never happened before and is not a 
likely scenario.  However, the increased expression of BMP2 across the cortex towards the 
medulla in both rats and humans does support the model in the previous chapter which 
hypothesises that BMP3b, expressed in the capsule, is inhibitory to BMP2 expression in the 
outer region of the cortex, and BMP2 exerts its most striking effect on enhancing 
steroidogenesis in the zR.  
 
According to the H295R results, effects of BMP2 that are modulated by BMP3b were mainly 
on androgen expression and these studies were carried out on mice, which do not produce 
androgens  Therefore, the mice model may not have been the most appropriate system for this 
study hence the results we had expected were not observed.  It is probably more appropriate to 
concentrate on expression studies in human adrenals, looking at expression of BMP3b, BMP2 
with the addition of SHH, WNT4 and RSPO3 within the adrenal cortex for potential co-
localisation.  
 
Limitations to these studies were present.   The ISH protocols have been altered many times to 
optimise detection but this did run the risk of over exposure and an increase in backgound 
noise.  ISH or IF expression were not quantified in the experiments and the studies were thus 
purely qualitative. This means I am only able to comment subjectively on the presence or 
absence of staining relative to negative and positive controls, so any subtle differencs in gene 
expression could have been overlooked.  In the study, it would have been ideal to confirm 
concordant expression using both ISH and IF techniques but this was not possible as the 
BMP3b antibody did not work for IF and BMP2 ISH was not concordant with IF findings, 
therefore further experiments would be needed to confirm the presence or absence of BMP2.  
The study could have been improved by the use of multiple labelling of the tissues to test for 
expression or co-expression of BMPs and their receptors simultaneously.  Other techniques 
could also have been considered; such as radioactive ISH, but this option was not used due to 
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the lack of a radioisotope facility and this remains a subjective measure of expression.  IHC 
would have been another option but the BMP antibodies were not reliable enough to ensure 
that any lack of expression was a true result or because of the ineffective antibody.  A new 
technology known as RNAscope would have been a good alternative method as it has been 
shown to reduce signal to noise ratio as it has a more specific RNA binding of two probes that 
are aligned next to each other before a signal is produced.  This method is able to quantify 
RNA that is anatomy specific and would be useful in the studies (Wang et al., 2012a). 
 
This study used normal rat adrenal glands sacrificed for other studies to gather initial 
information on RNA expression of Bmp3b and Bmp2 within the adrenal cortex.  However, this 
was not able to demonstrate the direct effect of Bmp3b and Bmp2 within the cortex.  This could 
have been demonstrated by manipulation of Bmp3b and Bmp2 within the cortex of rats.  This 
was attempted as part of the experiments where Bmp3b and Bmp2 soaked Affi-gel beads were 
inserted into the rat adrenals but the attempt was unsuccessful in obtaining rat adrenals with 
Affi-gel beads still in place to be observed and studied.    
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5 Is BMP3B involved in adrenal 
tumourigenesis? 
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5.1 Aim  
 
During the course of this study tissue was collected from adrenalectomies performed at Bart’s 
and the London and other London hospitals between September 2008 to September 2011. The 
tissues collected were from a number of different adrenal diseases along with adjacent normal 
adrenal tissue Table 5.1.  The ethical approval for adrenal tissue collection was granted by 
Redbridge and Waltham Forest Local Research ethics Committee on 8th August 2008.  REC 
reference number: 08/H0701/59 ‘Analysis of bone morphogenetic protein and sonic hedgehog 
signal transduction pathway components in adrenal tumours and adjacent normal tissue’.  
 
The aim was to investigate if BMP3b and other BMPs and Shh are biological markers of 
adrenal cortical disease: Adrenocortical carcinoma and APAs.  The prognosis for 
Adrenocortical carcinoma (ACC) remains poor over the years with no improvement in 
treatment modality or survival.  Although APAs are benign, the consequences of 
hyperaldosteronism can cause severe cardiovascular morbidity.   
 
 
5.2  Biological markers 
 
Biological markers for adrenal disease would be extremely helpful in predicting prognosis and 
response to treatment.  In ACC, the current biological markers of disease would be steroid 
secretion in up to 75% of cases (Abiven et al., 2006).  Usually a combination of steroid 
hormones are secreted, unlike benign tumours which mostly secrete one type.  Cortisol and 
androgens are most frequently secreted (Table 5.2) (Luton et al., 1990) but ACC is also capable 
of secreting mineralocorticoids and steroid precursors, which can be detected in urine (Arlt et 
al., 2011).  Steroid measurements help with guidance of disease activity in patients but cannot 
predict prognosis or treatment response.  Therefore, new biological markers that answer these 
questions would be extremely useful, so that patients are provided with more knowledge and 
treatment could potentially be tailored to each individual patient.  However, a biological 
marker must be robust: easily measurable, preferably from patient’s blood or urine, specific to 
CHAPTER 5: BMP3b and tumourigenesis 
137 
 
 
the disease and cost effective (Strimbu and Tavel, 2010).  Over the last decade, there has been 
work on microRNA (miRNA) as potential biological markers as they can be detected in the 
blood stream and also as a potential therapeutic target.  MicroRNAs are small, non-coding 
RNAs of 18-24 nucleotides in length that are highly conserved.  Their role is to silence target 
genes by degrading mRNA or inhibiting translation (Ambros, 2004; Cherradi, 2015; 
MacFarlane and Murphy, 2010).  Over 20 miRNAs has been associated with ACC, with a 
handful of them validated in patients, such as miR-483-5p, miR-100, miR-34a, miR-195 and 
miR-335 (Chabre et al., 2013; Patel et al., 2013; Szabó et al., 2014, 2013). 
 
 
5.3  Hyperaldosteronism 
 
The two most common subtypes of hyperaldosteronism are APAs and BAH. Treatment is 
vastly different in these two types of hyperaldosteronism: APA can be treated with an 
adrenalectomy, whereas medical therapy is the treatment of choice for BAH.  Currently, 
diagnosing APA or BAH would require biochemical testing, imaging and invasive adrenal vein 
catheterisation.  Therefore, a biological marker that is able to identify the different subtypes 
would be extremely helpful for diagnosis and treatment of patients.  Attempts have been made 
by many groups to distinguish between the two sets of patients, with postural aldosterone levels 
which were not very specific or sensitive enough to distinguish between the two (Lau et al., 
2012) or the use of urinary 18-hydroxycortisol (18-OHF) which is increased in APAs, though 
the measurement of 18-OHF is not readily available (Miyamori et al., 1992).  Currently, there 
is no published data on miRNA as biological markers for primary aldosteronism nor any other 
biological markers available. 
 
During the course of this PhD, Shh was suggested to be a marker of stem/progenitor cells in 
the adrenal cortex, and numerous studies had shown aberrant signalling to be a feature of 
several types of cancer and to be involved in the maintenance of cancer stem cells (Cochrane 
et al., 2015; Dierks et al., 2008; Kelleher, 2011; Lau et al., 2006; Song et al., 2011; Watkins et 
al., 2003).   Guasti et al., showed that in the rat Dlk1 (Delta-like 1 homolog), well documented 
as a negative regulator of adipogenesis (where it has been referred to as Pref-1), and has been 
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suggested to play a similar role in the adrenal (Guasti et al., 2013b), is co-expressed with Shh 
and can modulate its signalling. Dlk1 has also been suggested to be a marker of cancer stem 
cells in hepatocellular carcinoma (Xu et al., 2012).  It was therefore decided to investigate the 
expression of these markers and other pathway components in the adrenal tissues, as well as 
BMPs, the main focus of this thesis so far. BMPs are involved in organ development and in 
humans have been implicated in many tumour processes (Beck et al., 2006; Blanco Calvo et 
al., 2009; Huang and Klein, 2004).  Studies by Beuschlein’s group have already shown that 
BMP2 and BMP5 expression are suppressed in adrenocortical carcinomas compared to normal 
adrenal samples (Johnsen et al., 2009).  This project so far has shown that BMP3b has a 
suppressive effect on BMP2 in vitro, and this has been supported by the gradient of expression 
observed in the in vivo study.  Given the evidence that BMP2 is present in adrenal tumours 
(Johnsen et al., 2009), BMP3b expression in adrenal adenomas and carcinomas was 
investigated.  Furthermore, the Shh and BMP pathways show clear interplay (Bitgood and 
McMahon, 1995), such as in limb patterning (Dahn, 2000; Drossopoulou et al., 2000), 
hematopoietic cell proliferation (Bhardwaj et al., 2001; Bitgood and McMahon, 1995) and 
osteoblast differentiation (Zhao et al., 2006).  The hedgehog pathway itself also plays a role in 
many cancers.  For example, Shh is upregulated in dysplastic cells in colorectal cancer (Bian 
et al., 2007), activation of the pathway through patched mutation in basal cell carcinomas 
(Bale, 2001)  and increased expression of hedgehog pathway component target genes, Gli1 and 
Ptch is seen in gastric cancer stem cells (Song et al., 2011). 
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5.4 Adrenal samples 
 
Adrenal Tissue Type Numbers collected 
  
Adjacent normal tissue 13 
Aldosterone producing adenomas 12 
Adrenocortical carcinomas 4 
Adrenal hyperplasia from Cushing’s disease 5 
Phaeochromocytoma 2 
 
Table 5.1 Types of adrenocortical tissues collected between 2008-2010 at St. 
Bartholomew’s Hospital 
 
 
 
Tumour Type Average 9am cortisol 
level (nmol/L) 
Normal 200-600nmol/L 
Average recumbant 
aldosterone level (pmol/L) 
Normal 135-400pmol/L 
Aldosterone producing 
adenoma 
239 907 
Adrenocortical 
carcinomas 
575 162 
Adrenal hyperplasia 
from Cushing’s 
disease* 
1245 N/A 
 
Table 5.2 Average level of steroid production in patient cohort 
N/A – not done as part of workup, * bilateral adrenalectomy for Cushing’s disease 
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5.5 Real time qPCR of adrenal tissue 
 
5.5.1 Zone specific expression in adrenal tissue 
The first experiments were performed to confirm the presence and expression of CYP11B1 
representing zF and CYP11B2 representing zG in normal tissue compared with adrenal 
tumours of different aetiology.  It is expected that APAs would express the highest level of 
CYP11B2 expression in the adenoma, as in other published data (Enberg et al., 2004; 
Nakamuraa et al., 2014).  The results, shown in Figure 5.1 showed a significant reduction 
CYP11B1 expression in APAs (p<0.05) and phaeochromocytoma (p<0.01) patients compared 
to normal, which would be expected as neither of the two conditions are known to produce 
cortisol.  However, there were no significant difference between adjacent normal tissue and 
Adrenocortical carcinomas or hyperplastic samples, where a 2-fold and 6-fold increase in 
cortisol production respectively was measured in the patient’s serum cortisol.  However, the 
‘normal’ used was adjacent normal of APAs and the expression may not be the same as a truly 
normal adrenal gland, which could not be obtained as this was not part of the ethical approval.  
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Figure 5.1 CYP11B1 expression levels in different types of human adrenal tissue 
Comparison of CYP11B1 expression in different types of adrenal tumours against their 
adjacent normal adrenal tissue.  N=3, performed in triplicates.  Error bars indicate SEM. 
*p<0.05, **p<0.01, one way ANOVA used.   
AN=Adjacent normal adrenal tissue, APA=Aldosterone producing adenoma, 
ACC=adrenocortical carcinoma, HP=Hyperplasia, PCC=phaeochromocytoma 
 
 
With CYP11B2, expression level was as predicted with significantly increased CYP11B2 
expression (p<0.001) correlating with increased aldosterone production in APAs (Figure 5.2).  
There may also be a confounding factor that the normal tissues used in this study is adjacent 
normal, hence there may be more suppression of CYP11B2 expression than truly normal 
adrenal tissue.  The mRNA expression data showed no CYP11B1 or CYP11B2 expression in 
phaeochromocytoma samples, which are tumours of the adrenal medulla, where there should 
not be any cortisol or aldosterone production.   
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Figure 5.2 CYP11B2 expression levels in different types of adrenal tissue 
Comparison of CYP11B2 expression in different types of adrenal tumours against their 
adjacent normal adrenal tissue.  N=3, performed in triplicates.  Error bars indicate SEM. 
***p<0.001, one way ANOVA used.   
AN=Adjacent normal adrenal tissue, APA=Aldosterone producing adenoma, 
ACC=adrenocortical carcinoma, HP=Hyperplasia, PCC=phaeochromocytoma 
 
 
 
Following on from the above findings, DLK1, which plays a role in the maintenance of  
mesenchymal stem/progenitor cells (Kim et al., 2009; Lin and Yun, 2010; Sul et al., 2000), is 
only found in the subcapsular region of the adrenal cortex and the medulla (Guasti et al., 2013b; 
Raza et al., 1998).  With DLK1 being found in the subcapsular region, where progenitor cells 
are thought to reside, its presence in the samples may indicate an increase in progenitor cells.  
This real time qPCR (Figure 5.3 ) showed that DLK1 was present in the medulla, as expected 
but its expression in the other adrenal tissues was not significantly different from normal 
adrenal tissue.  This may be explained by the low expression of DLK1 in the inner cortex, 
which is included in the sample and not all samples definitely included the subcapsular 
fraction.   
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Figure 5.3 DLK1 expression in different types of adrenal tissue 
Comparison of DLK1 expression in different types of adrenal tumours against their adjacent 
normal adrenal tissue.  N=3, performed in triplicates.  Error bars indicate SEM. 
*p<0.05, one way ANOVA used.   
AN=Adjacent normal adrenal tissue, APA=Aldosterone producing adenoma, 
ACC=adrenocortical carcinoma, HP=Hyperplasia, PCC=phaeochromocytoma 
 
 
5.5.2 Sonic hedgehog and GLI1 expression   
The next experiments looked at SHH and GLI1 expression.  SHH has been implicated in many 
cancer processes such as basal cell carcinoma, prostate and pancreas (Chen et al., 2011; Datta 
and Datta, 2006; Lau et al., 2006; Lupi, 2007) and Shh plays an important role in development 
(King et al., 2008).  Gli1 expression is dependent on canonical activation of the Hh pathway 
and so Gli1 is used in many experiments as a marker for active Hh signalling (Vokes et al., 
2007).   
 
The expression of both SHH (Figure 5.4) and GLI1 (Figure 5.5) was reduced compared to 
normal.  These results indicate that SHH and its pathway components are present in both 
normal and abnormal adrenal cortex.  The expression of SHH does not vary significantly across 
the adrenocortical groups though there was also a large variance in the normal sample, which 
may have affected the statistics.  However, there was significantly reduced levels of GLI1 in 
the ACC and there was also a significant decrease of GLI1 in ACC compared to APAs.  SHH 
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levels in PCC are very low, which could be background levels as SHH is not found in the 
medulla.  However, there was an increase in expression of GLI1, which cannot be explained 
by SHH presence.  There is no published data on IHH or DHH hedgehog in PCC to account 
for the GLI1 expression.  However, in von Hippel Lindau syndrome, where patients can 
develop phaeochromocytomas, a mutation in the VHL gene is present.  VHL is a tumour 
suppressor gene that decreases GLI1 expression.  Therefore, a mutant gene would conversely 
allow GLI1 expression (Cho et al., 2013). 
 
 
 
 
Figure 5.4 SHH expression in different types of adrenal tissue 
Comparison of SHH expression in different types of adrenal tumours against their adjacent 
normal adrenal tissue.  N=3, performed in triplicates.  Error bars indicate SEM. 
*p<0.05, one way ANOVA used.   
AN=Adjacent normal adrenal tissue, APA=Aldosterone producing adenoma, 
ACC=adrenocortical carcinoma, HP=Hyperplasia, PCC=phaeochromocytoma 
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Figure 5.5 GLI1 expression in different types of adrenal tissue 
Comparison of GLI1 expression in different types of adrenal tumours against their adjacent 
normal adrenal tissue.  N=3, performed in triplicates.  Error bars indicate SEM. 
*p<0.05, one way ANOVA used.   
AN=Adjacent normal adrenal tissue, APA=Aldosterone producing adenoma, 
ACC=adrenocortical carcinoma, HP=Hyperplasia, PCC=phaeochromocytoma 
 
 
5.6 BMP expression 
 
Evidence of BMP expression in the H295R cells as shown in Chapter 3 led to the investigation 
of their expression in human adrenal tissue.  The BMPs investigated were those known to be 
present in the adrenal cortex or H295R cells. The in vitro studies have shown that BMP2 and 
BMP3b are present in the adrenal cortex (H295R cells), other published data confirms presence 
of BMP6 (Inagaki et al., 2007; Otani et al., 2010), BMP2 (Johnsen et al., 2009) and BMP4 
(Rege et al., 2015).    
 
BMP2 expression was not significantly lower in all the abnormal adrenal tissues, except the 
hyperplastic samples (Figure 5.6).  The reduced expression of BMP2 in ACC found in our 
cohort was not found to be significant, which may be due to the small number of samples used 
or the high variance in the normal samples, hence this experiment could not replicated the 
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results published by the Beuschlein group (Johnsen et al., 2009).  There was not a significant 
reduction in APAs, possibly due to very little BMP2 expression in the outer cortex.  Though 
the histology of an APA can have zG, zF or zR phenotypes, the most common phenotype seen 
in our cohort was zF and this is consistent with other published data.  Despite the zF like 
phenotype, the cells are still thought to express CYP11B2 (Boulkroun et al., 2010, 2011; 
Nishimoto et al., 2010).  
 
BMP4 is expressed at higher levels in the zG than the inner cortex, even though it exerts its 
effects on C19 synthesis (Rege et al., 2015),  but it did not show any significant difference in 
expression with APA or adrenocortical carcinoma patients (Figure 5.7).  However, there was 
a significant reduction in phaeochromocytoma samples. BMP4 has not been shown in other 
studies to be present in the adrenal medulla and this could explain this significantly low 
expression in phaeochromocytomas, which is likely to be background levels.  
 
BMP6 is involved in the induction of aldosterone production (Matsumoto et al., 2012).  The 
real time qPCR results did not show any significant difference in BMP6 expression in normal 
and abnormal adrenal tissue (Figure 5.8).  BMP6 is known to augment the production of 
aldosterone in adrenocortical cell lines in response to angiotensin II treatment (Suzuki et al., 
2004) and its lack of significant expression compared to normal tissue may indicate that in 
vivo, BMP6 may not have a major role in aldosterone production in APAs.  The phenotype of 
the APAs could have affected BMP6 expression due to the predominance of zF like cells and 
that adjacent ‘normal’ zG has been shown to express reduced levels of CYP11B2 in the 
presence of an adenoma (Boulkroun et al., 2010).    
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Figure 5.6 BMP2 expression in different types of adrenal tissue 
Comparison of BMP2 expression in different types of adrenal tumours against their adjacent 
normal adrenal tissue.  N=3, performed in triplicates.  Error bars indicate SEM. 
*p<0.05, one way ANOVA used.   
AN=Adjacent normal adrenal tissue, APA=Aldosterone producing adenoma, 
ACC=adrenocortical carcinoma, HP=Hyperplasia, PCC=phaeochromocytoma 
 
 
 
 
Figure 5.7 BMP4 expression in different types of adrenal tissue 
Comparison of BMP4 expression in different types of adrenal tumours against their adjacent 
normal adrenal tissue.  N=3, performed in triplicates.  Error bars indicate SEM. 
**p<0.01, one way ANOVA used.   
AN=Adjacent normal adrenal tissue, APA=Aldosterone producing adenoma, 
ACC=adrenocortical carcinoma, HP=Hyperplasia, PCC=phaeochromocytoma 
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Figure 5.8 BMP6 expression in different types of adrenal tissue 
Comparison of BMP6 expression in different types of adrenal tumours against their adjacent 
normal adrenal tissue.  N=3, performed in triplicates.  Error bars indicate SEM. 
One way ANOVA used.   
AN=Adjacent normal adrenal tissue, APA=Aldosterone producing adenoma, 
ACC=adrenocortical carcinoma, HP=Hyperplasia, PCC=phaeochromocytoma 
 
 
5.6.1  BMP3b expression 
BMP3b, expressed solely in the adrenal capsule, was investigated next.  It would be predicted 
that BMP3b would increase in expression, if BMP2 was downregulated in these samples 
(though our original samples did not reach significant downregulation of BMP2). The figures 
below showed BMP3b expression both within our study cohort (Figure 5.9, Figure 5.10, Figure 
5.11) and also from a German cohort (Figure 5.12) who had published data on the 
downregulation of BMP2 and BMP5 in adrenocortical carcinoma (Johnsen et al., 2009). 
   
There was a subjective difference in BMP3b expression in the 4 individual adrenocortical 
carcinoma cases, where 2 had lower expression and 2 with higher expression.  With BMP2 
expression, there were no significant difference in BMP3b and BMP2 levels.  
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Figure 5.9 BMP3b expression in different types of adrenal tissue 
Comparison of BMP3b expression in different types of adrenal tumours against their adjacent 
normal adrenal tissue.  N=3, performed in triplicates.  Error bars indicate SEM. 
*p<0.05, one way ANOVA used.   
AN=Adjacent normal adrenal tissue, APA=Aldosterone producing adenoma, 
ACC=adrenocortical carcinoma, HP=Hyperplasia, PCC=phaeochromocytoma 
 
 
Figure 5.10 BMP3b expression in each adrenocortical carcinoma patient 
BMP3b expression in individual adrenocortical carcinoma patients, represented by C1-C4.  
N=1, performed in triplicates.  Error bars indicate SEM. 
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Figure 5.11 BMP3b and BMP2 expression levels in each adrenocortical carcinoma 
patient 
Comparison of BMP3b and BMP2 expression in individual patients. 
N=1, performed in triplicates.  Error bars indicate SEM. 
 
 
 
Figure 5.12 BMP3b expression in adrenal tumours in a German cohort 
Comparison of BMP3b expression in APA and ACC.  N=3, performed in triplicates.  Error 
bars indicate SEM.  Student t-test used.  
APA = aldosterone producing adenoma, ACC = adrenocortical carcinoma 
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reviewing the clinical details of the 4 ACCs (Table 5.3), the 2 patients with the lowest grade 
of tumour on histology had the highest BMP3b expression and the one with the most 
suppressed expression was the most aggressive tumour histologically, though has survived 
beyond 5 years as all of these patients only had local disease.  The clinical details of the German 
cohort were not obtained hence conclusions cannot be drawn with clinical relevance. 
 
 
 Age/ 
Gender 
Size (mm)/ secretion Ki67 
(%) 
Weiss  
score  
Outcome/survival 
C1 24F 105 x 100 x 58 
Androgens 
5% 3 Alive – 7 years 
C2 55F 190 x 120 x 85 Cortisol 70% 8 Alive –  6 years 
C3 46F 98 x 105 x 68 Cortisol <5% 2 Alive – 7 year * 
C4 76F 105 x 90 x 52 None NA‡ NA Died – 4 years** 
 
Table 5.3 Details of four patients with adrenocortical carcinoma in the UK cohort 
C1 and C2 received mitotane as part of their ACC treatment.   
C3 and C4 did not and had very close clinical and radiological follow up.   
**patient died from a different cancer, *patient was treated as ACC due to the size of her 
tumour. ‡ Haemorrhagic on histology 
 
 
There was only a small number of ACC within our cohort as this is a very rare cancer, making 
further work and analysis more difficult.  However, given the number of APAs and the recent 
interest in primary aldosteronism (PA) with growing evidence of aldosterone excess leading 
to increased cardiovascular and metabolic risks (Catena et al., 2008; Fallo et al., 2006, 2012; 
Milliez et al., 2005; Rossi et al., 2008) and end organ damage (Savard et al., 2013), the study 
went on to look more specifically at each individual APA and its genetic variant.  Next 
generation sequencing has rapidly increased knowledge on genetic mutations causing familial 
PA with different phenotypes.  The first mutation described was KCNJ5 (Choi et al., 2011) 
and since, then many others have been described: ATP1A1, ATP2B3, CACNA1D and CTNNB1 
(Akerström et al., 2016; Azizan et al., 2013; Beuschlein et al., 2013; Fernandes-Rosa et al., 
2015; Williams et al., 2014).  The commonest mutation is KCNJ5 at about 40% of APAs, 7% 
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of ATPase mutations (ATP1A1 more than ATP2B3) and 9% have CACNA1D mutations 
(Monticone et al., 2014).  CTNNB1 had a prevalence of 5% in one study (Akerström et al., 
2016).  
 
 
5.7 Genetic mutations in APAs 
 
In our cohort (Table 5.4) , KCNJ5 was the commonest mutation at 48%, similar to published 
data and the ATPase mutations found in 12%, higher than published data (Williams et al., 
2014).  KCNJ5 mutations were found more commonly in females (Table 5.5) and they are of 
zF type predominantly.  There was no significant difference in age or aldosterone levels.  An 
interesting observation was that half of the patients with KCNJ5 mutations co-secretes 
aldosterone and cortisol. 
 
 KCNJ5 ATP1A1 ATP2B3 KCNJ5/ATP 
negative 
Male G151R (G to C) 2 
G151R (G to A) 1 
L168R (T to G) 0 
Total = 3 
1 1 7 
Female G151R (G to C) 4 
G151R (G to A) 2 
L168R (T to G) 3 
Total = 9 
0 1 3 
TOTAL 12 1 2 10 
 
Table 5.4 Genetic mutations found the UK Aldosterone producing adenoma cohort 
Aldosterone producing adenomas of 25 patients were sequenced for KCNJ5, ATP1A1 and 
ATP2B3 only.   
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Characteristics KCNJ5 ATP1A1 ATP2B3 KCNJ5/ATP  
negative 
Mean Age in years (range) 47.25 (27-
70) 
64 43 (34-52)   47.2  (37-68) 
M:F 3:9 1:0 1:1 7:3 
Mean Aldosterone pmol/L 
(range) 
988.25  
(405-1997) 
782 1230  
(490-1971) 
1280.2  
(406-3970) 
Histology** 4 zF 
1 zF/zR 
zF/zR 1 zF 
1zG/zF 
5 zF 
1 zF/zR 
2 zR 
Co-secretors*  6 0 0 0 
 
Table 5.5 Summary of the characteristics of each genetic mutation group 
*cortisol <50nmol/L after low dose dexamethasone suppression test (0.5mg dexamethasone 
six hourly for 48 hours) 
**incomplete collection of histological phenotype of all the patients 
 
 
 
5.8 Discussion 
 
Adrenal adenomas such as APAs are relatively common compared to adrenocortical 
carcinomas (ACC).  The prognoses of the two conditions differ immensely.  APAs are 
potentially curable surgically but ACC tend to present late and often with metastases, with a 5 
year survival rate of less than 10% (The American Association of Endocrine Surgeons – Patient 
education site).  To date, there are no satisfactory treatments for ACC and survival rates have 
not improved over the decades.  The options currently would be surgery, aiming for cure or for 
debulking.  This is followed by mitotane (o,p-DDD) which inhibits side chain cleavage and 11 
β-hydroxylase and hence adrenocortical steroidogenesis.  It also acts by inducing hepatic 
clearance of cortisol.  However, mitotane has many side effects which limits its use in many 
patients (Hogan et al., 1978; Huang and Fojo, 2008).  If mitotane is tolerated, reaching 
therapeutic levels, then it contributes to recurrence free survival, though overall survival may 
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not be affected (Else et al., 2014).  There are mixed reviews for the use of local radiotherapy 
to the adrenal bed, though the recent review by Else et al., felt that adjuvant radiotherapy can 
prevent local recurrence and reduce morbidity caused by large recurrences (Else et al., 2014).  
Other newer therapies such as epidermal growth factor receptor (EGFR) inhibitors, anti-
vascular growth factor antibodies and tyrosine kinase inhibitors have all had disappointing 
results on overall survival (Berruti et al., 2012; Cherradi, 2015; Kroiss et al., 2012; Quinkler 
et al., 2008).  The identification of potential pathways that are involved in adrenal 
tumourigenesis would be a big step to understanding the pathogenesis of ACC and more 
targeted therapy in the future.  The pathways investigated in this chapter were the Hh, Dlk1 
and BMP pathways. 
 
BMP2 and BMP5 down regulation in ACC have already been shown (Johnsen et al., 2009).  
The reduction in BMP2 expression in the ACC samples in this project, however, did not reach 
significance.  This project has also shown that BMP3b may be overexpressed in ACC, though 
when this is looked at in more detail, only 2 out of the 4 ACCs showed an overexpression of 
BMP3b.  The two that had the overexpression were ACCs of a less aggressive nature 
histologically and the patients are still alive. The down regulation of BMP2 and the over 
expression of BMP3b seen, especially in Figure 3.6, which ties in well with our in vitro findings 
as the higher the BMP3b expression, the lower the expression of BMP2 seen in patients C3 and 
C4.  Whether there was a direct link between the BMPs in the ACC samples was not 
investigated, as this would have required manipulation of the cells through primary culture but 
BMPs are well known to have the potential to be either tumour suppressors or promoters in 
different cancers (Ehata et al., 2013).  For example, BMP2 is a tumour suppressor in diffuse 
type gastric carcinomas (Shirai et al., 2011), breast cancers (Ghosh-Choudhury et al., 2000) 
and renal cell carcinoma (Wang et al., 2012b) yet it can also stimulate cancer cell proliferation 
in other types of cancer, such as the prostate, in the absence of androgen presence (Ide et al., 
1997).  The widespread use of recombinant BMP2 has also raised concerns on cancer 
development, again indicating that BMP2 can also promote cancers (Carragee et al., 2013).   
 
If BMPs were involved in ACC, this could also lead to potential therapeutic options in the 
future.  Rodent studies with Bmp7 therapy have shown an improvement in renal disease in 
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diabetic rats (Wang et al., 2003) and other BMPs are being studied and used in bone 
regeneration (Krebsbach et al., 2000).  BMP2 is already used in humans for spinal fusions 
since its approval by FDA in 2002 (Kleeman et al., 2001).  However, complications of using 
this are now emerging, as many are being used ‘off-license’ and the FDA has issued warnings 
on its use (Epstein, 2013).  This effect may have an impact on future developments of clinical 
application of BMPs.  Using BMPs as gene therapy would require a fine balance as they are 
present in most organs and their function can vary vastly between organs (Wang et al., 2014).   
This project has shown that BMPs are present in the adrenal glands but expression levels have 
been variable in the different tissue samples.  There was an overall suppression of BMP3b in 
APAs, except in one German sample and an increase in 2 of the 4 ACC samples from the UK 
cohort.  The increase found in the less aggressive tumours could be interesting as it could be 
used as a good prognostic factor.  However, the study of more ACCs will be needed in order 
to validate this theory. 
 
There has been a surge in research into the pathogenesis of APAs.  Up until 2010, there was 
only one genetic mutation associated with primary aldosteronism, a CYP11B1/CYP11B2 
chimeric gene, which results in type 1 familial primary aldosteronism (glucocorticoid 
remediable aldosteronism) and these patients are treated with glucocorticoids.  There has now 
been a big shift into the genetics of APAs with many more candidate genes being discovered 
including the ones we have tested for, with others emerging.  The cohort that has been 
genetically tested is small but the results concur with some of the findings in published data 
(Boulkroun et al., 2012): KCNJ5 is the commonest mutation (48%) and is also more common 
in females.  However, in this cohort, there was no difference in the age of presentation or the 
level of aldosterone.  Reports also suggest a higher prevalence of ATP1A1 (about 6%) 
compared to ATP2B3 (2%) (Beuschlein et al., 2013) but so far we have identified more 
ATP2B3 (2) mutations than ATP1A1 (1) in our cohort.  More samples and studies are needed 
in our cohort as we have not investigated CACNA1D mutations (Scholl et al., 2013) and 
CTNNB1 (Akerström et al., 2016) yet.   
 
The genetic mutations found so far, accounting for just over 50% of all APAs, mainly affect 
the cell membrane potential.  KCNJ5 acts on the inward rectifying potassium channel reducing 
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channel selectivity and increasing sodium permeability.  The ATPase mutations act on the 
Na/K ATPase, which affects the stimulation of aldosterone release.  CACN1AD encodes the L 
type calcium channel, which affects membrane potential via intracellular calcium regulation.  
CTNNB1 is the only mutation so far not associated with ion selectivity but the Wnt/b-catenin 
pathway as CTNNB1 is the b-catenin gene.  This shows that of the undiscovered genes, they 
may not all be ion channel specific.  The Wnt and BMP pathways can work synergistically 
together, such as in osteoblast differentiation, so BMPs may also play a role in APAs.  In this 
project, BMPs were investigated in APA samples.  BMP6, which induces aldosterone 
production in adrenocortical cell lines, was reduced in APAs, which was unexpected.  It could 
be explained that BMP6, although it can induce aldosterone production, can only enhance Ang 
II and not potassium induced aldosterone production (Inagaki et al., 2006).  Therefore, as many 
of the APAs are ion channel, hence potassium driven, hyperaldosteronism, BMP6 may not be 
upregulated in some APAs.   BMP2 expression was lower than normal and BMP3b expression 
was similar to normal tissue in APAs.  BMP2 has been shown in vitro to exert a more zR 
phenotype and so would be unlikely to be involved in the development of APAs as these 
adenomas only rarely show some zR morphology.  BMP3b  would be predicted to have a higher 
expression as it supports a zG phenotype, and therefore aldosterone production, but it was 
expressed at very similar levels to normal tissue.  Our data show that BMP3b is expressed in 
the adrenal capsule, and the expression levels may depend upon the amount of capsule present 
in the tissue sample obtained. It is still unclear why many of the APAs have a zF phenotype, 
although it is thought that cells in APAs have an intermediate phenotype in between zG and 
zF.  It has been reported that KCNJ5 mutations are more likely to have a zF phenotype and 
ATP1A1 and CACNA1D mutations have a more zG phenotype (Azizan et al., 2013, 2012).  
Another reason for a zF phenotype is that Choi et al., when they discovered KCNJ5, postulated 
that they caused hypertrophy of aldosterone secreting cells and this might give the cells a much 
‘fatter’ appearance, resembling zF cells (Choi et al., 2011).  These cells still express CYP11B2 
and another zG specific marker, Dab2 (Disabled 2) (Boulkroun et al., 2011).  It is likely that 
these cells are derived from zG and APAs form as they begin to transition into a zF phenotype 
(as per the centripetal theory) but their function remains that of zG.  Therefore, BMP3b 
expression may be low as cells are already beginning to transition to the zF phenotype, as 
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shown in our in vitro gradient theory or that BMP3b is not involved in APA formation or 
maintenance of these tumour cells.    
 
In conclusion, these results provide evidence of the presence of BMPs in the adrenal cortex 
but their expression levels were significantly different to each other.  This could be explained 
by the theory that BMPs may not be involved in the pathogenesis of these tumours, they are 
suppressed by another mechanism that is driving the tumourigenesis or that the ‘normal’ tissues 
used in this project were in fact ‘adjacent normal’, where the difference in gene expression 
may not be truly representative of expression within a whole normal adrenal gland.  However, 
in the ACC subgroup, the results were in agreement with our in vitro findings where an 
upregulation of BMP3b led to decreased BMP2 expression. 
 
Interesting outcomes from these experiments were firstly; the increased expression of BMP3b 
in ACC with a less aggressive histology and could potentially be looked at as a prognostic 
factor for ACCs.  Secondly, the observation of increased co-secretion of aldosterone and 
cortisol in patients with a KCNJ5 mutation would warrant further investigation.   
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The adrenal gland is essential for life and understanding its differentiation, maintenance and 
zonation mechanism is vital to understand for health and in disease.  Microarray results found 
Bmp3b expression to be exclusive to the outer cortex which includes the capsule and zG.  Given 
its restricted expression, it was hypothesised that Bmp3b played a role in zonation by 
influencing zG differentiation from, and/or maintenance of, the progenitor/stem cells found 
beneath the adrenal capsule. 
 
H295R cells were a useful model to investigate zonation, as the cells are able to express all the 
enzymes required for steroidogenesis and are able to produce aldosterone, cortisol and DHEA.  
This cell line can also be manipulated by prolonged treatment with Angiotensin II (to induce 
aldosterone production) and forskolin (to induce cortisol production).  With this model, it was 
shown that BMP3b is present in adrenocortical cells, can upregulate CYP11B2 and down 
regulate CYP11B1, CYTB5 and SULT2A1.  It also had a direct suppressive effect on BMP2, 
which is found most highly expressed in the inner cortex and promotes the zR cell phenotype, 
with these effects reversed on knocking down BMP3b with targeted siRNAs.  Therefore, from 
the in vitro experiments, we propose that BMP3b acts to promote a zG phenotype but as cells 
move centripetally, the cells move down the concentration gradient away from the influence 
of BMP3b and are then under the influence of BMP2, which promotes a zF/zR phenotype.  
This model fits well with the centripetal theory of cell migration and that cells have the 
potential to de-differentiate as they migrate to take on a new phenotype (Freedman et al., 2013; 
Kim et al., 2009; Salmon and Zwemer, 1941; Wright et al., 1973). 
 
Additional H295R studies would be useful to explore the interaction of BMP3b with other 
BMPs within the adrenocortical cells, such as BMP6, which plays a role in Ang II driven 
aldosterone production (Inagaki et al., 2006, 2007; Otani et al., 2010).  The interplay of BMP3b 
with other known capsular/zG pathways would also be of interest.  In other systems, BMP 
pathways work closely with WNT and SHH signalling pathways in development (Ding and 
Wang, 2017; Hu et al., 2005).  BMP and WNT cross talk is already well established and they 
even share a common complex (Smad/b-catenin/Lef protein) that regulates shared target genes 
(Itasaki and Hoppler, 2010).  BMP4 has been shown to be dependent on b-catenin expression 
in colon cancer (Kim et al., 2002) and BMP2/4 can regulate Wnt8 (Hoppler and Moon, 1998).  
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Smad7, part of the BMP pathway, is also able to bind directly to b-catenin and is involved in 
prostate cancer (Edlund et al., 2005).  Hence, it is highly likely that there is cross talk within 
the adrenal cortex that involves any combination of these pathways, with BMP3b involved, in 
part, in zG maintenance and differentiation.  This would require further investigation in the 
future.  
 
Bmp and Hh expression has been shown to co-localise in many areas, such as teeth, hair and 
gut (Bitgood and McMahon, 1995) and Shh can regulate BMP2 in chick limb bud formation 
(Laufer et al., 1994).  Vidal et al., showed that Rspo3 can initiate Shh activation and 
differentiation of steroidogenic cells through Gli1 activation.  We can extend this further and 
investigate if Bmp3b co-localises with Rspo3 in the adrenal capsule, or if it contributes to or is 
independent of Rspo3 to maintain a zG phenotype.  This can be achieved on an in vitro level 
by looking at the expression of Bmp3b in the presence and absence of Shh and Rspo3 and if 
Bmp3b expression is affected.  The in vivo model can then be used to see if BMP3b is present 
in Shh or Rspo3 KO models and if Bmp3b can reverse any of the effect of Shh and Rspo3 KO 
models (Vidal et al., 2016). 
 
Taking this hypothesis further in an in vivo model, the adrenal glands of the Bmp3b KO mouse 
was studied.  Bmp3b KO mice are viable but their adrenal glands had not been studied (Zhao 
et al., 1999).  The Bmp3b KO mice we studied was not histologically or morphologically 
different from wild type animals, indicating that adrenal development and differentiation does 
not solely rely on Bmp3b expression.  This is supported by other published evidence of the 
importance of Wnt, Shh and FGF pathways in adrenal development and zonation (Guasti et 
al., 2010, 2013b; Vidal et al., 2016).  Future work with BMP2 and BMP3b soaked Affigel 
beads to study the effect of BMP2 and BMP3b will be useful to understand their specific sites 
of action by inserting the beads randomly into the adrenal cortex at different depths and on 
sacrifice, investigating the histology and expression of zone-specific markers around the beads.  
If BMP3b and BMP2 can only act in the subcapsular region and the zR, respectively, then only 
beads placed in these locations would be expected to demonstrate an effect on zonation.  
However, if their effect is not dependent upon the site of insertion, then BMP2 or BMP3b 
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released from the beads would cause changes within the specific zones, regardless of where 
the beads are inserted.     
    
Studies using rodent models are straightforward in terms of accessibility and ethics.  However, 
performing in vivo experiments requires an accumulation of skills in handling and performing 
surgery on these animals.  During the course of this project we were unable to keep the Affigel 
beads in place in the adrenal gland for a period of 7 days in rat adrenal glands hence no results 
could be drawn from these experiments. Rodent data is not directly applicable to the human 
case, as although they do share some similarities structurally in terms of zonation, they differ 
in their steroidogenic output.  Rodents lack Cyp17 and are not able to produce cortisol or 
androgens.  This could mean that the presence and expression of BMPs could differ between 
the two species.  However, gathering initial data from rodents would help with future human 
studies.  
 
During this project, BMP2 and BMP5 were genes of interest as they were shown to be 
downregulated in human adrenocortical carcinoma (Johnsen et al., 2009).  This led the project 
to look at BMP3b in tumourigenesis.  There was a downward trend in BMP2 expression level 
in the ACC cohort, although this did not reach significance.  Overall, BMP3b was upregulated 
in ACC but on closer inspection of individual patients, only half of the patients demonstrated 
this trend.  The patients with increased BMP3b had less aggressive tumours on histology. In 
the German samples BMP3b was not upregulated in any of the samples, although no clinical 
data was available to correlate the aggressiveness of the tumours we received for investigation.  
Clearly more work needs to be done on ACCs to look for prognostic factors or potential 
pathways involved in driving ACC formation. However, progress has been limited by tissue 
collection in such a rare disease and collaboration between centres and countries is necessary 
to take such studies forward.  Understanding the pathways involved in ACC will allow targeted 
therapies to be developed.  Some therapies are already being used in clinical trials.  IGF2 is 
overexpressed in ACCs (Assié et al., 2010; Heaton et al., 2012; Soon et al., 2009) and an anti-
IGF1R monoclonal antibody (Haluska et al., 2010) is currently used in clinical trials as lone 
therapy or in combination with mTOR inhibitor (Naing et al., 2013), though results have not 
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been promising.  Therefore, for ACC treatment to be successful, we may need to target several 
pathways, and BMP may be one of these which is worth exploring in the future. 
 
APAs are benign tumours of the adrenal cortex.  Although the tumour itself is benign, the 
effects of aldosterone excess are not.  Other than the effects of uncontrolled hypertension, 
hyperaldosteronism has independent effects on cardiovascular, renal and metabolic morbidity 
and mortality (Rossi et al., 2008).  APAs are the commonest treatable cause of hypertension if 
diagnosed, but many go undiagnosed for many years, as it was previously thought to be a rare 
condition.  The prevalence of APAs, with more readily available screening tests, is about 11% 
in all hypertensive patients and even higher in the resistant hypertension cohort (Rossi et al., 
2006).  Therefore, understanding the mechanism of hyperaldosteronism is important to offer 
treatment for those that cannot undergo surgery and those diagnosed with BAH, where surgery 
is not appropriate.  In this project, BMP3b was downregulated in the UK cohort but appears 
upregulated in the German cohort, although we lacked German normal control samples for 
comparison.  BMP3b is associated with zG phenotype and upregulates CYP11B2, hence 
aldosterone production, so it would be predicted that BMP3b would be overexpressed in APAs 
but this was not the case and BMP3b may not be involved in APA formation or maintenance. 
Within the last decade, genetics have superseded the diagnosis of APAs with the discovery of 
mutations within genes coding for ion channels (KCNJ5, ATP1A1, ATP2B3 and CACNA1D) 
and most recently the WNT signalling pathway, CNNTB1 (Akerström et al., 2016; Beuschlein 
et al., 2013; Choi et al., 2011; Scholl et al., 2013).  This has increased our understanding of 
APAs with many studies attempting to correlate the genetics with clinical presentation and 
possibly treatment outcomes (Azizan et al., 2012; Kitamoto et al., 2015, 2016; Lenzini et al., 
2015).  So far, these mutations account for approximately 50-60% of APAs, therefore, the 
scope to discover more mutations associated with APAs and clinical correlation may be 
important as the genetics may dictate treatment and prognosis, such as in glucocorticoid 
remedial hyperaldosteronism, where a mutation in the chimeric CYP11B1/CYP11B2 gene, is 
treated successfully with glucocorticoids (Lifton et al., 1992).  Future studies of APAs would 
require detailed clinical information and a big cohort of patients to allow correlation with the 
genetic findings.  There may be phenotypic differences in patients with APAs with and without 
a known genetic mutation.  In addition, further work should be carried out in the KCNJ5 
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subgroup, with an unexpected increased incidence of aldosterone and cortisol co-secreting 
adenomas and to further characterise them. 
 
In conclusion, this project has shown the presence of Bmp3b in the adrenal capsule as 
discovered in the rat microarray.  It is potentially able to act locally to support zG 
differentiation and in a gradient to affect Bmp2 expression and thus the differentiation into 
other zone specific phenotypes.  BMP3b is likely to play a role in zonation, rather than being 
the main pathway, as the absence of Bmp3b is viable and the adrenals have not been shown to 
be severely affected. From the limited samples available it is tantalising to speculate that there 
is a role for BMP3b in tumourigenesis but this needs to be further studied using a much larger 
patient cohort.  Ultimately, BMP3b may play a role in fine tuning adrenocortical cell 
differentiation but the lack of a mouse phenotype suggests it is unlikely to be essential in 
adrenal differentiation and zonation.  There were many limitations to this project and further 
investigations with adequate controls will be needed in the future to further contribute to the 
unravelling of the many different pathways that could interact and determine adrenocortical 
zonation.     
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List of reagents used and Suppliers 
Abcam: 
BMP2 antibody 
Side chain cleavage antibody 
Ambion: 
10x turbo buffer 
Glycogen 
siBMP2 
siBMP3b 
Abnova: 
Recombinant BMP3b 
BioSepra: 
Ultroser G 
Demeditec Diagnostics 
Aldosterone ELISA kit  
Cortisol ELISA kit  
DHEAS ELISA kit  
Gibco, Paisley, UK: 
F12 nutrient media (Ham) 
Invitrogen:  
Goat anti mouse antibody 
Goat anti rabbit antibody 
Lipofectamine 2000  
Optimem I  
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Jackson ImmunoResearch: 
Donkey anti goat antibody 
Donkey anti rabbit antibody 
Lamb Laboratories 
OCT medium  -  
New England Biolabs, MA, US 
S6 RNA polymerase (M0207S) 
T7 RNA polymerase (M0251S) 
Taq DNA Polymerase wit standard Taq buffer (M0273S 
Promega: 
2x rapid ligation buffer 
5x reverse transciptase 
10x restriction buffer –  
dATP,  dCTP, dGTP, dTTP 
E.Coli competent cells  JM109
Isopropyl-β-d-thiogalactopyranoside (IPTG)
M-MLV Reverse Transcriptase (M1701)
PGEMTeasy system 1 (A1360)
Random primers (C118A)
RNase Inhibitor
T4 DNA ligase
X-Gal (V3941)
Qiagen: 
DNase I, RNase-Free 
RNase-Free water 
RNeasy kit 
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Roche: 
0.5% Blocking Reagent   
Anti-DIG alkaline phosphatase-Fab fragments 
DIG RNA Labellling Mix 10x conc 
NBT/BCIP  
Santa Cruz Biotechnology, INC: 
BMP2 antibody for immunofluorescence (BMP2 (N-14): sc-6895) 
Sigma-Aldrich: 
8-Hydroxyquinoline
Acetic acid
Agar powder
Agarose powder
Angiotensin II (human) (A9525)
Bovine serum albumin (BSA)
Denhardt’s solution
Denatured salmon sperm DNA
Deoxyribonuclease I
Diethyl pyrocarbonate (DEPC)
Dimethyl sulfoxide (DMSO)
DPX mounting medium
Dulbecco’s Modified Eagle’s Medium (DMEM)
Ethylenediaminetetraacetic acid (EDTA)
Ethidium bromide
Fetal bovine serum (FBS)
Forskolin
Insulin-Transferrin-Selenium (ITS) (100 x)
LB Broth
Orange G
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Phosphate buffered saline (PBS)   
Penicillin/Streptomycin 
Phenol  
SOC medium 
Sodium acetate 
TESPA (3-triethoxysilylpropylamine) 
Tris base 
Tris hydrochloride 
Thermo Fisher Scientific: 
GelRed 
GeneRuler DNA Ladder mix 
Shenandoah Biotechnology, inc: 
Recombinant Human BMP2 
Vectorlabs: 
ABC reagents (Avidin + Biotinylated horseradish peroxidise macromolecular Complex) 
Avidin  
Biotin 
Levisimole 
Generous gift from Prof Gomez-Sanchez: 
CYP11B1 antibody 
CYP11B2 antibody 
Generous gift from Prof Gavin Vinson: 
Pref-1 (Dlk1) antibody 
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Abcam 330 Cambridge Science Park, Cambridge CB4 0FL  
Abnova Boxbergring 107, 69126 Heidelberg, Germany   
Ambion Life Technologies, 3 Fountain Drive, Inchinnan Business Park,  
Paisley PA4 9RF 
Biosepra Clarendon House, 125 Shenley Rd, Borehamwood,  
Hertfordshire WD6 1AG 
Demeditec Diagnostics Lise-Meitner-Str. 2 24145 Kiel, Germany  
Invitrogen Life Technologies, 3 Fountain Drive, Inchinnan Business Park, 
Paisley PA4 9RF  
Jackson ImmunoResearch Unit 7, Acorn Business Centre, Oaks Drive, Newmarket, 
Suffolk CB8 7SY  
Kapa Biosystems Anachem House, 1 & 2 Titan Court, Laporte Way,  
Bedfordshire LU4 8EF  
Lamb Laboratories Fisher Scientific, Bishop Meadow Road,  
Loughborough LE11 5RG 
New England Biolabs 75-77 Knowl Piece, Hitchin SG4 0TY
Promega  Delta House, Southampton Science Park, Southampton SO16 7NS
Qiagen  Fleming Way, Crawley, West Sussex RH10 9NQ
Roche   Roche Diagnostics Limited, Charles Avenue, Burgess Hill,
West Sussex, RH15 9RY
Shenandoah Biotechnology Shenandoah Biotechnology, Inc., 101 Camars Drive, 
Warwick, PA USA 18974 
Sigma-Aldrich  The Old Brickyard, New Road, Gillingham, Dorset SP8 4XT  
Thermo Fisher Scientific Stafford House, 1 Boundary Park, Hemel Hempstead HP2 7GE 
Vector Laboratories   3, Accent Park, Bakewell Road, Orton Southgate,  
Peterborough PE2 6XS 
